<body style="font: 10pt Times New Roman, Times, Serif"> <document>  <type>   10-K   <sequence>    1    <filename>     tm211142d1_10k.htm     <description>      FORM 10-K      <text>       <title>       </title>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <!-- Field: Rule-Page -->       <div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%">        <div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">        </div>       </div>       <!-- Field: /Rule-Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         UNITED STATES        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         SECURITIES AND EXCHANGE COMMISSION        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         Washington, D.C. 20549        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         FORM 10-K        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         (Mark One)        </b>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in; text-align: left">           <font style="font-family: Wingdings">            x           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">            ANNUALREPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        For the fiscal year ended December 31,2020       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        OR       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in; text-align: left">           <font style="font-family: Wingdings">            ¨           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">            TRANSITIONREPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        For the transition period from __ to __       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">        Commission file number 001-36333       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 14pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">        <u>         BIO-PATH HOLDINGS, INC.        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">        (Exact name of registrant as specified inits charter)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           Delaware          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           87-0652870          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           (State or other jurisdiction of incorporation          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           (I.R.S. Employer Identification No.)          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           or organization)          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; padding-left: 3.25pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: center; padding-bottom: 1pt; padding-left: 3.25pt">           4710 Bellaire Boulevard, Suite 210, Bellaire, Texas          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center; padding-bottom: 1pt; padding-left: 3.25pt">           77401          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           (Address of principal executive offices)          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           (Zip Code)          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <u>         Registrant’s telephone number,including area code: (832) 742-1357        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        Securities registered pursuant to Section 12(b) ofthe Act:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 33%; text-align: center">           Title of each class          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 33%; text-align: center">           Trading Symbol          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center">           Name of each exchange on which           <br/>           registered          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">           Common Stock, par value $0.001           <br/>           per share          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">           BPTH          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">           The Nasdaq Capital Market          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        Securities registered pursuant to Section 12(g) ofthe Act: None       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Indicateby check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes        </font>        <font style="font-family: Wingdings">         <font style="font-family: Wingdings">          ¨         </font>        </font>        <font style="font-family: Times New Roman, Times, Serif">         No        </font>        <font style="font-family: Wingdings">         <font style="font-family: Wingdings">          x         </font>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Indicateby check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.Yes        </font>        <font style="font-family: Wingdings">         <font style="font-family: Wingdings">          ¨         </font>        </font>        <font style="font-family: Times New Roman, Times, Serif">         No        </font>        <font style="font-family: Wingdings">         <font style="font-family: Wingdings">          x         </font>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">         Indicateby check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of theSecurities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required tofile such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes        </font>        <font style="font-family: Wingdings">         <font style="font-family: Wingdings">          x         </font>        </font>        <font style="font-family: Times New Roman, Times, Serif">         No        </font>        <font style="font-family: Wingdings">         <font style="font-family: Wingdings">          ¨         </font>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">         Indicateby check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuantto Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter periodthat the registrant was required to submit such files). Yes        </font>        <font style="font-family: Wingdings">         <font style="font-family: Wingdings">          x         </font>        </font>        <font style="font-family: Times New Roman, Times, Serif">         No        </font>        <font style="font-family: Wingdings">         <font style="font-family: Wingdings">          ¨         </font>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Indicate by check mark whether the registrant is a large acceleratedfiler, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitionsof “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerginggrowth company” in Rule 12b-2 of the Exchange Act.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="width: 70%; font-size: 10pt; text-align: justify; padding-left: 3.25pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Large accelerated filer           </font>           <font style="font-family: Wingdings; font-size: 10pt">            <font style="font-family: Wingdings">             ¨            </font>           </font>          </td>          <td style="width: 30%; font-size: 10pt; text-align: justify; padding-left: 3.25pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Accelerated filer           </font>           <font style="font-family: Wingdings; font-size: 10pt">            <font style="font-family: Wingdings">             ¨            </font>           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt; text-align: justify; padding-left: 3.25pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Non-accelerated filer           </font>           <font style="font-family: Wingdings; font-size: 10pt">            <font style="font-family: Wingdings">             x            </font>           </font>          </td>          <td style="font-size: 10pt; text-align: justify; padding-left: 3.25pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Smaller reporting company           </font>           <font style="font-family: Wingdings; font-size: 10pt">            <font style="font-family: Wingdings">             x            </font>           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt; padding-left: 3.25pt">          </td>          <td style="font-size: 10pt; text-align: justify; padding-left: 3.25pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Emerging growth company           </font>           <font style="font-family: Wingdings; font-size: 10pt">            <font style="font-family: Wingdings">             ¨            </font>           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">         Ifan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the ExchangeAct.        </font>        <font style="font-family: Wingdings">         ¨        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; background-color: white">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; background-color: white">         Indicateby check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectivenessof its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) bythe registered public accounting firm that prepared         <font style="color: #333333">          or issued its audit report.         </font>        </font>        <font style="font-family: Wingdings">         <font style="font-family: Wingdings">          ¨         </font>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Indicateby check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes        </font>        <font style="font-family: Wingdings">         <font style="font-family: Wingdings">          ¨         </font>        </font>        <font style="font-family: Times New Roman, Times, Serif">         No        </font>        <font style="font-family: Wingdings">         <font style="font-family: Wingdings">          x         </font>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        As of March 1, 2021, there were 6,947,912 shares of theregistrant’s common stock issued and outstanding. The aggregate market value of the voting stock held by non-affiliatesof the registrant was approximately $18,472,208.15 as of June 30, 2020, the last business day of the registrant’s mostrecently completed second fiscal quarter, based on the last sales price of the registrant’s common stock as reported onThe Nasdaq Capital Market on such date. For purposes of the preceding sentence only, all directors, executive officers and beneficialowners of 10% or more of the shares of the registrant’s common stock are assumed to be affiliates.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">        DOCUMENTS INCORPORATED BY REFERENCE: NONE       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Rule-Page -->       <div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%">        <div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">        </div>       </div>       <!-- Field: /Rule-Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="margin: 0pt">        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        TABLE OF CONTENTS       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr>          <td style="vertical-align: top; width: 95%">          </td>          <td style="vertical-align: bottom; width: 5%; text-align: center; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             <u>              Page             </u>            </b>           </font>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top; font-size: 10pt">           <a href="#Seng_001">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             PART I            </font>           </a>          </td>          <td style="vertical-align: bottom; font-size: 10pt; text-align: right">           <a href="#Seng_001">            2           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top; font-size: 10pt">           <a href="#Seng_002">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Item    1. Business            </font>           </a>          </td>          <td style="vertical-align: bottom; font-size: 10pt; text-align: right">           <a href="#Seng_002">            2           </a>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top; font-size: 10pt">           <a href="#Seng_003">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Item    1A. Risk Factors            </font>           </a>          </td>          <td style="vertical-align: bottom; font-size: 10pt; text-align: right">           <a href="#Seng_003">            25           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top; font-size: 10pt">           <a href="#Seng_004">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Item    1B. Unresolved Staff Comments            </font>           </a>          </td>          <td style="vertical-align: bottom; font-size: 10pt; text-align: right">           <a href="#Seng_004">            51           </a>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top; font-size: 10pt">           <a href="#Seng_005">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Item    2. Properties            </font>           </a>          </td>          <td style="vertical-align: bottom; font-size: 10pt; text-align: right">           <a href="#Seng_005">            51           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top; font-size: 10pt">           <a href="#Seng_006">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Item    3. Legal Proceedings            </font>           </a>          </td>          <td style="vertical-align: bottom; font-size: 10pt; text-align: right">           <a href="#Seng_006">            51           </a>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top; font-size: 10pt">           <a href="#Seng_007">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Item    4. Mine Safety Disclosures            </font>           </a>          </td>          <td style="vertical-align: bottom; font-size: 10pt; text-align: right">           <a href="#Seng_007">            51           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top; font-size: 10pt">           <a href="#Seng_008">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             PART II            </font>           </a>          </td>          <td style="vertical-align: bottom; font-size: 10pt; text-align: right">           <a href="#Seng_008">            52           </a>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top; font-size: 10pt">           <a href="#Seng_009">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Item    5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities            </font>           </a>          </td>          <td style="vertical-align: bottom; font-size: 10pt; text-align: right">           <a href="#Seng_009">            52           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top; font-size: 10pt">           <a href="#Seng_010">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Item    6. [Reserved]            </font>           </a>          </td>          <td style="vertical-align: bottom; font-size: 10pt; text-align: right">           <a href="#Seng_010">            52           </a>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top; font-size: 10pt">           <a href="#Seng_011">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Item    7. Management’s Discussion and Analysis of Financial Condition and Results of Operations            </font>           </a>          </td>          <td style="vertical-align: bottom; font-size: 10pt; text-align: right">           <a href="#Seng_011">            52           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top; font-size: 10pt">           <a href="#Seng_012">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Item    7A. Quantitative and Qualitative Disclosures About Market Risk            </font>           </a>          </td>          <td style="vertical-align: bottom; font-size: 10pt; text-align: right">           <a href="#Seng_012">            60           </a>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top; font-size: 10pt">           <a href="#Seng_013">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Item    8. Financial Statements and Supplementary Data            </font>           </a>          </td>          <td style="vertical-align: bottom; font-size: 10pt; text-align: right">           <a href="#Seng_013">            60           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top; font-size: 10pt">           <a href="#Seng_014">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Item    9. Changes and Disagreements with Accountants on Accounting and Financial Disclosure            </font>           </a>          </td>          <td style="vertical-align: bottom; font-size: 10pt; text-align: right">           <a href="#Seng_014">            60           </a>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top; font-size: 10pt">           <a href="#Seng_015">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Item    9A. Controls and Procedures            </font>           </a>          </td>          <td style="vertical-align: bottom; font-size: 10pt; text-align: right">           <a href="#Seng_015">            60           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top; font-size: 10pt">           <a href="#Seng_016">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Item    9B. Other Information            </font>           </a>          </td>          <td style="vertical-align: bottom; font-size: 10pt; text-align: right">           <a href="#Seng_016">            61           </a>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top; font-size: 10pt">           <a href="#Seng_017">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             PART III            </font>           </a>          </td>          <td style="vertical-align: bottom; font-size: 10pt; text-align: right">           <a href="#Seng_017">            62           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top; font-size: 10pt">           <a href="#Seng_018">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Item    10. Directors, Executive Officers and Corporate Governance            </font>           </a>          </td>          <td style="vertical-align: bottom; font-size: 10pt; text-align: right">           <a href="#Seng_018">            62           </a>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top; font-size: 10pt">           <a href="#Seng_019">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Item    11. Executive Compensation            </font>           </a>          </td>          <td style="vertical-align: bottom; font-size: 10pt; text-align: right">           <a href="#Seng_019">            67           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top; font-size: 10pt">           <a href="#Seng_020">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Item    12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters            </font>           </a>          </td>          <td style="vertical-align: bottom; font-size: 10pt; text-align: right">           <a href="#Seng_020">            76           </a>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top; font-size: 10pt">           <a href="#Seng_021">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Item    13. Certain Relationships and Related Party Transactions, and Director Independence            </font>           </a>          </td>          <td style="vertical-align: bottom; font-size: 10pt; text-align: right">           <a href="#Seng_021">            77           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top; font-size: 10pt">           <a href="#Seng_022">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Item    14. Principal Accounting Fees and Services            </font>           </a>          </td>          <td style="vertical-align: bottom; font-size: 10pt; text-align: right">           <a href="#Seng_022">            78           </a>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top; font-size: 10pt">           <a href="#Seng_023">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             PART IV            </font>           </a>          </td>          <td style="vertical-align: bottom; font-size: 10pt; text-align: right">           <a href="#Seng_023">            80           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top; font-size: 10pt">           <a href="#Seng_024">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Item    15. Exhibits and Financial Statement Schedules            </font>           </a>          </td>          <td style="vertical-align: bottom; font-size: 10pt; text-align: right">           <a href="#Seng_024">            80           </a>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top; font-size: 10pt">           <a href="#Seng_025">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Item    16. Form 10-K Summary            </font>           </a>          </td>          <td style="vertical-align: bottom; font-size: 10pt; text-align: right">           <a href="#Seng_025">            82           </a>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Unless the context requires otherwise,references in this Annual Report on Form 10-K to “we,” “our,” “us,” “the Company”and “Bio-Path” refer to Bio-Path Holdings, Inc. and its subsidiary. Bio-Path Holdings, Inc.’s wholly-ownedsubsidiary, Bio-Path, Inc., is sometimes referred to herein as “Bio-Path Subsidiary.”       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         CAUTIONARY NOTE REGARDING FORWARD-LOOKINGSTATEMENTS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        This Annual Report on Form 10-K contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).Forward-looking statements can be identified by words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” “project,” “goal,” “strategy,” “future,” “likely,” “may,” “should,” “will”and variations of these words and similar references to future periods, although not all forward-looking statements contain theseidentifying words. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, theyare based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies,projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relateto the future, they are subject to inherent risks, uncertainties and changes in circumstances, including those discussed in “Item1A. Risk Factors” of this Annual Report on Form 10-K and in other reports or documents we file with the U.S. Securitiesand Exchange Commission (“SEC”). As a result, our actual results and financial condition may differ materially fromthose expressed or forecasted in the forward-looking statements, and you should not rely on such forward-looking statements. Wecan give no assurances that any of the events anticipated by the forward-looking statements will occur or, if any of them do,what impact they will have on our results of operations and financial condition. Important factors that could cause our actualresults and financial condition to differ materially from those indicated in the forward-looking statements include, among others,the following:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="margin: 0pt">        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 6%">          </td>          <td style="width: 1%; font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="width: 93%; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the impact, risks and uncertainties related to COVID-19 and actions taken by governmental authorities or others in connection therewith;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            our lack of significant revenue to date, our history of recurring operating losses and our expectation of future operating losses;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            our need for substantial additional capital and our need to delay, reduce or eliminate our drug development and commercialization efforts if we are unable to raise additional capital;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the highly-competitive nature of the pharmaceutical and biotechnology industry and our ability to compete effectively;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the success of our plans to use collaboration arrangements to leverage our capabilities;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            our ability to retain and attract key personnel;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the risk of misconduct of our employees, agents, consultants and commercial partners;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            disruptions to our operations due to expansions of our operations;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the costs we would incur if we acquire or license technologies, resources or drug candidates;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            risks associated with product liability claims;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            our reliance on information technology systems and the liability or interruption associated with cyber-attacks or other breaches of our systems;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            our ability to use net operating loss carryforwards;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            provisions in our charter documents and state law that may prevent a change in control;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            work slowdown or stoppage at government agencies could negatively impact our business;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            our need to complete extensive clinical trials and the risk that we may not be able to demonstrate the safety and efficacy of our drug candidates;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            risks that that our clinical trials may be delayed or terminated;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            our ability to obtain domestic and/or foreign regulatory approval for our drug candidates;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            changes in existing laws and regulations affecting the healthcare industry;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            our reliance on third parties to conduct clinical trials for our drug candidates;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            our ability to maintain orphan drug exclusivity for our drug candidates;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            our reliance on third parties for manufacturing our clinical drug supplies;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            risks associated with the manufacture of our drug candidates;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            our ability to establish sales and marketing capabilities relating to our drug candidates;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            market acceptance of our drug candidates;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            third-party payor reimbursement practices;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            our ability to adequately protect the intellectual property of our drug candidates;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            infringement on the intellectual property rights of third parties;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            costs and time relating to litigation regarding intellectual property rights;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            our ability to adequately prevent disclosure by our employees or others of trade secrets and other proprietary information;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            our need to raise additional capital;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the volatility of the trading price of our common stock;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            our common stock being thinly traded;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            our ability to issue shares of common or preferred stock without approval from our stockholders;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            our ability to pay cash dividends;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            costs and expenses associated with being a public company; and           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            our ability to maintain compliance with the listing standards of the Nasdaq Capital Market.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Please also refer to “Item 1A. RiskFactors” of this Annual Report on Form 10-K and other reports or documents we file with the SEC for a discussion ofrisks and factors that could cause our actual results and financial condition to differ materially from those expressed or forecastedin this Annual Report on Form 10-K.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Any forward-looking statement made by usin this Annual Report on Form 10-K is based only on information currently available to us and speaks only as of the dateon which it is made. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information,future developments or otherwise. However, you should carefully review the risk factors set forth in other reports or documentswe file from time to time with the SEC.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">       </p>       <!-- Field: Page; Sequence: 3 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="margin: 0pt">        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">       </p>       <!-- Field: Split-Segment; Name: 1 -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="text-transform: uppercase">         <b>          <u>           <a name="Seng_001">           </a>           PART I          </u>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="text-transform: uppercase">         <b>          <a name="Seng_002">          </a>          ITEM 1. BUSINESS         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Overview        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        We are a clinical and preclinical stageoncology focused RNAi nanoparticle drug development company utilizing a novel technology that achieves systemic delivery for targetspecific protein inhibition for any gene product that is over-expressed in disease. Our drug delivery and antisense technology,called DNAbilize®, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intendedto protect the DNA from destruction by the body’s enzymes when circulating in vivo, incorporated inside of a lipid bilayerhaving neutral charge. We believe this combination allows for high efficiency loading of antisense DNA into non-toxic, cell-membrane-likestructures for delivery of the antisense drug substance into cells. In vivo, the DNAbilize® delivered antisense drug substancesare systemically distributed throughout the body to allow for reduction or elimination of target proteins in blood diseases andsolid tumors. Through testing in numerous animal studies and treatment in over 80 patients, the Company’s DNAbilize®drug candidates have demonstrated an excellent safety profile. DNAbilize® is a registered trademark of the Company.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Using DNAbilize® as a platform fordrug development and manufacturing, we currently have four drug candidates in development to treat at least five different cancerdisease indications. Our lead drug candidate, prexigebersen (pronounced prex” i je ber’ sen), which targets growthfactor receptor-bound protein 2 (Grb2), initially started the efficacy portion of a Phase 2 clinical trial for untreated acutemyeloid leukemia (“AML”) patients in combination with low-dose cytarabine (“LDAC”). The interim data wereleased on March 6, 2019 showed that 11 (65%) of the 17 evaluable patients had a response, including five (29%) who achievedcomplete remission (“CR’), including one CR with incomplete hematologic recovery (“CR        <sub>         i        </sub>        “) andone morphologic leukemia free state, and six (35%) stable disease responses, including two patients who had greater than a 50%reduction in bone marrow blasts. However, DNA hypomethylating agents are now the most frequently used agents in the treatmentof elderly AML patients in the U.S. and Europe. As a result, Stage 2 of the Phase 2 trial in AML was amended to, among other things,remove the combination treatment of prexigebersen and LDAC and replace it with the combination treatment of prexigebersen anddecitabine, a DNA hypomethylating agent, for treatment of a second cohort of untreated AML patients. Since decitabine is alsoused as a treatment for relapsed/refractory AML patients, a cohort of relapsed/refractory AML patients was also added to the study.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The U.S. Food and Drug Administration (“FDA”)recently granted approval of venetoclax in combination with LDAC, decitabine, or azacytidine (the latter two drugs are DNA hypomethylatingagents) as frontline therapy for newly diagnosed AML in adults who are 75 years or older, or who have comorbidities precludingintensive induction chemotherapy. We believe this recent frontline therapy approval provides an opportunity to include prexigebersenwith the combination therapy for the treatment of        <i>         de novo        </i>        AML patients. Preclinical efficacy studies for the triple combinationtreatment of prexigebersen, decitabine and venetoclax in AML have been successfully completed. In the preclinical efficacy studies,four AML cancer cell lines were treated with three different combinations of decitabine, venetoclax and prexigebersen. Decreasein AML cell viability was the primary measure of efficacy. The triple combination of decitabine, venetoclax and prexigebersen showedsignificant improvement in efficacy in three of the four AML cell lines. Based on these results, the Company believes that addingprexigebersen to the treatment combination of decitabine and venetoclax could lead to improved efficacy in AML patients. Accordingly,the Company further amended Stage 2 of this Phase 2 clinical trial to add the triple combination treatment comprised of prexigebersen,decitabine and venetoclax, which amendment has been approved by the FDA.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Bio-Path’s approved amended Stage2 for this Phase 2 clinical trial currently has three cohorts of patients. The first two cohorts will treat patients with the triplecombination of prexigebersen, decitabine and venetoclax. The first cohort will include untreated AML patients, and the second cohortwill include relapsed/refractory AML patients. Finally, the third cohort will treat relapsed/refractory AML patients, who are venetoclax-resistantor -intolerant, with the two-drug combination of prexigebersen and decitabine. The full trial design plans have approximately 98evaluable patients for the first cohort having untreated AML patients with a preliminary review performed after 19 evaluable patientsand a formal interim analysis after 38 evaluable patients. The full trial design plans have approximately 54 evaluable patientsfor each of the second cohort, having relapsed/refractory AML patients, and the third cohort, having AML patients who are venetoclax-resistantor -intolerant, in each case with a review performed after 19 evaluable patients. The study is anticipated to be conducted at tenclinical sites in the U.S., and Gail J. Roboz, MD will be the national coordinating Principal Investigator for the Phase 2 trial.Dr. Roboz is a professor of medicine and director of the Clinical and Translational Leukemia Program at the Weill MedicalCollege of Cornell University and the New York-Presbyterian Hospital in New York City. On August 13, 2020, we announced theenrollment and dosing of the first patient in this approved amended Stage 2 of the Phase 2 clinical study.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 4; Options: NewSection; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            2            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Our second drug candidate, Liposomal Bcl-2(“BP1002”), targets the protein Bcl-2, which is responsible for driving cell survival in up to 60% of all cancers.On November 21, 2019, we announced that the FDA cleared an Investigational New Drug (“IND”) application for BP1002.An initial Phase 1 clinical trial will evaluate the safety of BP1002 in refractory/relapsed lymphoma and chronic lymphocytic leukemia(“CLL”) patients. Initially, a total of six evaluable patients are scheduled to be treated with BP1002 monotherapyin a standard 3+3 design. The Phase 1 clinical trial is being conducted at several leading cancer centers, including The Universityof Texas MD Anderson Cancer Center (“MD Anderson”), the Georgia Cancer Center and the Sarah Cannon Research Institute,and is now open for enrollment. Ian W. Flynn, MD is the national coordinating Principal Investigator for the Phase 1 trial. Dr. Flynnserves as the director of lymphoma research at the Sarah Cannon Research Institute.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Our third drug candidate, Liposomal STAT3(“BP1003”), targets the STAT3 protein and is currently in IND enabling studies as a potential treatment of pancreaticcancer, non-small cell lung cancer (“NSCLC”) and AML. Preclinical models have shown BP1003 to inhibit cell viabilityand STAT3 protein expression in NSCLC and AML cell lines. Further, BP1003 successfully penetrated pancreatic tumors and significantlyenhanced the efficacy of gemcitabine, a treatment for patients with advanced pancreatic cancer, in a pancreatic cancer patientderived tumor model. Our lead indication for BP1003 is pancreatic cancer due to the severity of this disease and the lack of effective,life-extending treatments. For example, pancreatic adenocarcinoma is projected to be the second most lethal cancer behind lungcancer by 2030. Typical survival for a metastatic pancreatic cancer patient is about three to six months from diagnosis. We expectto complete several IND enabling studies of BP1003 in 2021. If those studies are successful, our goal is to file an IND in late2021 for the first-in-humans Phase 1 study of BP1003 in patients with refractory, metastatic solid tumors, including pancreaticcancer and NSCLC.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        In addition, a modified product named prexigebersen-A,Bio-Path’s fourth drug candidate, has shown to enhance chemotherapy efficacy in preclinical solid tumor models. Prexigebersen-Aincorporates the same drug substance as prexigebersen but has a slightly modified formulation designed to enhance nanoparticleproperties. In late 2019, we filed an IND application to initiate a Phase 1 clinical trial of prexigebersen-A in patients withsolid tumors, including ovarian, endometrial, pancreatic and breast cancer. Ovarian cancer is one of the most common type of gynecologicmalignancies, with approximately 50% of all cases occurring in women older than 63 years. This trial is expected to commence afterthe IND has been cleared by the FDA, which we currently anticipate being in 2021.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Our DNAbilize® technology-based products are availablefor out-licensing or partnering. We intend to apply our drug delivery technology template to new disease-causing protein targetsto develop new nanoparticle antisense RNAi drug candidates. We have a new product identification template in place to define aprocess of scientific, preclinical, commercial and intellectual property evaluation of potential new drug candidates for inclusioninto our drug product development pipeline. As we expand, we will look at indications where a systemic delivery is needed andantisense RNAi nanoparticles can be used to slow, reverse or cure a disease, either alone or in combination with another drug.On September 25, 2019, we announced that the United States Patent and Trademark Office (“USPTO”) issued a patentfor claims related to DNAbilize®, including its use in the treatment of cancers, autoimmune diseases and infectious diseases.On October 22, 2020 we announced that the USPTO issued a Notice of Allowance for U.S. Patent Application No. 16/333,221entitled “Combination Therapy with Liposomal Antisense Oligonucleotides.” On February 10, 2021, we announcedthat the USPTO granted U.S. Patent No. 10,898,506 titled, “P-ethoxy nucleic acids for liposomal formulation.”The new patent builds on earlier patents granted that protect the platform technology for DNAbilize        <sup>         ®        </sup>        , the Company’snovel RNAi nanoparticle drugs. The new patent is the third patent in our family of platform intellectual property and offers expandeddefense of our DNAbilize        <sup>         ®        </sup>        platform technology. In addition, the USPTO has mailed an Issue Notification for a patentrelated to the Company’s lead product candidate, prexigebersen, in combination with either a cytidine analogue, such asdecitabine, or the Bcr-Abl tyrosine kinase inhibitors dasatinib and nilotinib. This patent was issued as U.S. Patent No. 10,927,379on February 23, 2021. The patent will offer target-specific protection for on-going clinical trials using prexigebersen incombination with decitabine as a treatment for AML. We continue our efforts to build protection around our technology as it safeguardsour platform technology and target-specific technology, is a deterrent to would-be competitors and creates value around our corecompetencies.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 5; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            3            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        We have certain intellectual property asthe basis for our current drug products in clinical development, prexigebersen, prexigebersen-A, BP1002 and BP1003. We are developingRNAi antisense nanoparticle drug candidates based on our own patented technology to treat cancer and autoimmune disorders wheretargeting a single protein may be advantageous and result in reduced patient adverse effects as compared to small molecule inhibitorswith off-target and non-specific effects. We have composition of matter and method of use intellectual property for the designand manufacture of antisense RNAi nanoparticle drug products.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Our pipeline for development of antisensetherapeutics is set forth in Figure 1 below:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         Figure 1. Bio-Path Pipeline for Developmentof Therapeutics        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <img alt="" src="tm211142d1_10kimg002.jpg"/>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">        * Received orphan drug designationfrom the U.S. FDA and from the European Medicines Agency (EMA) for AML       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Our basic drug development concept is toblock expression of proteins associated with disease. Messenger RNA (mRNA) is essential in the process of creating proteins. Wehave developed DNAbilize        <sup>         ®        </sup>        nanoparticle drug delivery systems to deliver short strands of antisense DNA drugs tocells and block the production of proteins associated with disease progression (Figure 2).       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 6; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            4            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         Figure 2.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <img alt="" src="tm211142d1_10kimg001.jpg" style="height: 211px; width: 369px"/>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Antisense DNA therapeutics is the fieldof designing short DNA sequences that are complementary to a mRNA for a protein of interest with the intention of inhibiting theproduction of the targeted protein. The DNA will find the matching RNA and form a complex. The complexed RNA will not have accessto the protein-making machinery, which prevents the cell from translating it into a protein. Thus, protein production is turnedoff and levels of the targeted protein are reduced in the cell. This gene-specific process of controlling protein expression hasled to great interest in using antisense DNA to shut off the production of proteins involved in disease. Antisense therapeuticshave been in development for over 20 years. However, challenges to antisense therapeutics, such as instability of antisense drugsinside of the body and inefficient delivery of antisense to disease cells, have thawed antisense therapeutic potential.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        We believe our DNAbilize        <sup>         ®        </sup>        technology, which is the combination of the protected P-ethoxy antisense DNA backbone with the neutral liposome nanoparticle, isthe ideal approach for antisense DNA therapeutics because it overcomes the challenges associated with both antisense stabilityand intracellular delivery. The P-ethoxy modification used in our DNAbilize        <sup>         ®        </sup>        technology is completely sulfur free.We avoid using sulfur-containing antisense because it has been associated with causing liver toxicity and life-threatening bleedingand clotting complications. We prefer neutral lipids to cationic lipids for intracellular delivery because encapsulating the antisenseDNA inside a neutral charged lipid bilayer facilitates the delivery and transfer of DNA into the cell to be fluid and gentle. Whilemany companies have focused research on either the DNA stabilization problem or the lipid delivery problem, we are not aware ofany company that has developed improvements in both areas. DNAbilize        <sup>         ®        </sup>        is truly a stand-alone platform because, asdemonstrated by our published preclinical studies, it allows for high doses of drug products to be delivered throughout the entirebody while minimizing toxicity. This allows our research and development efforts to focus on drug targets rather than on indicationsbecause the DNAbilize        <sup>         ®        </sup>        system should not be limited in what types of indications it can treat. As such, we believethat DNAbilize        <sup>         ®        </sup>        represents the first ever antisense therapeutic approach that can successfully treat hematologicaland systemic diseases.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Because of our unique ability to addressunmet needs in hematological malignancies, our lead drug candidates focus on cancers of the blood and lymph. Our lead drug candidate,prexigebersen, targets the protein Grb2, a bridging protein between activated and mutated cellular kinases and the proteins involvedin cell propagation, and in particular, the Ras protein. When mutations occur that activate these kinases, the cell propagatesuncontrollably, via Grb2, and this results in disease progression. Inhibition of Grb2 interrupts this pathway and shuts off propagationsignals.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The efficacy of prexigebersen in combinationwith standard of care therapies is being evaluated in a Phase 2 clinical trial for AML patients. The multi-site trial is beingconducted at leading cancer centers, including Weill Medical College of Cornell University, Baylor Scott &amp;White Health,The University of Kansas, New Jersey Hematology Oncology Associates, West Virginia University/Mary Babb Randolph Cancer Centerand MD Anderson.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 7; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            5            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Our second drug candidate, BP1002, targetsthe protein Bcl-2. Bcl-2 is an anti-apoptotic member of the Bcl-2 family of proteins that regulate cell death. Overexpressionof Bcl-2 results in deregulated cell survival in cancer cells, thus reducing their sensitivity to many of the drugs currentlyused in the clinic, which mediate their therapeutic effects (at least in part) through the activation of the Bcl-2-regulated apoptoticpathway. The Phase 1 clinical trial will evaluate the safety of BP1002 in refractory/relapsed lymphoma and CLL patients. The Phase1 clinical trial is being conducted at several leading cancer centers, including MD Anderson, the Georgia Cancer Center and theSarah Cannon Research Institute.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The intended indications of our two otherdrug candidates, prexigebersen-A and BP1003, are in solid tumors. Safety and efficacy of prexigebersen-A in combination with paclitaxelwill be investigated in patients with recurrent ovarian or endometrial cancer. Safety and efficacy of BP1003 in combination withgemcitabine will be investigated in patients with refractory, metastatic pancreatic cancer.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Strategy        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Our strategy is to develop our lead candidates,prexigebersen, prexigebersen-A, BP1002 and BP1003, for multiple indications where the pathways involving Grb2, Bcl-2 and STAT3,respectively, are utilized to promote cancer growth, survival, angiogenesis and tumor surveillance evasion. Using DNAbilize        <sup>         ®        </sup>        technology, we plan to develop therapeutics to a wide range of diseases and disorders independently and in partnership with others.The key elements of our strategy include:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in">          </td>          <td style="width: 0.25in; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (1)           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Developprexigebersen for treatment of AML and MDS in combination therapies.            </b>            The efficacy of prexigebersen, our first drug candidate,is being assessed in a Phase 2 study in three cohorts of AML patients. The first cohort enrolls untreated AML patients, and thesecond cohort enrolls relapsed/refractory AML patients. Both the first and the second patient cohorts will be treated with thetriple combination of prexigebersen, decitabine and venetoclax. The third patient cohort, which enrolls relapsed/refractory AMLpatients who are venetoclax-resistant or -intolerant, will be treated with the two-drug combination of prexigebersen and decitabine.The Company expects to design a clinical trial in the future evaluating MDS patients with prexigebersen.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in">          </td>          <td style="width: 0.25in; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (2)           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Developprexigebersen-A for treatment of solid tumors.            </b>            Preclinical studies demonstrating that prexigebersen-A enhances the efficacyof paclitaxel (a standard of care) in ovarian and endometrial cancer models have been published in the scientific journal Oncotargetin July 2020. In late 2019, we filed an IND application to initiate a Phase 1 clinical trial of prexigebersen-A in patientswith recurrent solid tumors. This trial is expected to commence after the IND has been cleared by the FDA, which we currentlyanticipate being in 2021, at several leading cancer centers and will evaluate the safety of prexigebersen-A in these patients.Assuming positive Phase 1 results, we expect that we would advance to a Phase 1b clinical trial of prexigebersen-A in combinationwith paclitaxel in patients with recurrent ovarian or endometrial cancer.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin: 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in">          </td>          <td style="width: 0.25in; text-align: left">           (3)          </td>          <td style="text-align: left">           <b>            Develop BP1002 for lymphoma and CLL           </b>           . The safety,pharmacokinetics and efficacy of BP1002, our second drug candidate, is being evaluated in a Phase 1 clinical trial in refractory/relapsedlymphoma and CLL patients. The Phase 1 clinical trial is being conducted at several leading cancer centers, including MD Anderson,the Georgia Cancer Center and the Sarah Cannon Research Institute and is now open for enrollment. On November 19, 2020, weannounced the enrollment and dosing of the first study patient.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in">          </td>          <td style="width: 0.25in; text-align: left">           (4)          </td>          <td style="text-align: left">           <b>            Develop BP1002 for AML patients who have relapsedfrom venetoclax.           </b>           The Bcl-2 inhibitor venetoclax is used in frontline combination therapies to treat elderly AML patients;however, venetoclax resistance has been observed. A recent study found that AML patients who had relapsed from frontline venetoclax-basedtreatment had a very poor prognosis, with a median survival of less than 3 months. Since venetoclax and BP1002 utilize differentmechanisms of action, we believe that BP1002 may be a potential treatment for venetoclax-relapsed AML patients. Preclinical studiessuggest that the combination of BP1002 with decitabine is efficacious in venetoclax-resistant cells. Bio-Path's goal is to filean IND in mid-2021 for a Phase 1/1b study of BP1002 in combination with decitabine in AML patients who have relapsed from venetoclax-basedtreatment.          </td>         </tr>        </tbody>       </table>       <p style="margin: 0">       </p>       <!-- Field: Page; Sequence: 8; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            6            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="margin: 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in">          </td>          <td style="width: 0.25in; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (5)           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             DevelopBP1003 for pancreatic cancer, NSCLC and AML            </b>            . Our third drug candidate, BP1003, targets the STAT3 protein and is currentlyin IND enabling studies as a potential treatment of pancreatic cancer, NSCLC and AML. Bio-Path expects to complete several INDenabling studies of BP1003 in 2021. If those studies are successful, Bio-Path's goal is to file an IND in late 2021 for the first-in-humansPhase 1 study of BP1003 in patients with refractory, metastatic solid tumors. Assuming positive Phase 1 results, we expect thatwe would advance to a Phase 1b clinical trial of BP1003 in combination with gemcitabine in patients with refractory, metastaticpancreatic cancer.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        <font style="font: 10pt Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in">          </td>          <td style="width: 0.25in; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (6)           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             ExpandDNAbilize             <sup>              ®             </sup>             to evaluate targets beyond cancer.            </b>            We plan to apply the DNAbilize            <sup>             ®            </sup>            delivery technologytemplate to new protein targets that meet scientific, preclinical and commercial criteria and file new patents on these targets.We expect that these efforts will include collaboration with scientific key opinion leaders in the field of study and includedeveloping drug candidates for diseases other than cancer. On September 25, 2019, we announced that the USPTO issued a patentfor claims related to DNAbilize®, including its use in the treatment of cancers, autoimmune diseases and infectious diseases.On October 22, 2020, we announced that the USPTO issued a Notice of Allowance for U.S. Patent Application No. 16/333,221entitled “Combination Therapy with Liposomal Antisense Oligonucleotides.” Additionally, on February 10, 2021,we announced that the USPTO granted U.S. Patent No. 10,898,506 titled, “P-ethoxy nucleic acids for liposomal formulation.”The new patent builds on earlier patents granted that protect the platform technology for DNAbilize            <sup>             ®            </sup>            , the Company’snovel RNAi nanoparticle drugs. The new patent is the third patent in our family of platform intellectual property and offers expandeddefense of our DNAbilize            <sup>             ®            </sup>            platform technology.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0; margin-bottom: 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.5in">          </td>          <td style="width: 0.25in; text-align: left">           <p style="margin-top: 0; margin-bottom: 0">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            </font>           </p>           <p style="margin-top: 0; margin-bottom: 0">            <font style="font: 10pt Times New Roman, Times, Serif">             (7)            </font>           </p>          </td>          <td style="text-align: left">           <b>            Establish DNAbilize            <sup>             ®            </sup>            as the antisensedrug delivery method of choice by forming partnerships with pharmaceutical and academic clinical research labs.           </b>           We plan toutilize our business and scientific expertise to identify potential partners and initiate a wide-ranging, proactive licensingprogram that will include co-development of specific liposomal antisense drug candidates, licensing the delivery template foroutside development of one or more liposomal antisense drug candidates or an out-license of a partially developed drug for finaldevelopment and marketing.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Overview of Drug Candidates        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The historical perspective of cancer treatmentshas been the use of drugs that affect the entire body. Advances in the past decade have shifted to treating the tumor tissue itself.One of the main strategies in these developments has been targeted therapy, involving drugs that are targeted to block the expressionof specific disease-causing proteins while having little or no effect on other healthy tissue. We believe that nucleic acid drugproducts, specifically antisense, are a promising field of targeted therapy. Development of antisense as cancer drugs, however,has been limited by the lack of a suitable method to deliver antisense drugs to cancer cells with high uptake into the cancer cellswithout causing toxicity to non-cancer cells. Our currently licensed DNAbilize        <sup>         ®        </sup>        neutral-lipid based liposome technologyis designed to overcome these limitations. We have published preclinical studies demonstrating that our DNAbilize        <sup>         ®        </sup>        technology could efficiently deliver antisense therapeutics to mouse models of hematological malignancies and solid tumors, decreasetarget proteins production and suppress tumor progression. In addition, to date, no adverse effects attributed to the study drugshave been observed in our leukemia and lymphoma clinical trials.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">        <font style="text-transform: uppercase">         <b>          <i>           PREXIGEBERSEN          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Prexigebersen is targeted at the proteinGrb2. Antisense inhibition of Grb2 interrupts the signals between mutated and activated receptors that connect to a well-knowncancer associated switch called Ras protein. Inhibition of Grb2 suppresses cancer cells propagation and does not result in adverseevents typically observed with receptor inhibitors or Ras pathway inhibitors. We believe that prexigebersen has the potentialto be an ideal combination for any number of cancer therapeutics where the Ras pathway is aberrantly activated and patient fitnessis a major concern, such as in AML.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 9; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            7            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">        <i>         Indications for Acute Myeloid Leukemia (AML),Myelodysplastic Syndrome (MDS)        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <i>         AML - Background and Common Treatments        </i>        .AML is the rapid accumulation of immature myeloid cells in the blood, resulting in a drop of the other cell types such as redblood cells and platelets. The expansion of immature monocytes leaves the patient unable to fight infection. If AML is left untreated,it usually results in death within three months. AML incidence increases with age, with more than 50% of the cases in people age60 or older. AML is the most common acute leukemia in adults, and the National Cancer Institute estimates that approximately 20,000new cases occur each year (Figure 3). The cure rate is between 5 to 15% in older adults, and those who cannot receive the standardcourse of chemotherapy have an average survival rate of five to ten months. Prior to venetoclax approval, the frontline low-intensitytherapies for elderly AML patients were LDAC, decitabine or azacytidine (the latter two drugs are DNA hypomethylating agents).The FDA recently granted approval of venetoclax (a Bcl-2 inhibitor) for the newly diagnosed AML patients aged 75 years and olderor adults who cannot be treated with intensive induction chemotherapy. Venetoclax is used in combination with LDAC, decitabineor azacytidine. Mutation in the Bcl-2 binding domain, which reduces venetoclax’s ability to bind to Bcl-2, has been linkedwith venetoclax resistance in CLL patients. Such venetoclax resistance may also occur in AML patients. AML remains an area ofhigh unmet need for both the relapsed and the de novo elderly population who are typically ineligible for induction therapy.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         Figure 3. Basic Statistics for AML        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        <img alt="" src="tm211142d1_10kimg003.jpg"/>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <i>         MDS - Background and Common Treatments.        </i>        MDS is a bone marrow disease, characterized by a reduced number of mature blood cells. MDS is diagnosed in about 15,000 peoplein the United States (“U.S.”) yearly. MDS patients are stratified into different risk groups. Higher risk MDS patientshave a survival of less than two years and, if untreated, can evolve into secondary AML. Secondary AML patients are often olderand treated with DNA hypomethylating agents. Higher risk MDS and secondary AML patients who have progressed from DNA hypomethylatingagents have very poor prognosis. Novel treatment strategies for these patients are needed. The Company expects to design a clinicaltrial in the future evaluating MDS patients with prexigebersen.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <i>         Prexigebersen Development and Treatmentfor Leukemia        </i>        . The safety, pharmacokinetics, and efficacy of our lead DNAbilize        <sup>         ®        </sup>        antisense drug candidate, prexigebersen,was assessed in patients having AML, CML, MDS or ALL in a Phase 1 trial. The Phase 1 clinical trial was a dose-escalating studyto determine the safety and tolerability of escalating doses of prexigebersen. Additionally, the pharmacokinetics and anti-leukemiceffects, including down-regulation of the target Grb2 protein in patient samples, of the drug candidate were determined. Resultsof the clinical study were published in the scientific journal Lancet Haematology in 2018.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <i>         <u>          Phase 1 Clinical Trial         </u>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Two new assays to provide scientific proofof concept of the delivery technology were developed in the Phase 1 clinical trial. The first assay involved a method to measuredown-regulation of the target protein in a patient blood sample that was achieved. The measurement provided critical proof thatDNAbilize® neutral liposome delivery technology delivered the drug substance to the cell and was able to transport it acrossthe cell membrane into the interior to block cellular production of the Grb2 protein. The second assay involved a novel detectionmethod for the drug substance in blood samples to assess the pharmacokinetics of the drug.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 10; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            8            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        In August 2013, we announced thatour DNAbilize® liposomal delivery technology achieved a major milestone in the development of antisense therapeutics basedon a scientific assay confirming that treating patients with our drug candidate prexigebersen inhibits the Grb2 disease-causingtarget protein in patients with blood cancers (Figure 4). Inhibition of the disease-causing protein has the effect of down regulatingthe disease. This will allow for prexigebersen to be used potentially in combination with current frontline treatments. This discoveryalso points to the potential use of a liposomal antisense treatment as a standalone treatment to transform and manage a diseasethat has a disease-causing protein as a chronic disorder. This accomplishment is a potentially significant breakthrough for antisensetherapeutics, whose development, to date, as a class of therapeutics has been severely limited by a lack of a systemic deliverymechanism that can safely distribute the drug throughout the body and deliver the antisense drug substance across the cell membraneinto the interior of the cell. Further, we expect that scientific proof of principle for DNAbilize® may lead to licensingand business development opportunities, supporting our business model.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <i>         Inhibition of Target Grb2 Protein        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 75px">          </td>          <td style="width: 56px; font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Grb2 levels were compared to baseline prior to treatment.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            By end of treatment, prexigebersen decreased Grb2 in 10 out of 12 samples (83%) tested (average reduction 50%).           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">            Phosphorylated ERK (pERK, extracellular signal related kinase),        a protein downstream of the Ras protein, was decreased in 58% of samples.           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">           </p>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         Figure 4. Grb2 Protein and DownstreampERK are        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         Downregulated in Prexigebersen TreatedPatient’s Cells        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         Grb2 levels decreased in 10 out of 12patient samples by end of treatment (EOT)        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         pErk levels decreased in 7 of 12 patientsamples by EOT        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table align="CENTER" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 75%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           Subject          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Prexigebersen             <br/>             (mg/m             <sup>              2             </sup>             )            </b>           </font>          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           Cohort          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           Grb2           <br/>           Decrease           <br/>           (EOT)          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           pERK           <br/>           Decrease           <br/>           (EOT)          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 20%; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           22          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 19%; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           20          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 19%; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           3          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 17%; font: 10pt Times New Roman, Times, Serif; text-align: right">           57          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 17%; font: 10pt Times New Roman, Times, Serif; text-align: right">           0          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           23          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           20          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           3          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           28          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           45          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           24          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           20          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           3          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           47          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           35          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           25          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           40          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           4          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           54          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           91          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           26          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           40          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           4          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           0          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           0          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           27          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           40          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           4          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           34          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           27          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           28          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           60          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           5          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           30          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           54          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           29          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           60          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           5          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           65          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           0          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           30          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           60          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           5          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           43          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           47          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           31          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           90          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           6          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           0          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           0          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           32          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           90          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           6          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           91          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           63          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           34          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           90          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           6          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           40          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           0          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        A Phase 1 clinical trial is typically endedwhen a maximum tolerated dose (“MTD”) is encountered. However, due to the lack of toxicity of prexigebersen, a MTDwas not observed. Lack of toxicity is a major advantage for the drug candidate prexigebersen since it allows higher levels of drugto be administered to the patient, increasing the potential therapeutic benefit. During the Phase 1 trial, 80% of the evaluablepatients had refractory/relapsed AML, having failed at least 6 prior therapies. In our study, 83% of patients showed decreasedcirculating blasts and anti-leukemic activity and eight patients stabilized for extended treatments.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 11; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            9            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <i>         Phase 2 Clinical Trials        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        On February 9, 2015, we announcedthat we began enrollment into the combination therapy Phase 1b clinical trial for prexigebersen in patients with AML. The combinationtherapy Phase 1b clinical trial consisted of two dosing cohorts of prexigebersen (60 mg/m        <sup>         2        </sup>        and 90 mg/m        <sup>         2        </sup>        )to test the safety profile of treating AML patients with prexigebersen in combination with LDAC. Patients ineligible for intensiveinduction therapy are currently treated with LDAC.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        An important outcome of the Phase 1b clinicaltrial was the ability to assess the pharmacokinetics of the drug. On June 6, 2016, we announced that no dose limiting toxicitieswere observed in patients treated with the combination therapy of prexigebersen and LDAC. Of the six evaluable patients from thePhase 1b clinical trial, four patients completed more than two cycles of treatment, three patients achieved CR and two patientshad over 50% decrease in bone marrow blast counts (Figure 5). Pharmacokinetics of prexigebersen demonstrated a half-life at 60mg/m        <sup>         2        </sup>        of 30 hours, significantly better than the 90 mg/m        <sup>         2        </sup>        dose. The final analysis of these data, alongwith the demonstrated reductions in bone marrow blasts, suggested that 60 mg/m        <sup>         2        </sup>        is the appropriate dose for use inthe Phase 2 trial.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         Figure 5. Five out of six patients incohorts 7 and 8 receiving the combination         <br/>         prexigebersen + LDAC have greater than 50% decrease in bone marrow blasts        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        <img alt="" src="tm211142d1_10kimg005.jpg"/>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        A summary of the clinical trial resultsfor the Phase 1 monotherapy for indications of AML, CML, MDS and ALL, and Phase 1b combination therapy for prexigebersen for indicationsof AML is shown in Figure 6 below. The first six cohorts, patients 001 to 034, were treated in the Phase 1 clinical trial usingprexigebersen as a monotherapy. The seventh cohort, patients 035, 037 and 038, were treated in our Phase 1b clinical trial evaluatingthe combination therapy of 60 mg/m        <sup>         2        </sup>        prexigebersen. The eighth cohort, patients 039, 040 and 041, were treated withcombination therapy of 90 mg/m        <sup>         2        </sup>        .       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 12; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            10            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         Figure 6. Summary Cohorts 1-8 PrexigebersenClinical Trial Phase 1 and 1B        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table align="CENTER" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="5" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           Peripheral or bone           <br/>           marrow blast %          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           Patients          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           Diagnosis          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           Baseline          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           Nadir          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <b>             Off-             <br/>             Tx            </b>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">           </p>          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           Reason           <br/>           Discontinued          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           Cycles           <br/>           Completed          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 14%; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           1          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">          </td>          <td style="width: 14%; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           CML          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">          </td>          <td style="width: 14%; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           51          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 13%; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           No          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 13%; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           97          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">          </td>          <td style="width: 13%; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           DLT          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">          </td>          <td style="width: 13%; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           &lt;1          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           6          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           AML          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           15          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           2          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           5          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           PD          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           5          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           7          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           MDS          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           8          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           4          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           6          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           PD          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           5          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           10          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           AML          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           23          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           10          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           10          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           PD          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           1          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           11          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           CML          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           7          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           No          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           50          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           PD          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           1          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           14          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           AML          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           48          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           5          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           21          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           PD          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           1          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           15          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           AML          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           54          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           31          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           72          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           PD          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           1          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           20          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           AML          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           76          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           5          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           63          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           PD          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           1          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           21          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           AML          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           71          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           43          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           74          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           PD          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           2          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           22          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           AML          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           1          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           0          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           1          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           PD          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           2          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           23          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           MDS          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           NE          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           NE          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           NE          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           PD          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           1          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           24          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           MDS          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           0          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           0          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           0          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           PD          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           5          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           25          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           AML          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           10          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           3          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           19          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           PD          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           2          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           26          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           AML          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           11          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           No          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           80          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           PD          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           1          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           27          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           AML          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           93          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           No          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           97          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           PD          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           1          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           28          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           AML          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           96          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           93          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           98          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           PD          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           1          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           29          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           AML          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           35          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           7          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           24          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           PD          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           1          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           30          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           AML          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           51          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           17          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           82          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           PD          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           1          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           31          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           AML          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           17          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           No          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           17          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           PD          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           1          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           32          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           AML          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           24          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           22          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           22          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           PD          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           2          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           34          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           AML          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           66          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           ND          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           ND          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           PD          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           1          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           35          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           AML          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           17          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           2          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           2          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           CRi          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           1          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           37          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           AML          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           25          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           33          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           ND          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           PD          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           1          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           38          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           AML          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           23          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           2          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           3          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           CR          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           5          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           39          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           AML          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           36          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           16          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           58          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           SD          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           3          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           40          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           AML          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           31          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           2          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           2          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           CR          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           3          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           41          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           AML          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           18          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           9          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           14          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           SD          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3.25pt">           3          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Nadir: the lowest point, Off-TX: off treatment, No: no reductionin blasts, DLT: dose limiting toxicity, PD: progressive disease, NE: not enough sample to evaluate, ND: not done, CR: completeremission with incomplete hematologic recovery, CR: complete remission, SD: stable disease       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Results from the Phase 1b clinical trialdemonstrated it is safe to add prexigebersen to LDAC, which appears to yield better response rates in this AML patient population.On November 2, 2016, we announced that the first patient in the efficacy portion of the Phase 2 trial was dosed. The fulltrial design includes approximately 54 evaluable patients with an interim analysis to be performed after 19 patients are treatedwith the combination. The multi-site trial was conducted at leading cancer centers, among them are Weill Medical College of CornellUniversity, Baylor Scott &amp; White Health, The University of Kansas, New Jersey Hematology Oncology Associates, West VirginiaUniversity/Mary Babb Randolph Cancer Center, and MD Anderson.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Thirty-three patients were pre-screenedfor the efficacy portion of the Phase 2 prexigebersen + LDAC combination study. Thirty patients were enrolled and 17 patientswere deemed evaluable. The interim data that we released on March 6, 2019 showed that 11 (65%) of the 17 evaluable patientshad a response, including five (29%) who achieved CR, including one CR        <sub>         i        </sub>        and one morphologic leukemia free state, andsix (35%) stable disease responses, including two patients who had greater than a 50% reduction in bone marrow blasts. The efficacydata from the 17 evaluable patients was very favorable compared to the reported CR, CRp and CRi rates of 7 to 13% with LDAC treatmentalone. Importantly, through investigation by the principal investigators, it was observed that 68% of patients were secondaryAML patients, a difficult class to treat.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Results to date have shown prexigebersen,with its efficacy and excellent safety profile, to be an effective combination candidate with frontline therapy. However, DNAhypomethylating agents are now the most frequently used agents in the treatment of elderly AML patients in the U.S. and Europe.As a result, we amended Stage 2 of the Phase 2 trial in AML to remove the combination treatment of prexigebersen and LDAC andreplace it with the combination treatment of prexigebersen and decitabine. Since decitabine is also used as a treatment for relapsed/refractoryAML patients, a cohort of relapsed/refractory AML patients was also added to the study.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        We believe the recent approval of the frontlinevenetoclax and decitabine combination therapy provides an opportunity for combining prexigebersen with the combination therapyfor the treatment of        <i>         de novo        </i>        AML patients. Preclinical testing of prexigebersen with venetoclax and decitabine demonstratedthe potential to enhance efficacy of the frontline treatment combination. The triple combination of prexigebersen, venetoclax anddecitabine showed significant improvement in decreasing the viability of three of the four AML cell lines tested. Bio-Path’sapproved amended Stage 2 for this Phase 2 clinical trial has three cohorts of patients. The first two cohorts will treat patientswith the triple combination of prexigebersen, decitabine and venetoclax with the first cohort including untreated AML patientsand the second cohort including relapsed/refractory AML patients. Finally, the third cohort will treat relapsed/refractory AMLpatients who are venetoclax-resistant or -intolerant with the two-drug combination of prexigebersen and decitabine.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 13; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            11            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Split-Segment; Name: 2 -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The first step in establishing the amendedStage 2 of the Phase 2 trial in AML was demonstrating the safety of treating patients with the two-drug combination of prexigebersenand decitabine, which was reported in November 2019. The safety segment of Stage 2 of the Phase 2 clinical trial comprisedsix evaluable patients who were treated with the combination of prexigebersen and decitabine. Although the treatment combinationof prexigebersen and decitabine is not the treatment planned for the efficacy evaluation of Stage 2 of the Phase 2 clinical trial,the efficacy profile in this safety segment of the study was encouraging with 50% of patients having a response, including twocomplete responses (33%) with incomplete hematologic recovery and one patient (17%) showing partial response. For reference, inthis class of AML patients, the complete response rate to treatment with decitabine alone is approximately 20%.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Importantly, results from patients whowere previously treated with the two-drug combination of prexigebersen and decitabine prior to the amendment to Stage 2 of thePhase 2 trial in AML and who meet the criteria for enrollment in the third cohort of the amended Stage 2 of the Phase 2 trialin AML can be included in the third cohort results. This represents a beneficial head-start in the third cohort enrollment. Thisthird cohort represents a significant, unmet opportunity in clinical treatment, as options are limited for AML patients who failfrontline therapy.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        On August 13, 2020, we announced theenrollment and dosing of the first patient in the amended Stage 2 of the Phase 2 clinical study. This patient was in the relapsed/refractorycohort and treated with the triple combination of prexigebersen, decitabine and venetoclax. Additionally, the first six evaluablepatients in the amended Stage 2 of the Phase 2 trial in AML have now been treated with the triple combination of prexigebersen,decitabine and venetoclax to test the safety of this treatment combination. Pending safety review, the dosing of the triplet combinationwill continue as planned.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Development of new therapeutics for AMLcan meet currently unmet needs for patients who have very few treatment options due to age, fitness or treatment-resistance ofadvanced genetically unstable cells. Elderly patients unfit to receive a stem cell transplant or induction therapy face a likelihoodof relapse to a more resistant leukemia. Prexigebersen and DNAbilize        <sup>         ®        </sup>        technology offer new hope for achieving remissionfor fragile populations. We believe that the combination of prexigebersen with frontline chemotherapy can provide a way to treatcancer without added toxicity so that the patient can remain under treatment long enough to reach complete remission.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <b>         <i>          PREXIGEBERSEN-A         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Data supports a prominent role of Grb2in the progression of solid tumors, and overexpression of Grb2 has been associated with chemosensitivity, poor prognosis and advanceddisease in several malignancies including gynecologic malignancies.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <i>         Indications for Solid Tumors (e.g.,Ovary, Endometrium)        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Ovarian cancer is one of the most commontype of gynecologic malignancies, with 50% of all cases occurring in women older than 63 years. It is the fifth most frequentcause of cancer death in women. In the U.S., 21,750 new cases of and 13,940 deaths from ovarian cancer were expected in 2020.Around 70% of patients diagnosed with ovarian cancer will have a recurrence. Recurrent ovarian cancer is treatable but rarelycurable. The average duration of survival after recurrence of ovarian cancer is less than 2 years. The 5-year survival rate forpatients with recurrent ovarian cancer following standard salvage chemotherapy treatment is less than 10%. Given the poor outcomesof treatment for ovarian cancer, novel drug treatments are urgently needed.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 14; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            12            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Endometrial cancer is the most common gynecologicmalignancy in the U.S. In the U.S., 65,620 new cases of and 12,590 deaths from endometrial cancer were expected in 2020. The majorityof cases are diagnosed at an early stage and are amenable to treatment with surgery alone. However, approximately 50% of advancedstage endometrial cancers will recur. Recurrent endometrial cancer is incurable with currently available standard therapies. Themedian survival for patients with recurrent endometrial carcinoma hardly exceeds 12 months. Novel drug treatments for recurrentendometrial carcinoma are urgently needed.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <i>         Development and Treatment for ovarianand endometrial cancer        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Grb2 may be a novel potential therapeutictarget for ovarian and endometrial cancer, and prexigebersen-A may provide clinical benefit against these gynecologic malignancies.Preclinical experiments were conducted in collaboration with leaders in the field of ovarian cancer at MD Anderson. Results ofthe preclinical study were published in the scientific journal Oncotarget in July 2020. Prexigebersen-A effectively penetratedovarian tumors and decreased target Grb2 protein level in preclinical ovarian tumor models. Prexigebersen-A was demonstrated toreduce tumor burden both as a monotherapy and in combination with paclitaxel, a therapy commonly used to treat patients with advancedovarian or endometrial cancer. In late 2019, we filed an IND application to initiate a Phase 1 clinical trial of prexigebersen-Ain patients with advanced or recurrent solid tumors. This trial is expected to commence after the IND has been cleared by theFDA, which we currently anticipate being in 2021, at several leading cancer centers and will evaluate the safety of prexigebersen-Ain these patients. Assuming positive Phase 1 results, we expect that we would advance to a Phase 1b clinical trial of prexigebersen-Ain combination with paclitaxel in patients with recurrent ovarian or endometrial tumors.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <i>         Indications for Triple Negative BreastCancer (TNBC) and Inflammatory Breast Cancer (IBC)        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <i>         TNBC and IBC - Background and CommonTreatments        </i>        . Approximately 15 to 20% of breast cancers fall into the category of triple-negative. TNBC tumors do not expressestrogen receptors, progesterone receptors, and low human epidermal growth factor receptor 2 (HER2). These negative indicatorsmean that the growth of the cancer is not supported by the hormones estrogen and progesterone, or by the presence of HER2 receptors.Therefore, TNBC does not respond to hormonal therapy or therapies that target HER2 receptors. In addition, TNBC tumors are veryaggressive. IBC is a rare and very aggressive type of breast cancer that accounts for 2 to 5% of all breast cancers. A lack oftargeted treatments for these types of breast cancer has led to development of new therapeutics currently in clinical trials.Overexpression of receptor tyrosine kinases has been reported for TNBC and IBC. Since Grb2 is vital in the cancer signaling ofreceptor tyrosine kinases, the Company and collaborators at MD Anderson are interested in developing prexigebersen-A as a potentialtreatment for TNBC and IBC.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">        <font style="text-transform: uppercase">         <b>          <i>           BP1002          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        BP1002, also known by its scientific nameas Liposomal Bcl-2, is our second liposome delivered antisense drug candidate. BP1002 is intended to target the lymphoma, CLLand certain solid tumor markets. We believe that BP1002 has the potential to treat 40 to 60% of solid tumors.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Bcl-2 is a protein that is involved inregulating apoptosis, or programmed cell death. Apoptosis is a physiologic mechanism of cell turnover by which cells activelycommit suicide in response to aberrant external signals. Over-expression of Bcl-2 prevents the induction of apoptosis in responseto cellular insults such as treatment with chemotherapeutic agents. Bcl-2 is over-expressed in more than 90% of follicular lymphoma(FL) due to a chromosomal rearrangement and is the key factor in the initiation of this malignancy. Bcl-2 was also found to contributeto the pathophysiology of other lymphomas, such as CLL, mantle cell lymphoma, Waldenströms macroglobulinemia and double-hitdiffused large B-cell lymphoma, all of which are subtypes of non-Hodgkin’s lymphoma (NHL).       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <i>         Non-Hodgkin’s Lymphoma - Backgroundand Common Treatments.        </i>        Lymphoma can start anywhere in the body where lymph tissue is found. The major sites of lymph tissueare lymph nodes, bone marrow, spleen, thymus, adenoids and tonsils and the digestive tract. NHL is a term used for many differenttypes of lymphoma that share some common characteristics. In the U.S., approximately 77,240 new cases of and 19,940 deaths fromNHL were expected in 2020 (Figure 7). Approximately 40% of NHLs are indolent lymphomas and approximately 60% are more aggressivelymphomas. Indolent lymphomas grow and spread slowly. Some indolent lymphomas might not need to be treated right away but canbe monitored closely instead. On the other hand, aggressive lymphomas usually need to be treated right away, as they grow andcan spread quickly to other parts of the lymph system or to other parts of the body, such as the liver, brain or bone marrow.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 15; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            13            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         Figure 7. Basic statistics of Non-Hodgkin’sLymphoma        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <img alt="" src="tm211142d1_10ksp03img001.jpg" style="height: 178px; width: 624px"/>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <i>         BP1002 - Development and Treatment forlymphoma        </i>        . On December 22, 2014, we announced that we initiated development of BP1002 as a treatment for refractory/relapsedpatients with NHL (including CLL, mantle cell lymphoma, Waldenströms macroglobulinemia, diffused large B-cell lymphoma, peripheralT-cell lymphoma, cutaneous T-cell lymphoma, and marginal zone lymphoma) and Hodgkin’s lymphoma.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Therapies that directly and specificallyblock or inhibit protein synthesis of Bcl-2 could be transformative for NHL. Previous attempts at a Bcl-2 antisense by Genta Inc.and ProNAi failed to show an improvement in remission or overall survival rates. The Genta antisense was a phosphorothioate DNAwith dose-limiting toxicity and it also did not have a lipid delivery mechanism to aid in prevention of clearance by the liver,reducing the levels of antisense reaching diseased cells. The ProNAi antisense was administered with an anionic, pH-tunable liposome.The drug was tolerable but its low response rate in DLBCL patients in a Phase 2 study prompted the company to discontinue furtherclinical development. We believe that BP1002 overcomes the failures of previous antisense attempts at inhibiting Bcl-2. With BP1002,more drug substance can reach the lymphoma cells so that the cancer cells can be treated with a safe and therapeutically relevantdose. The small molecule Bcl-2 inhibitor venetoclax was approved by the FDA in June 2018 for the treatment of patients withCLL and SLL who have received at least one prior therapy. In May 2019, the FDA approved venetoclax in combination with obinutuzumabfor the treatment of adult CLL and SLL patients with previously untreated disease. However, treatment with venetoclax can leadto the development of drug resistance, resulting in disease recurrence. One of the proposed mechanisms of venetoclax resistanceis an acquired mutation in Bcl-2, which reduces venetoclax’s ability to bind and inhibit Bcl-2. Because BP1002 activityis based on blocking the Bcl-2 messenger RNA and BP1002 targets Bcl-2 at a site different from venetoclax, we expect BP1002 toovercome such venetoclax resistance mechanism and be an effective approach for patients who have relapsed from venetoclax. Webelieve BP1002 provides a new tool for cancer treatment for not just lymphomas, but also many cancers for which Bcl-2 expressionis driving cell survival. The introduction of a new, non-toxic, and specific Bcl-2 inhibitor could be a major advance in cancertherapeutics.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        On November 21, 2019 we announcedthat the FDA cleared an IND application for BP1002. An initial Phase 1 clinical trial will evaluate the ability of BP1002 to treatrefractory/relapsed lymphoma and CLL patients. The Phase 1 clinical trial is being conducted at several leading cancer centers,including MD Anderson, the Georgia Cancer Center and the Sarah Cannon Research Institute and is now open for enrollment. Initially,a total of six evaluable patients are scheduled to be treated with BP1002 monotherapy in a standard 3+3 design, with a startingdose of 20 mg/m        <sup>         2        </sup>        . The approved treatment cycle is two doses per week over four weeks, resulting in eight doses administeredover twenty-eight days.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">        <font style="text-transform: uppercase">         <b>          <i>           BP1003          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        BP1003 is our thirdliposome delivered antisense drug candidate. BP1003 is a DNAbilize        <sup>         ®        </sup>        RNAi nanoparticle containing antisense DNAtargeting STAT3, whose elevated expression/activity is associated with a poorer survival outcome for patients with solid tumors,including those of gastric cancer, lung cancer, hepatic cancer, osteosarcoma, prostate cancer and pancreatic adenocarcinoma (PDAC).We believe that a therapeutic that shuts down the STAT3 protein can have significant clinical impact for solid tumors that haveelevated expression/activity of STAT3.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 16; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            14            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Our lead indication for BP1003 is pancreaticcancer due to the severity of this disease and the lack of effective, life-extending treatments. PDAC is a cancer of the exocrinecells of the pancreas. In the U.S. in 2020, approximately 57,600 people were diagnosed with PDAC, and approximately 47,050 (82%)died from the disease. It is estimated that less than 10% of PDAC patients survive beyond 5 years, and it is projected that by2030, PDAC will become the second most lethal cancer behind lung cancer. Treatment of the disease is hampered by the locationof the pancreas, which is difficult to reach with conventional therapies and the fibrotic nature of the tumors, which protectsthem from penetration by chemotherapeutics. We believe a novel and unconventional therapeutic is needed to overcome these barriersto treatment.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        While competition for therapeutics thattarget the STAT3 pathway exist, the competition for specific STAT3 inhibitors is very small. Many peptides designed to bind toSTAT3 suffered from poor intrinsic pharmacokinetic properties, including poor cellular permeability and lack of stability in vivo,which curtailed their further development. Even second-generation peptidomimetics have failed to overcome these limitations. Mostcompounds under development target the pathway upstream of STAT3, such as the JAK2 kinase. However, lack of efficacy of the JAK2kinase inhibitors was observed in PDAC clinical studies. Ionis Pharmaceuticals, Inc. has developed an antisense DNA-basedSTAT3 inhibitor called IONIS-STAT3-2.5Rx. It is being evaluated in clinical trials by AstraZeneca under the name AZD9150 for solidtumors and NHL. However, due to the toxicity of the DNA chemistry, thrombocytopenia continues to limit the systemic delivery andefficacy of such compounds for the treatment of cancer. We believe BP1003 avoids these complications.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        We hypothesized that the natural lipiddelivery vesicle would have unique characteristics that would allow for penetration of the fibrotic stroma to reach the PDAC cells.An abstract of the preclinical study was presented in the 2019 American Association for Cancer Research Annual Meeting. Our preclinicalwork demonstrated that BP1003 was successful in crossing the scar tissue matrix and delivering antisense drug into the tumor tissue.Subsequent studies evaluating the combination of BP1003 with gemcitabine, a standard of care for PDAC patients with metastaticdisease, suggest that the regimen has synergistic anti-tumor effects. We expect to complete several IND enabling studies of BP1003in 2021. If those studies are successful, our goal is to file an IND in late 2021 for the first-in-humans Phase 1 study of BP1003in patients with refractory, metastatic solid tumors. Assuming positive Phase 1 results, we expect that we would advance to aPhase 1b clinical trial of BP1003 in combination with gemcitabine in patients with refractory metastatic pancreatic cancer.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        We believe that the excellent safety profileof the DNAbilize        <sup>         ®        </sup>        chemistry, the novel lipid formula that allows for penetration of the tumor stroma, and the abilityto target a single protein with precision, makes BP1003 an ideal candidate for combination with approved treatments to extendsurvival while maintaining quality of life for the patient.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">        <font style="text-transform: uppercase">         <b>          <i>           DNAbilize           <sup>            ®           </sup>          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        DNAbilize        <sup>         ®        </sup>        technology isavailable for out-licensing. We intend to apply our drug delivery technology template to new disease-causing protein targets asa means to develop new liposomal antisense drug candidates. A new product identification template was recently approved that definesa process of scientific, preclinical, commercial and intellectual property evaluation of potential new drug candidates for inclusioninto our drug product development pipeline. A significant amount of capital is expected to be allocated to in-license promisingprotein targets that can be developed as new liposomal antisense drug candidates. As we expand, we will look at indications wherea systemic delivery is needed and antisense can be used to slow, reverse or cure a disease, either alone or in combination withanother drug. On September 25, 2019, we announced that the USPTO issued a patent for claims related to DNAbilize®, includingits use in the treatment of cancers, autoimmune diseases and infectious diseases. This is the second patent issued to the Company.On October 22, 2020, we announced that the USPTO issued a Notice of Allowance for U.S. Patent Application No. 16/333,221entitled “Combination Therapy with Liposomal Antisense Oligonucleotides.” Additionally, on February 10, 2021,we announced that the USPTO granted U.S. Patent No. 10,898,506 titled, “P-ethoxy nucleic acids for liposomal formulation.”The new patent builds on earlier patents granted that protect the platform technology for DNAbilize        <sup>         ®        </sup>        , the Company’snovel RNAi nanoparticle drugs.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 17; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            15            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        We are interested in pursuing a wide-ranging,proactive licensing program to include co-development of specific liposomal antisense drug candidates, sub-licensing our deliverytemplate for outside development of liposomal antisense drug candidates or out-licensing a partially-developed drug candidatefor final development and marketing.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Research and Development        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Our research and development expense primarilyconsists of third-party clinical, preclinical and manufacturing development activities, salaries and benefits expense and stock-basedcompensation. As we advance and expand our pipeline of drug candidates, we anticipate our research and development expenses willcontinue to increase in conjunction with these activities. Research and development expenses incurred during the years ended December 31,2020 and 2019 were $6.6 million and $4.6 million, respectively.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Manufacturing        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        We do not own or operate, and currentlyhave no plans to establish, any manufacturing facilities. Accordingly, we have no ability to internally manufacture the drug candidatesthat we need to conduct our clinical trials. For the foreseeable future, we expect to continue to rely on third-party manufacturersand other third parties to produce, package and store sufficient quantities of our drug candidates and any future drug candidatesfor use in our clinical trials. We have entered into agreements with third-party manufacturers for the manufacture of our drugrequirements, including agreements for the manufacture of prexigebersen for use in our Phase 2 clinical trial in AML, as wellas agreements for the manufacture of BP1002, BP1003 and prexigebersen-A for use in our Phase 1 clinical trials. However, we mayface various risks and uncertainties in connection with our reliance on third-party manufacturers, as discussed in “Item1A. Risk Factors” of this Annual Report on Form 10-K under the heading “Risks Related to Manufacturing Our DrugCandidates.” If the FDA or other regulatory agencies approve any of our drug candidates for commercial sale, we expect thatwe would continue to rely, at least initially, on third-party manufacturers to produce commercial quantities of such approveddrug candidates. However, we may in the future elect to manufacture certain of our drug candidates in our own manufacturing facilities.If we do so, we will require substantial additional funds and need to recruit qualified personnel in order to build or lease andoperate any manufacturing facilities.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Sales and Marketing        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        We currently do not have any commercialdrug products or an organization for the sales and marketing of pharmaceutical products. In order to successfully commercializeany drug candidates that may be approved in the future by the FDA or comparable foreign regulatory authorities, we must buildour sales and marketing capabilities or make arrangements with third parties to perform these services. For certain drug candidatesin selected indications where we believe that an approved product could be commercialized by a specialty sales force that callson a limited but focused group of physicians, we may commercialize these products ourselves. However, in therapeutic indicationsthat require a large sales force selling to a large and diverse prescribing population, we may enter into arrangements with othercompanies for commercialization. If we are unable to establish adequate sales, marketing and distribution capabilities, whetherindependently or with third parties, we may not be able to generate product revenue and may not become profitable.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Intellectual Property        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Patents, trademarks, trade secrets, technology,know-how and other proprietary rights are important to our business. Our success depends in large part on our ability to obtainand maintain patent protection both in the U.S. and in other countries for our drug candidates and on our ability to operate withoutinfringing the proprietary rights of third parties. Our ability to protect our drug candidates from unauthorized or infringinguse by third parties depends in substantial part on our ability to obtain and maintain valid and enforceable patents.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 18; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            16            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        We rely on trade secrets to protect ourtechnology, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficultto protect. In order to protect our proprietary technology and processes, we also rely in part on confidentiality and intellectualproperty assignment agreements with our corporate partners, employees, consultants, outside scientific collaborators, sponsoredresearchers and other advisors. These agreements may not effectively prevent disclosure of confidential information nor resultin the effective assignment to us of intellectual property, and may not provide an adequate remedy in the event of unauthorizeddisclosure of confidential information or other breaches of the agreements. In addition, others may independently discover ourtrade secrets and proprietary information, and in such case we could not assert any trade secret rights against such party. Tothe extent that we enter into out-license and in-license agreements in the future, our success will depend in part on the abilityof our licensors to obtain, maintain and enforce patent protection for their intellectual property, in particular, any patentsto which we secure exclusive rights.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        We have expanded our intellectualproperty portfolio by filing patent applications that are applicable to our technology and business strategy. We announced onSeptember 25, 2019 that the USPTO issued a patent for claims related to DNAbilize        <sup>         ®        </sup>        , including its use inthe treatment of cancers, autoimmune diseases and infectious diseases. Additionally, on February 10, 2021, we announcedthat the USPTO granted U.S. Patent No. 10,898,506 titled, “P-ethoxy nucleic acids for liposomalformulation.” The new patent builds on earlier patents granted that protect the platform technology forDNAbilize        <sup>         ®        </sup>        , the Company’s novel RNAi nanoparticle drugs. Our patent portfolio currently includes threeissued patents (No. 9,744,187, No. 10,335,428 and No. 10,898,506) in the U.S. for claims related toDNAbilize        <sup>         ®        </sup>        , as well as four additional pending patents for composition and methods of use of specific drugtargets. We announced on October 22, 2020 that the USPTO issued a Notice of Allowance for U.S. Patent ApplicationNo. 16/333,221 entitled “Combination Therapy with Liposomal Antisense Oligonucleotides.” There can be noassurances that patents related to our existing patent applications or applications we may file in the future will be issuedor that any issued patents will provide meaningful protection for our drug candidates, which could materially and adverselyaffect our competitive business position, business prospects and financial condition.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        In the U.S., individual patents extendfor varying periods of time depending on the date of filing of the patent application or the date of patent issuance. Generally,patents issued in the U.S. are effective for 20 years from the earliest non-provisional filing date. In addition, a patent termcan sometimes be extended to recapture a portion of the term effectively lost during the FDA’s regulatory review period;however, the restoration period cannot be longer than five years, and the total patent term cannot exceed 14 years following FDAapproval.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Employees        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        We currently employ ten full-time employees.We also have contractual relationships with additional professionals who perform certain medical officer, regulatory, drug developmentand administrative duties. We believe relations with such professionals and employees are good.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Competition        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        We are engaged in segments of the pharmaceuticaland biotechnology industry that are highly competitive and characterized by rapid and significant technological change. Many largepharmaceutical and biotechnology companies, academic and research institutions, governmental agencies and other public and privateresearch organizations are pursuing the development of novel drugs that target AML, MDS, CML, lymphoma, ovarian and breast cancer,solid tumors, and other cancers generally. We face, and expect to continue to face, intense and increasing competition as newproducts enter the market and advanced technologies become available. Our competitors may discover, develop or commercialize productsor other novel technologies that are more effective, safer or less costly than our drug candidates. Our competitors may also obtainFDA or other regulatory approval for their products more rapidly than we may obtain approval for our drug candidates.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 19; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            17            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Many of our competitors have:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 10%">          </td>          <td style="width: 2%; font-size: 10pt">           <font style="font: 10pt Symbol">            ·           </font>          </td>          <td style="width: 88%; font-size: 10pt">           <font style="font: 10pt Times New Roman, Times, Serif">            significantly greater capital, technical and human resources than we have and may be better equipped to discover, develop, manufacture and commercialize drug candidates;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font: 10pt Symbol">            ·           </font>          </td>          <td style="font-size: 10pt">           <font style="font: 10pt Times New Roman, Times, Serif">            more experience in drug discovery, development and commercialization, obtaining regulatory approvals and manufacturing and marketing pharmaceutical products;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font: 10pt Symbol">            ·           </font>          </td>          <td style="font-size: 10pt">           <font style="font: 10pt Times New Roman, Times, Serif">            drug candidates that have been approved or are in late-stage clinical development; and/or           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font: 10pt Symbol">            ·           </font>          </td>          <td>           collaboration arrangements in our target markets with leading companies and research institutions.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Mergers and acquisitions in the pharmaceuticaland biotechnology industry may result in even more resources being concentrated among a smaller number of our competitors. Smalleror early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with largeand established companies. These competitors also compete with us in recruiting and retaining qualified scientific and managementpersonnel, establishing clinical trial sites and patent registration for clinical trials, and acquiring technologies complementaryto, or necessary for, our drug candidates and programs.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Competitive products and technologicaldevelopments may render our drug candidates noncompetitive or obsolete before we can recover the expenses of developing and commercializingour drug candidates. Furthermore, the development of new treatment methods and/or the widespread adoption or increased utilizationof any vaccine for the diseases we are targeting could render our drug candidates noncompetitive, obsolete or uneconomical. Ifwe successfully develop and obtain approval for any of our drug candidates, we will face competition based on the safety and effectivenessof our drug candidates, the timing of their entry into the market in relation to competitive products in development, the availabilityand cost of supply, marketing and sales capabilities, reimbursement coverage, price, patent position and other factors. If wesuccessfully develop drug candidates but those drug candidates do not achieve and maintain market acceptance, our business willnot be successful.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Government Regulation        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">        <b>         <i>          Overview         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Government authorities in the U.S., atthe federal, state and local level, and other countries extensively regulate, among other things, the research, development, testing,manufacture, labeling, record keeping, packaging, promotion, storage, advertising, distribution, marketing and export and importof products such as those we are developing. The nature and extent to which such regulations will apply to us will vary dependingon the nature of any drug candidates we develop. We anticipate that all of our drug candidates will require regulatory approvalby governmental agencies prior to commercialization. This process and subsequent compliance with appropriate federal, state, local,and foreign statutes and regulations will require the expenditure of substantial time and financial resources.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">        <b>         <i>          U.S. Drug Development Process         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        In the U.S., drugs are subject to rigorousregulation by the FDA under the Federal Food, Drug and Cosmetic Act (the “FDCA”), and implementing regulations, aswell as other federal and state statutes. Failure by us or our collaborators to comply with the applicable U.S. requirements atany time during the drug candidate development process, approval process or after approval, may subject us to administrative orjudicial sanctions. These sanctions could include the FDA’s refusal to approve pending applications, license suspensionor revocation, withdrawal of an approval, a clinical hold, warning letters, product recalls, product seizures, total or partialsuspension of production or distribution, injunctions, fines, civil penalties or criminal prosecution. Any agency or judicialenforcement action could have a material adverse effect on us.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 20; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            18            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The process required by the FDA beforea new drug may be marketed in the U.S. generally involves the following:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 10%">          </td>          <td style="width: 2%; font-size: 10pt">           <font style="font: 10pt Symbol">            ·           </font>          </td>          <td style="width: 88%; font-size: 10pt">           <font style="font: 10pt Times New Roman, Times, Serif">            completion of preclinical laboratory tests, animal studies and formulation studies according to FDA’s Good Laboratory Practice regulations;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font: 10pt Symbol">            ·           </font>          </td>          <td style="font-size: 10pt">           <font style="font: 10pt Times New Roman, Times, Serif">            submission of an IND, which must become effective before human clinical trials may begin and which must include approval by an institutional review board at each clinical site before the trials are initiated;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font: 10pt Symbol">            ·           </font>          </td>          <td style="font-size: 10pt">           <font style="font: 10pt Times New Roman, Times, Serif">            performance of adequate and well-controlled human clinical trials according to FDA’s Good Clinical Practice (“GCP”) regulations to establish the safety and efficacy of the proposed drug for its intended use;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font: 10pt Symbol">            ·           </font>          </td>          <td style="font-size: 10pt">           <font style="font: 10pt Times New Roman, Times, Serif">            submission to, and acceptance by, the FDA of a new drug application (an “NDA”);           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font: 10pt Symbol">            ·           </font>          </td>          <td style="font-size: 10pt">           <font style="font: 10pt Times New Roman, Times, Serif">            completion of an FDA inspection of the manufacturing facility or facilities at which the drug is produced to assess compliance with current Good Manufacturing Practice (“cGMP”) regulations to assure that the facilities, methods and controls are adequate to preserve the drug’s identity, strength, quality and purity; and           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font: 10pt Symbol">            ·           </font>          </td>          <td>           FDA review and approval of the NDA.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <i>         Pre-Approval Studies        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Once a drug candidate is identified fordevelopment, it enters the preclinical testing stage. Preclinical tests include laboratory evaluations of drug candidate chemistry,toxicity and formulation, as well as animal studies. Prior to beginning human clinical trials, an IND sponsor must submit an INDto the FDA, which includes submitting the results of the preclinical tests, together with manufacturing information and analyticaldata. Some preclinical or nonclinical testing may continue even after the IND is submitted. The IND automatically becomes effective30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises concerns or questions about the conductof the trial. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial canbegin. Even after the 30-day time period, the FDA may impose a clinical hold on ongoing clinical trials. If the FDA imposes aclinical hold, clinical trials cannot commence or recommence without FDA authorization and then only under terms authorized bythe FDA. The IND application process may be extremely costly and substantially delay the development of our drug candidates forcertain indications. Moreover, positive results of preclinical tests will not necessarily indicate positive results in subsequentclinical trials in humans. The FDA may require additional animal testing after an initial IND application is approved and priorto Phase 3 trials.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Clinical trials involve the administrationof the IND to volunteers or patients under the supervision of one or more qualified investigators in accordance with FDA’sGCP regulations. Clinical trials must be conducted under protocols detailing the objectives of the trial and the safety and effectivenesscriteria to be evaluated. Each protocol must be submitted to the FDA as part of the IND. Further, an institutional review boardat each institution participating in the clinical trial must review and approve each protocol before any clinical trial commencesat that institution. All research subjects must provide informed consent, and informed consent information must be submitted tothe institutional review board for approval prior to initiation of the trial. Progress reports detailing the results of the clinicaltrials must be submitted at least annually to the FDA and more frequently if adverse events or other certain types of other changesoccur.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Human clinical trials are typically conductedin three sequential phases that may overlap or be combined:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 10%">          </td>          <td style="width: 2%; font-size: 10pt">           <font style="font: 10pt Symbol">            ·           </font>          </td>          <td style="width: 88%; font-size: 10pt">           <font style="font: 10pt Times New Roman, Times, Serif">            <i>             Phase 1:            </i>            The drug candidate is initially introduced into human subjects or patients with the disease and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion. In the case of some drug candidates for severe or life-threatening diseases, the initial human testing is often conducted in patients.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font: 10pt Symbol">            ·           </font>          </td>          <td style="font-size: 10pt">           <font style="font: 10pt Times New Roman, Times, Serif">            <i>             Phase 2:            </i>            Involves studies in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the drug candidate for specific targeted diseases and to determine dosage tolerance and optimal dosage.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font: 10pt Symbol">            ·           </font>          </td>          <td>           <i>            Phase 3:           </i>           Clinical trials are undertaken to further evaluate dosage, clinical efficacy and safety in an expanded patient population, typically at geographically dispersed clinical study sites. These studies are intended to establish the overall risk-benefit ratio of the drug candidate and provide, if appropriate, an adequate basis for product labeling.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 21; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            19            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Phase 1, Phase 2 and Phase 3 testing maynot be completed successfully within any specified period, if at all. The FDA or an institutional review board or the sponsormay suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are beingexposed to an unacceptable health risk.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Concurrent with clinical trials, companiesusually complete additional animal studies and must also develop additional information about the chemistry and physical characteristicsof the drug candidate and finalize a process for manufacturing the product in accordance with cGMP requirements. The manufacturingprocess must be capable of consistently producing quality batches of the drug candidate and, among other requirements, the manufacturermust develop methods for testing the identity, strength, quality and purity of the final drug. Additionally, appropriate packagingmust be selected and tested and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptabledeterioration over its shelf life.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Our business model relies on developingdrug candidates through Phase 2a and either entering into out-license agreements with pharmaceutical licensee partners who willbe responsible for post-Phase 2 clinical testing and working with the FDA on necessary regulatory submissions resulting in approvalof new drug applications for commercialization, or internally developing a drug candidate through commercialization.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <i>         Approval Process        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        After successful completion of the requiredclinical trials, an NDA is generally submitted, which is required before marketing of the product may begin in the U.S. The NDAmust include the results of drug development, preclinical studies and clinical studies, together with other detailed information,including information on the chemistry, manufacture and composition of the drug. The FDA has 60 days from its receipt of the NDAto review the application to ensure that it is sufficiently complete for substantive review before accepting it for filing andmay request additional information rather than accept an NDA for filing. If additional information is requested, the NDA mustbe resubmitted. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submissionis accepted for filing, the FDA begins an in-depth substantive review. The submission of an NDA is also subject to the paymentof user fees, which may be waived under certain limited circumstances.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The FDA reviews an NDA that has been acceptedfor filing to determine, among other things, whether a product is safe and effective for its intended use. The approval processfor an NDA is lengthy and the FDA may refuse to approve an NDA if the applicable regulatory criteria are not satisfied or mayrequire additional clinical or other data and information. Even if such data and information is submitted, the FDA may ultimatelydecide that the NDA does not satisfy the criteria for approval. The FDA may also refer applications for drug candidates whichpresent difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and otherexperts, for review, evaluation and a recommendation as to whether the application should be approved. The FDA is not bound bythe recommendation of an advisory committee. Before approving an NDA, the FDA will also inspect the facility or facilities wherethe product is manufactured to determine whether its manufacturing is cGMP-compliant to assure and preserve the product’sidentity, strength, quality, purity and stability.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        There are various programs that are intendedto expedite the development and review of drug candidates, and/or provide for approval on the basis of surrogate endpoints, includingFast Track, breakthrough therapy, priority review and accelerated approval. Even if a drug candidate qualifies for one or moreof these programs, the FDA may later decide that the drug candidate no longer meets the conditions for qualification or that thetime period for FDA review or approval will not be shortened. Generally, drug candidates that may be eligible for these programsare those for serious or life-threatening conditions, those with the potential to address unmet medical needs or those that offermeaningful benefits over existing treatments.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 22; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            20            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Fast Track is a process designed to facilitatethe development, and expedite the review of drug candidates to treat serious diseases and fill an unmet medical need. Breakthroughtherapy requires preliminary clinical evidence that demonstrates the drug candidate may have substantial improvement on at leastone clinically significant endpoint over available therapy. A breakthrough therapy designation conveys all of the Fast Track programfeatures, as well as more intensive FDA guidance on an efficient drug development program. Priority review is designed to givedrug candidates that offer major advances in treatment or provide a treatment where no adequate therapy exists an initial reviewwithin six months as compared to a standard review time of 10 months. Although Fast Track, breakthrough therapy and priority reviewdo not affect the standards for approval, the FDA will attempt to facilitate early and frequent meetings with a sponsor of a FastTrack designated drug candidate and expedite review of the application for a drug candidate designated for priority review. Acceleratedapproval provides an earlier approval of drugs to treat serious diseases and that fill an unmet medical need based on a surrogateendpoint, which is a laboratory measurement or physical sign used as an indirect or substitute measurement representing a clinicallymeaningful outcome. As a condition of approval, the FDA may require that a sponsor of a product receiving accelerated approvalperform post-marketing clinical trials.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        If the FDA evaluations of the applicationand the manufacturing facilities are favorable, the FDA may issue an approval letter or an “approvable” letter. Anapprovable letter will usually contain a number of conditions that must be met in order to secure final approval of the NDA andauthorization of commercial marketing of the drug for certain indications. An approval letter authorizes commercial marketingof the drug with specific prescribing information for a specific indication. As a condition of NDA approval, the FDA may requirepost-approval testing, including Phase 4 trials, and surveillance to monitor the drug’s safety or efficacy and may imposeother conditions, including labeling or distribution restrictions which can materially impact the potential market and profitabilityof the drug. Once granted, product approvals may be withdrawn if compliance with regulatory standards is not maintained or problemsoccur after the product reaches the market. The FDA may also refuse to approve the NDA or issue a “not approvable”letter outlining the deficiencies in the submission and often requiring additional testing or information.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        To date, we have not submitted a marketingapplication for any drug candidate to the FDA or any foreign regulatory agency, and none of our drug candidates have been approvedfor commercialization in any country. We have limited experience in conducting and managing the clinical trials necessary to obtainregulatory approvals, including approval by the FDA. The time required to complete clinical trials and for the FDA’s reviewprocesses is uncertain and typically takes many years. Our analysis of data obtained from preclinical and clinical activitiesis subject to confirmation and interpretation by regulatory authorities, which could delay, limit or prevent regulatory approval.We may also encounter unanticipated delays or increased costs due to government regulation from future legislation or administrativeaction or changes in FDA policy during the period of product development, clinical trials, and FDA regulatory review.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <i>         Timing to Approval        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        We estimate that it generally takes 10to 15 years or possibly longer to discover, develop and bring to market a new pharmaceutical product in the U.S. as outlined below:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr>          <td style="vertical-align: bottom; width: 11%; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Phase:            </b>           </font>          </td>          <td style="vertical-align: top; width: 1%">          </td>          <td style="vertical-align: bottom; width: 69%; text-align: center; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Objective:            </b>           </font>          </td>          <td style="vertical-align: top; width: 1%">          </td>          <td style="vertical-align: top; width: 18%; text-align: center; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Estimated             <br/>             Duration:            </b>           </font>          </td>         </tr>         <tr>          <td style="vertical-align: bottom; font-size: 10pt">          </td>          <td style="vertical-align: top; font-size: 10pt">          </td>          <td style="vertical-align: bottom; text-align: center; font-size: 10pt">          </td>          <td style="vertical-align: top; font-size: 10pt">          </td>          <td style="vertical-align: top; text-align: center; font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top; background-color: #CCEEFF">          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Discovery           </font>          </td>          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Lead identification and target validation.           </font>          </td>          <td>          </td>          <td style="text-align: center; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2 to 4 years           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: white">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="text-align: center; font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top; background-color: #CCEEFF">          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Preclinical           </font>          </td>          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Initial toxicology for preliminary identification of risks for humans; gather early pharmacokinetic data.           </font>          </td>          <td>          </td>          <td style="text-align: center; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1 to 2 years           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: white">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="text-align: center; font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top; background-color: #CCEEFF">          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Phase 1           </font>          </td>          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Test for safety, dosage tolerance, absorption, metabolism, distribution and excretion.           </font>          </td>          <td>          </td>          <td style="text-align: center; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1 to 2 years           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: white">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="text-align: center; font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top; background-color: #CCEEFF">          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Phase 2           </font>          </td>          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Identify possible adverse effects and safety risks; preliminarily evaluate the efficacy of the drug candidate for specific targeted diseases; determine dosage tolerance and optimal dosage.           </font>          </td>          <td>          </td>          <td style="text-align: center; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2 to 4 years           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: white">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="text-align: center; font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top; background-color: #CCEEFF">          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Phase 3           </font>          </td>          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Further evaluate dosage, clinical efficacy and safety in an expanded patient population, typically at geographically dispersed clinical study sites; establish the overall risk-benefit ratio of the drug candidate and provide, if appropriate, an adequate basis for product labeling.           </font>          </td>          <td>          </td>          <td style="text-align: center; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2 to 4 years           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: white">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="text-align: center; font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top; background-color: #CCEEFF">          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            FDA approval           </font>          </td>          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Approval by the FDA to sell and market the drug for the approved indication.           </font>          </td>          <td>          </td>          <td style="text-align: center; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            6 months to 2 years           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 23; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            21            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        A drug candidate may fail at any pointduring this process. Animal and other non-clinical studies typically are conducted during each phase of human clinical trials.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Our business model is primarily focusedon the preclinical to Phase 2a interval. This greatly reduces the time frame for us from in-license of a new, preclinical stagedrug candidate to be developed to out-licensing to a pharmaceutical partner.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <i>         Post-Approval Studies        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Once an approval is granted, the FDA maywithdraw the approval if compliance with regulatory standards is not maintained or if problems occur after the product reachesthe market. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changesand additional labeling claims, are subject to further FDA review and approval. In addition, the FDA may require testing and surveillanceprograms to monitor the effect of approved products that have been commercialized, and the FDA has the power to prevent or limitfurther marketing of a product based on the results of these post-marketing programs.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Any drug products manufactured or distributedby us pursuant to FDA approvals are subject to continuing regulation by the FDA, including, among other things:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 10%">          </td>          <td style="width: 2%; font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="width: 88%; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            record-keeping requirements;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            reporting of adverse experiences with the drug;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            providing the FDA with updated safety and efficacy information;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            drug sampling and distribution requirements;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            notifying the FDA and gaining its approval of specified manufacturing or labeling changes;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            complying with certain electronic records and signature requirements; and           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            complying with FDA promotion and advertising requirements.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Drug manufacturers and their subcontractorsare required to register their establishments with the FDA and some state agencies, and are subject to periodic unannounced inspectionsby the FDA and some state agencies for compliance with cGMP and other laws.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        We rely, and expect to continue to rely,on third parties for the production of clinical quantities of our drug candidates. Future FDA and state inspections may identifycompliance issues at the facilities of our contract manufacturers that may disrupt production or distribution, or require substantialresources to correct.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        From time to time, legislation is drafted,introduced and passed in Congress that could significantly change the statutory provisions governing the approval, manufacturingand marketing of products regulated by the FDA. In addition, FDA regulations and guidance are often revised or reinterpreted bythe agency in ways that may significantly affect our business and our drug candidates. It is impossible to predict whether legislativechanges will be enacted, or FDA regulations, guidance or interpretations changed or what the impact of such changes, if any, maybe.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 24; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            22            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">        <b>         <i>          Foreign Regulations         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Whether or not we obtain FDA approval fora drug candidate, we must obtain the requisite approvals from regulatory authorities in non-U.S. countries prior to the commencementof clinical trials or marketing of our products in those countries. Certain countries outside of the U.S. have a process thatrequires the submission of a clinical trial application (“CTA”), much like an IND, prior to the commencement of humanclinical trials. In the E.U., for example, a CTA must be submitted to the competent national health authority and to independentethics committees in each country in which a company intends to conduct clinical trials. Once the CTA is approved in accordancewith a country’s requirements, clinical trial development may proceed in that country.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The requirements and process governingthe conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country, but typically takesseveral years and requires significant resources. In all cases, the clinical trials must be conducted in accordance with GCP andother applicable regulatory requirements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        To obtain regulatory approval of an investigationaldrug under E.U. regulatory systems, we must submit a marketing authorization application. This application is similar to the NDAin the U.S., with the exception of, among other things, country-specific document requirements. Drugs can be authorized in theE.U. by using (i) the centralized authorization procedure, (ii) the mutual recognition procedure, (iii) the decentralizedprocedure or (iv) national authorization procedures.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The EMA implemented the centralized procedurefor the approval of human drugs to facilitate marketing authorizations that are valid throughout the E.U. This procedure resultsin a single marketing authorization granted by the European Commission that is valid across the E.U., as well as in Iceland, Liechtensteinand Norway. The centralized procedure is compulsory for certain human drugs including those that are: (i) derived from biotechnologyprocesses, such as genetic engineering, or (ii) contain a new active substance indicated for the treatment of certain diseases.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">        <b>         <i>          Reimbursement         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Sales of pharmaceutical products dependin significant part on the availability of third-party reimbursement, which is time consuming and expensive. Reimbursement maynot be available or sufficient to allow us to sell our future products, if any, on a competitive and profitable basis.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The passage of the Medicare PrescriptionDrug and Modernization Act of 2003 (the “MMA”) imposed requirements for the distribution and pricing of prescriptiondrugs for Medicare beneficiaries, which may affect the marketing of our future products, if any. The MMA also introduced a reimbursementmethodology, part of which went into effect in 2004, and a prescription drug plan, which went into effect on January 1, 2006.While the MMA applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy andpayment limitations in setting their own payment rates. Any reduction in payment that results from the MMA may result in a similarreduction in payments from non-governmental payors.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        In addition, in some foreign countries,the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing varywidely from country to country. For example, the E.U. provides options for its member states to restrict the range of medicinalproducts for which their national health insurance systems provide reimbursement and to control the prices of medicinal productsfor human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of director indirect controls on the profitability of the company placing the medicinal product on the market.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        There have been and we expect that therewill continue to be frequent federal and state proposals to impose governmental pricing controls or cost containment measuresfor prescription drugs. While we cannot predict whether such legislative or regulatory proposals will be adopted, the adoptionof such proposals could have a material adverse effect on our business, financial condition and profitability. For example, thePatient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act of 2010,contains provisions that may reduce the profitability of drugs, including, for example, increased rebates for drugs sold to Medicaidprograms, extension of Medicaid rebates to Medicaid managed care plans, mandatory discounts for certain Medicare Part D beneficiariesand annual fees based on pharmaceutical companies’ share of sales to federal health care programs. Even if favorable coverageand reimbursement status is attained for one or more of our drug candidates for which we receive regulatory approval, less favorablecoverage policies and reimbursement rates may be implemented in the future.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 25; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            23            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">        <b>         <i>          Other Regulations         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Pursuant to the Drug Price Competitionand Patent Term Restoration Act of 1984, known as the Hatch-Waxman Act, under certain conditions a sponsor may be granted marketingexclusivity for a period of five years following FDA approval. During this period, third parties would not be permitted to obtainFDA approval for a similar or identical drug through an Abbreviated NDA, which is the application form typically used by manufacturersseeking approval of a generic drug. The Hatch-Waxman Act also permits a patent extension term of up to five years as compensationfor patent term lost during product development and the FDA regulatory review process. However, patent extension cannot extendthe remaining term of a patent beyond a total of 14 years. The patent term restoration period is generally one-half the time betweenthe effective date of an IND and the submission date of an NDA, plus time of active FDA review between the submission date ofan NDA and the approval of that application. Only one patent applicable to an approved drug is eligible for the extension andit must be applied for prior to expiration of the patent and within 60 days of the approval of the NDA.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        In April 2015 and October 2016,prexigebersen received orphan drug designations for AML in the U.S. from the FDA and in the E.U. from the EMA, respectively. Orphandesignation is available in the U.S. to drugs intended to treat, diagnose or prevent a rare disease or condition that affectsfewer than 200,000 people in the U.S. at the time of application for orphan designation. Orphan drug designation must be requestedbefore submitting an application for marketing authorization. Orphan designation qualifies the sponsor of the product for a taxcredit and marketing incentives. The first sponsor to receive FDA marketing approval for a drug with an orphan designation isentitled to a seven-year exclusive marketing period in the U.S. for that product for that indication and, typically, a waiverof the prescription drug user fee for its marketing application. However, a drug that the FDA considers to be clinically superiorto, or different from, the approved orphan drug, even though for the same indication, may also obtain approval in the U.S. duringthe seven-year exclusive marketing period. Orphan drug exclusive marketing rights may also be lost if the FDA later determinesthat the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of thedrug. To receive orphan drug designation from the EMA, a therapy must be intended for the treatment of a life-threatening or chronicallydebilitating rare condition with a prevalence of less than five in 10,000 in the E.U. Orphan drug designation provides incentivesdesigned to facilitate development, including fee reductions for protocol assistance, scientific advice and importantly, may provideup to ten years of market exclusivity in the E.U. following product approval.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        There is no guarantee that any of our otherdrug candidates will receive orphan drug designation or that, even if such drug candidate is granted such status, the drug candidate’sclinical development and regulatory approval process will not be delayed or will be successful.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Pharmaceutical companies are also subjectto various federal and state laws pertaining to health care “fraud and abuse,” including anti-kickback laws and falseclaims laws. Anti-kickback laws make it illegal for any entity or person to solicit, offer, receive, or pay any remuneration inexchange for, or to induce, the referral of business, including the purchase or prescription of a particular drug. False claimslaws prohibit anyone from knowingly and willingly presenting, or causing to be presented, for payment to third party payors, includingMedicare and Medicaid, claims for reimbursed drugs or services that are false or fraudulent, claims for items or services notprovided as claimed, or claims for medically unnecessary items or services.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Company History and Available Information        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The Company was incorporated in May 2000as a Utah corporation. In February 2008, Bio-Path Subsidiary completed a reverse merger with the Company, which at the timewas traded over the counter and had no current operations. The prior name of the Company was changed to Bio-Path Holdings, Inc.and the directors and officers of Bio-Path Subsidiary became the directors and officers of Bio-Path Holdings, Inc. On March 10,2014, our common stock ceased trading on the OTCQX and commenced trading on the Nasdaq Capital Market under the ticker symbol “BPTH.” Effective December 31, 2014, we changed our state of incorporation from Utah to Delaware through a statutoryconversion pursuant to the Utah Revised Business Corporation Act and the Delaware General Corporation Law.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 26; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            24            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        On February 8, 2018, we effected areverse stock split of our outstanding shares of common stock at a ratio of 1-for-10, and our common stock began trading on thesplit-adjusted basis on the Nasdaq Capital Market at the commencement of trading on February 9, 2018. In addition, on January 17,2019, we effected a reverse stock split of our outstanding shares of common stock at a ratio of 1-for-20, and our common stockbegan trading on the split-adjusted basis on the Nasdaq Capital Market at the commencement of trading on January 18, 2019.All common stock share and per share amounts in this Annual Report on Form 10-K have been adjusted to give effect to boththe 1-for-10 reverse stock split and the 1-for-20 reverse stock split, retrospectively.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Our principal executive offices are locatedat 4710 Bellaire Boulevard, Suite 210, Bellaire, Texas 77401, and our telephone number is (832) 742-1357. Our Internet addressis        <i>         www.biopathholdings.com        </i>        . We are not including the information contained in our website as part of, or incorporatingit by reference into, this Annual Report on Form 10-K. We make available free of charge through our website our Annual Reportson Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to these reports filedor furnished pursuant to Section 13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after weelectronically file such materials with, or furnish it to, the SEC. We also make available on our website our Corporate GovernanceGuidelines; the charters for our Audit Committee, Nominating/Corporate Governance Committee and Compensation Committee; our EmployeeCode of Business Conduct and Ethics, which applies to all of our employees, including our executive officers; and our Code ofBusiness Conduct and Ethics for Members of the Board of Directors. All such information is also available in print and free ofcharge to any of our stockholders who request it. In addition, we intend to disclose on our website any amendments to, or waiversfrom, our codes of business conduct and ethics that are required to be publicly disclosed pursuant to rules of the SEC.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="text-transform: uppercase">         <b>          <a name="Seng_003">          </a>          ITEM 1A. RISK FACTORS         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Risk Factor Summary        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We are providing the following summary of the risk factorsdisclosed in this Annual Report on Form 10-K to enhance the readability and accessibility of our risk factor disclosures.We encourage our stockholders to carefully review the risk factors disclosed in this Form 10-K in their entirety for additionalinformation regarding the material factors that make an investment in the Company speculative or risky.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">            The COVID-19 pandemic could adversely impact our business, includingour clinical trials.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">            We are a clinical stage biotechnology company with no significantrevenue. We have incurred significant operating losses since our inception, and we expect to incur losses for the foreseeable futureand may never achieve profitability.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">            We will continue to require substantial additional capital for theforeseeable future. If we are unable to raise additional capital when needed, we may be forced to delay, reduce or eliminate ourdrug development programs and commercialization efforts.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">            The pharmaceutical and biotechnology industry is highly competitive.If we are unable to compete effectively, our drug candidates may be rendered noncompetitive or obsolete.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">            Future collaboration arrangements to leverage our capabilities maynot be successful.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">            If we are unable to attract and retain key management, scientificpersonnel and advisors, we may not successfully develop our drug candidates or achieve our other business objectives.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">            Our employees, agents, consultants and commercial partners may engagein misconduct or other improper activities, including non-compliance with applicable regulatory standards and requirements.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">            We expect to expand our operations, including clinical trials, inthe future and may face challenges in managing our growth, which may result in disruptions to our operations.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">            If we acquire or license technologies, resources or drug candidates,we will incur a variety of costs and may never realize benefits from the transaction.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">            Our business has a substantial risk of product liability claims. Ifwe are unable to obtain or maintain appropriate levels of insurance, a product liability claim could adversely affect our business.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">       </p>       <!-- Field: Page; Sequence: 27; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            25            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">            We are increasingly dependent on information technology systems tooperate our business and a cyber-attack or other breach of our systems, or those of third parties on whom we may rely, could subjectus to liability or interrupt the operation of our business.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">            Our ability to use our net operating loss carryforwards and certainother tax attributes may be limited.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">            Provisions of our charter documents or Delaware law could delay orprevent an acquisition of our company, even if the acquisition would be beneficial to our stockholders, and could make it moredifficult to change management.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">            We face competition from entities that have developed or may developtherapeutic candidates for our target disease indications, including companies developing novel treatments and technology platformsbased on modalities and technology that may be similar to ours. If these companies develop technologies, including delivery technologies,or therapeutic candidates more rapidly than we do, or their technologies are more effective, our ability to develop and successfullycommercialize therapeutic candidates may be adversely affected.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">            We may be subject, directly or indirectly, to certain U.S. federaland state healthcare laws and regulations, such as anti-kickback, false claims laws, physician payment transparency laws or similarfraud and abuse laws, which could expose us to potential criminal sanctions, civil penalties, contractual damages, reputationalharm and diminished profits and future earnings.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">            Inadequate funding for the FDA, the SEC and other government agencies,or a work slowdown or stoppage at those agencies as part of a broader federal government shutdown, could hinder their abilityto hire and retain key leadership and other personnel, prevent new products and services from being developed or commercializedin a timely manner, or otherwise prevent those agencies from performing normal business functions on which the operation of ourbusiness may rely, which could negatively impact our business.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">            We must complete extensive clinical trials to demonstrate the safetyand efficacy of our drug candidates. If we are unable to demonstrate the safety and efficacy of our drug candidates, we will notbe successful.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">            Delays in the commencement of clinical trials of our drug candidatescould result in increased costs to us and delay our ability to generate revenues.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">            Delays in the completion of, or the termination of, clinical trialsof our drug candidates could result in increased costs to us and could delay or prevent us from generating revenues.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">            If we are unable to obtain U.S. and/or foreign regulatory approval,we will be unable to commercialize our drug candidates.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">            In addition to regulations in the U.S., we may be subject to a varietyof regulations in other jurisdictions governing, among other things, clinical trials and any commercial sales and distributionof our products, if approved.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">            Changes in existing laws and regulations affecting the healthcareindustry could increase our costs and otherwise adversely affect our business.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">            We rely on third parties to conduct clinical trials for our drug candidates,and their failure to timely and properly perform their obligations may result in costs and delays that prevent us from obtainingregulatory approval or successfully commercializing our drug candidates.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">            We may not be able to obtain or maintain orphan drug exclusivity forour product candidates.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">            We rely on third parties for manufacturing of our clinical drug supplies;our dependence on these manufacturers may impair the development of our drug candidates.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">            There are underlying risks associated with the manufacture of ourdrug candidates, which have never been manufactured in large scale. Furthermore, we anticipate continued reliance on third-partymanufacturers if we are successful in obtaining marketing approval from the FDA or other regulatory agencies for any of our drugcandidates.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">            Identification of previously unknown problems with respect to a drugcandidate, manufacturer or facility may result in restrictions on the drug candidate, manufacturer or facility.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">            We may experience delays in the development of our drug candidatesif the third-party manufacturers of our drug candidates cannot meet FDA requirements relating to current Good Manufacturing Practices.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">            If we are unable to establish sales and marketing capabilities orenter into agreements with third parties to market and sell our drug candidates, we may not generate product revenue.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">            If our future drugs do not achieve market acceptance, we may be unableto generate significant revenue, if any.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">       </p>       <!-- Field: Page; Sequence: 28; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            26            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">       </p>       <!-- Field: Split-Segment; Name: 3 -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           •          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">            If third-party payors do not adequately reimburse patients for anyof our drug candidates that are approved for marketing, they might not be purchased or used, and our revenues and profits willnot develop or increase.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           •          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">            If our patent position does not adequately protect our drug candidates,others could compete against us more directly, which would harm our business.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           •          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">            If any third-party owners of intellectual property we may licensein the future do not properly maintain or enforce the patents underlying such licenses, our competitive position and business prospectswill be harmed.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           •          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">            If we infringe or are alleged to infringe intellectual property rightsof third parties, our business could be harmed.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           •          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">            Litigation regarding patents, intellectual property and other proprietaryrights may be expensive and time consuming. If we are involved in such litigation, it could cause delays in bringing drug candidatesto market and harm our ability to operate.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           •          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">            Confidentiality agreements with employees and others may not adequatelyprevent disclosure of trade secrets and other proprietary information and may not adequately protect our intellectual property.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           •          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">            Raising additional capital may cause dilution to existing stockholders,restrict our operations or require us to relinquish rights. Additionally, sales of a substantial number of shares of our commonstock or other securities in the public market could cause our stock price to fall.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           •          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">            We may issue additional shares of our common stock in accordance withour equity incentive plans or upon exercise or conversion of outstanding securities that are exercisable for or convertible intoshares of our common stock, which may cause dilution to existing stockholders.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           •          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">            The trading price of our common stock has been volatile and is likelyto be volatile in the future.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           •          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">            Our common stock is thinly traded and in the future may continue tobe thinly traded, and our stockholders may be unable to sell at or near asking prices or at all if they need to sell their sharesto raise money or otherwise desire to liquidate such shares.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           •          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">            Our certificate of incorporation grants our Board of Directors thepower to designate and issue additional shares of common and/or preferred stock.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           •          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">            We do not anticipate paying cash dividends, and accordingly stockholdersmust rely on stock appreciation for any return on their investment in us.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           •          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">            Our management is required to devote substantial time and incur additionalexpense to comply with public company regulations.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           •          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">            Our common stock may be delisted from The Nasdaq Capital Market whichcould negatively impact the price of our common stock and our ability to access the capital markets.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Risks Related to Our Business        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          The COVID-19 pandemic could adversely impact our business,including our clinical trials.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        In December 2019, a novel strain ofcoronavirus, COVID-19, was reported to have surfaced in Wuhan, China. Since then, COVID-19 has evolved into a global pandemic,spreading to many countries, including the United States. Depending upon the severity of the COVID-19 outbreak, we may experiencedisruptions that could severely impact our business.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        For instance, our clinical trials may beaffected by the pandemic. Site initiation, participant recruitment and enrollment, participant dosing, distribution of clinicaltrial materials, study monitoring and data analysis may be paused or delayed due to changes in hospital or university policies,federal, state or local regulations, prioritization of hospital resources toward pandemic efforts, or other reasons related tothe pandemic. If COVID-19 continues to spread, some participants and clinical investigators may not be able to comply with clinicaltrial protocols. For example, quarantines or other travel limitations (whether voluntary or required) may impede participant movement,affect sponsor access to study sites, or interrupt healthcare services, and we may be unable to conduct our clinical trials. Additionally,infections and deaths related to the pandemic may disrupt the United States’ healthcare and healthcare regulatory systems.Such disruptions could divert healthcare resources away from, or materially delay FDA review and/or approval of, our clinical trials.It is unknown how long these disruptions could continue, were they to occur. Any elongation or de-prioritization of our clinicaltrials or delay in regulatory review resulting from such disruptions could materially affect the development and study of our productcandidates.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 29; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            27            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        To date, COVID-19’s impact on ouroperations has been limited to the inability to travel to clinical trial sites, clinical trial sites not allowing nonessentialpersonnel on site for the purpose of monitoring activity and delays in the manufacture of our drug requirements by contractedthird-party manufacturers. We anticipate COVID-19 may have an effect on patient recruiting in the near term as social distancingmandates are in effect. We believe these operational issues can be managed through remote monitoring capabilities currently beingdeveloped and deployed.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The global outbreak of COVID-19 continuesto rapidly evolve. The extent to which COVID-19 may impact our business, including our clinical trials, will depend on future developments,which are highly uncertain and cannot be predicted with confidence, such as the duration of the outbreak, travel restrictions andsocial distancing in the United States and other countries, business closures or business disruptions and the effectiveness ofactions taken in the United States and other countries to contain and treat the disease. We will continue to monitor the situationclosely.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          We are a clinical stage biotechnology company with nosignificant revenue. We have incurred significant operating losses since our inception, and we expect to incur losses for the foreseeablefuture and may never achieve profitability.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        We have incurred significant operating lossessince our inception. As of December 31, 2020, we had an accumulated deficit of $67.2 million. To date, we have not generatedany revenue from the sale of our drug candidates and we do not expect to generate any revenue from sales of our drug candidatesfor the foreseeable future. We expect to continue to incur significant operating losses and we anticipate that our losses may increasesubstantially as we expand our drug development programs and commercialization efforts.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        To achieve profitability, we must successfullydevelop and obtain regulatory approval for one or more of our drug candidates and effectively commercialize any drug candidateswe develop. Even if we succeed in developing and commercializing one or more of our drug candidates, we may not be able to generatesufficient revenue and we may never be able to achieve or sustain profitability.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          We will continue to require substantial additional capitalfor the foreseeable future. If we are unable to raise additional capital when needed, we may be forced to delay, reduce or eliminateour drug development programs and commercialization efforts.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        We expect to continue to incur significantoperating expenses in connection with our ongoing activities, including conducting clinical trials, manufacturing and seeking regulatoryapproval of our drug candidates, prexigebersen, prexigebersen-A, BP1002 and BP1003. In addition, if we obtain regulatory approvalof one or more of our drug candidates, we expect to incur significant commercialization expenses related to product sales, marketing,manufacturing and distribution.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        As of December 31, 2020, we had $13.8million in cash on hand, compared to $20.4 million as of December 31, 2019. Our ongoing future capital requirements will dependon numerous factors, including:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 10%">          </td>          <td style="width: 2%; font-size: 10pt">           •          </td>          <td style="width: 88%; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the rate of progress, results and costs of completion of ongoing clinical trials of our drug candidates;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           •          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the rate of progress, results and costs of completion of ongoing preclinical testing of our drug candidates;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           •          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the size, scope, rate of progress, results and costs of completion of any potential future clinical trials and preclinical tests of our drug candidates that we may initiate;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           •          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the costs to obtain adequate supply of the compounds necessary for our drug candidates;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           •          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the costs of obtaining regulatory approval of our drug candidates;           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin: 0">       </p>       <p style="margin: 0">       </p>       <!-- Field: Page; Sequence: 30; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            28            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="margin: 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 10%">          </td>          <td style="font-size: 10pt; width: 2%">           •          </td>          <td style="font-size: 10pt; width: 88%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the scope, prioritization and number of drug development programs we pursue;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           •          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the costs for preparing, filing, prosecuting, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           •          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the extent to which we acquire or in-license other products and technologies and the costs to develop those products and technologies;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           •          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the costs of future commercializing activities, including product sales, marketing, manufacturing and distribution, of any of our drug candidates or other products for which marketing approval has been obtained;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           •          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            our ability to establish strategic collaborations and licensing or other arrangements on terms favorable to us; and           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">           </font>           •          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            competing technological and market developments.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Any additional fundraising efforts may divertour management from their day to day activities, which may adversely affect our ability to develop and commercialize our drug candidates.Our ability to raise additional funds will depend, in part, on the success of our product development activities and other factorsrelated to financial, economic and market conditions, many of which are beyond our control. There can be no assurance that we willbe able to raise additional capital when needed or on terms that are favorable to us, if at all. If adequate funds are not availableon a timely basis, we may be forced to:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 10%">          </td>          <td style="width: 2%; font-size: 10pt">           •          </td>          <td style="width: 88%; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            delay, reduce the scope of or eliminate one or more of our drug development programs;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           •          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            relinquish, license or otherwise dispose of rights to technologies, drug candidates or products that we would otherwise seek to develop or commercialize ourselves at an earlier stage or on terms that are less favorable than might otherwise be available; or           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           •          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            liquidate and dissolve the Company.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        If our operating plans change, we may requireadditional capital sooner than planned. Such additional financing may not be available when needed or on terms favorable to us.In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believewe have sufficient funds for our current and future operating plan.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          The pharmaceutical and biotechnology industry is highlycompetitive. If we are unable to compete effectively, our drug candidates may be rendered noncompetitive or obsolete.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        We are engaged in segments of the pharmaceuticaland biotechnology industry that are highly competitive and characterized by rapid and significant technological change. Many largepharmaceutical and biotechnology companies, academic and research institutions, governmental agencies and other public and privateresearch organizations are pursuing the development of novel drugs that target AML, CML, ALL, MDS, lymphoma, ovarian, breast cancer,solid tumors and other cancers generally. We face, and expect to continue to face, intense and increasing competition as new productsenter the market and advanced technologies become available. Our competitors may discover, develop or commercialize products orother novel technologies that are more effective, safer or less costly than our drug candidates. Our competitors may also obtainFDA or other regulatory approval for their products more rapidly than we may obtain approval for our drug candidates.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Many of our competitors have:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 10%">          </td>          <td style="width: 2%; font-size: 10pt">           •          </td>          <td style="width: 88%; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            significantly greater capital, technical and human resources than we have and may be better equipped to discover, develop, manufacture and commercialize drug candidates;           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin: 0">       </p>       <p style="margin: 0">       </p>       <!-- Field: Page; Sequence: 31; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            29            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="margin: 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="padding-right: 3.25pt; width: 10%">          </td>          <td style="padding-right: 3.25pt; font-size: 10pt; width: 2%">           •          </td>          <td style="padding-right: 3.25pt; font-size: 10pt; width: 88%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            more experience in drug discovery, development and commercialization, obtaining regulatory approvals and manufacturing and marketing pharmaceutical products;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding-right: 3.25pt">          </td>          <td style="padding-right: 3.25pt; font-size: 10pt">          </td>          <td style="padding-right: 3.25pt; font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding-right: 3.25pt">          </td>          <td style="padding-right: 3.25pt; font-size: 10pt">           •          </td>          <td style="padding-right: 3.25pt; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            drug candidates that have been approved or are in late-stage clinical development; and/or           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding-right: 3.25pt">          </td>          <td style="padding-right: 3.25pt; font-size: 10pt">          </td>          <td style="padding-right: 3.25pt; font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding-right: 3.25pt">          </td>          <td style="padding-right: 3.25pt; font-size: 10pt">           •          </td>          <td style="padding-right: 3.25pt; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            collaboration arrangements in our target markets with leading companies and research institutions.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Mergers and acquisitions in the pharmaceuticaland biotechnology industry may result in even more resources being concentrated among a smaller number of our competitors. Smalleror early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with largeand established companies. These competitors also compete with us in recruiting and retaining qualified scientific and managementpersonnel, establishing clinical trial sites and patent registration for clinical trials, and acquiring technologies complementaryto, or necessary for, our drug candidates and programs.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Competitive products and technological developmentsmay render our drug candidates noncompetitive or obsolete before we can recover the expenses of developing and commercializingour drug candidates. Furthermore, the development of new treatment methods and/or the widespread adoption or increased utilizationof any vaccine for the diseases we are targeting could render our drug candidates noncompetitive, obsolete or uneconomical. Ifwe successfully develop and obtain approval for any of our drug candidates, we will face competition based on the safety and effectivenessof our drug candidates, the timing of their entry into the market in relation to competitive products in development, the availabilityand cost of supply, marketing and sales capabilities, reimbursement coverage, price, patent position and other factors. If we successfullydevelop drug candidates but those drug candidates do not achieve and maintain market acceptance, our business will not be successful.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Future collaboration arrangements to leverage our capabilitiesmay not be successful.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        As part of our business strategy, we mayenter into collaborative arrangements for the development and commercialization of our drug candidates. For our collaboration effortsto be successful, we must identify partners whose competencies complement ours. We must also successfully enter into collaborationagreements with them on terms attractive to us and integrate and coordinate their resources and capabilities with our own. We maybe unsuccessful in entering into collaboration agreements with acceptable partners or negotiating favorable terms in these agreements.In addition, we may face a disadvantage in seeking to enter into or negotiating collaborations with potential partners becauseother potential collaborators may have greater management and financial resources than we do.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        If we do enter into collaborative arrangements,the success of these collaboration arrangements will depend heavily on the efforts and activities of our collaborators. Furthermore,we may face risks and uncertainties in connection with collaborative arrangements, including:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 10%">          </td>          <td style="width: 2%; font-size: 10pt">           •          </td>          <td style="width: 88%; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            inability to integrate the resources or capabilities of collaborators;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           •          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            collaborators may prove difficult to work with or less skilled than we originally expected;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           •          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            disputes may arise with respect to the ownership of rights to technology developed with collaborators;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           •          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            disagreements with collaborators could delay or terminate the research, development or commercialization of products or result in litigation or arbitration;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           •          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            difficulty enforcing our arrangements if one of our collaborators fails to perform;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           •          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            termination of our collaboration arrangements by collaborators, which could make it difficult for us to attract new collaborators or adversely affect the perception of us in the business or financial communities;           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin: 0">       </p>       <p style="margin: 0">       </p>       <!-- Field: Page; Sequence: 32; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            30            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="margin: 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 10%">          </td>          <td style="font-size: 10pt; width: 2%">           •          </td>          <td style="font-size: 10pt; width: 88%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            collaborators may have considerable discretion in electing whether to pursue the development of any additional drug candidates and may pursue technologies or products either on their own or in collaboration with our competitors that are similar to or competitive with our technologies; and           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           •          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            collaborators may change the focus of their development and commercialization efforts.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        If we are unsuccessful in our collaborativeefforts, our ability to develop and market drug candidates could be severely limited.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          If we are unable to attract and retain key management,scientific personnel and advisors, we may not successfully develop our drug candidates or achieve our other business objectives.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Our success depends on the availabilityand contributions of members of our senior management team, scientific team and other key personnel. The loss of services of anyof these individuals could delay, reduce or prevent our drug development and other business objectives. Furthermore, recruitingand retaining qualified scientific personnel to perform drug development work will be critical to our success. We face intensecompetition for qualified individuals from numerous pharmaceutical and biotechnology companies, universities, governmental entitiesand other public and private research institutions. We may be unable to attract and retain these individuals, and our failure todo so could materially adversely affect our business and financial condition.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Our employees, agents, consultants and commercial partnersmay engage in misconduct or other improper activities, including non-compliance with applicable regulatory standards and requirements.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        We are exposed to the risk of fraud or othermisconduct by our employees, principal investigators, consultants, advisors and commercial partners. Misconduct by these personscould include intentional failures to comply with the regulations of the FDA and non-U.S. regulators, comply with healthcare fraudand abuse laws and regulations in the U.S. and abroad, report financial information or data accurately or disclose unauthorizedactivities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensivelaws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulationsmay restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programsand other business arrangements. Such misconduct could involve the improper use of information obtained in the course of clinicalstudies, which could result in regulatory sanctions and cause serious harm to our business, financial condition and reputation.We currently have codes of business conduct and ethics applicable to all of our employees, but it is not always possible to identifyand deter employee misconduct, and our codes of business conduct and ethics and the other precautions we take to detect and preventimproper activities may not be effective in controlling unknown or unmanaged risks or losses, or in protecting us from governmentalinvestigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actionsare instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could resultin the imposition of significant fines or other sanctions, which could materially adversely affect our business and financial condition.Whether or not we are successful in defending against such actions or investigations, we could incur substantial costs, includinglegal fees, and divert the attention of management in defending ourselves against any of these claims or investigations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          We expect to expand our operations, including clinicaltrials, in the future and may face challenges in managing our growth, which may result in disruptions to our operations.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        We expect to expand our operations, includingclinical trials for our drug candidates, over time. To successfully manage future growth, we may need to implement and improveour managerial, operational and financial resources, and may need to expand our facilities and recruit and train additional qualifiedpersonnel. Our expected growth may also require significant financial resources, which may not be available when needed or on termsfavorable to us. Our senior management may be required to devote substantial attention to managing growth activities and may beunable to effectively manage the expansion of our operations due to our limited resources, which may result in disruptions to ourbusiness operations and could harm our business and financial condition.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 33; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            31            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          If we acquire or license technologies, resources or drugcandidates, we will incur a variety of costs and may never realize benefits from the transaction.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        If appropriate opportunities become available,we may license or acquire technologies, resources, drugs or drug candidates. We may never realize the anticipated benefits of sucha transaction. In particular, due to the risks inherent in drug development, we may not successfully develop or obtain marketingapproval for the drug candidates we acquire. Future licenses or acquisitions could result in potentially dilutive issuances ofour equity securities, the incurrence of debt, the creation of contingent liabilities, material impairment expenses related togoodwill and impairment or amortization expenses related to other intangible assets, which could harm our business and financialcondition.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Our business has a substantial risk of product liabilityclaims. If we are unable to obtain or maintain appropriate levels of insurance, a product liability claim could adversely affectour business.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Our business exposes us to significant potentialproduct liability risks that are inherent in the development, manufacturing and sales and marketing of human therapeutic products.Although we do not currently commercialize any products, claims could be made against us based on the use of our drug candidatesin clinical trials. Product liability claims could delay or prevent completion of our clinical development programs        <b>         .        </b>        Wecurrently have product liability insurance, but we may not be able to maintain such insurance on acceptable terms. However, evenif we maintain or obtain other product liability insurance, our insurance may not provide adequate coverage against potential liabilities.As a result, we may be unable to obtain or maintain insurance coverage at a reasonable cost to protect against losses that couldharm our business and financial condition. If any claims are brought against us, and we are not successful in defending ourselves,those claims could result in damage awards against us, which could materially adversely affect our business and financial condition.Whether or not we are successful in defending against such claims, we could incur substantial costs, including legal fees, anddivert the attention of management in defending ourselves against any of these claims.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          We are increasingly dependent on information technologysystems to operate our business and a cyber-attack or other breach of our systems, or those of third parties on whom we may rely,could subject us to liability or interrupt the operation of our business.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        We are increasingly dependent on informationtechnology systems to operate our business. A breakdown, invasion, corruption, destruction or interruption of critical informationtechnology systems by employees, others with authorized access to our systems or unauthorized persons could negatively impact operations.In the ordinary course of business, we collect, store and transmit confidential information and it is critical that we do so ina secure manner to maintain the confidentiality and integrity of such information. Additionally, we outsource certain elementsof our information technology systems to third parties. As a result of this outsourcing, our third party vendors may or could haveaccess to our confidential information making such systems vulnerable. Data breaches of our information technology systems, orthose of our third party vendors, may pose a risk that sensitive data may be exposed to unauthorized persons or to the public.For example, the loss of clinical trial data from completed or ongoing clinical trials or preclinical studies could result in delaysin our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. While we believe thatwe have taken appropriate security measures to protect our data and information technology systems, and have been informed by ourthird party vendors that they have as well, there can be no assurance that our efforts will prevent breakdowns or breaches in oursystems, or those of our third party vendors, that could materially adversely affect our business and financial condition.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Our ability to use our net operating loss carryforwardsand certain other tax attributes may be limited.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Under Section 382 of the Internal RevenueCode of 1986, as amended (the “Code”), if a corporation experiences an “ownership change,” generally definedas a greater than 50% change (by value) in its equity ownership over a three-year period, the corporation’s ability to utilizeits pre-change net operating loss carryforwards and other pre-change tax attributes (such as research tax credits) to offset itspost-change taxable income or taxes may be limited. Our prior and potential future equity offerings and other changes in our stockownership, some of which are outside of our control, may have resulted or could in the future result in an ownership change underSection 382 of the Code. If a limitation were to apply, utilization of a portion of our domestic net operating loss and taxcredit carryforwards could be limited in future periods and a portion of the carryforwards could expire before being availableto reduce future income tax liabilities.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 34; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            32            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        On December 22, 2017, the U.S. governmentenacted legislation referred to as the Tax Cuts and Jobs Act (the “Tax Act”). Under the Tax Act, net operating lossesgenerated prior to 2018 will continue to be governed by the net operating loss tax rules as they existed prior to the adoptionof the new Tax Act, which means that generally they will expire 20 years after they were generated if not used prior thereto. Accordingly,our net operating losses could expire unused and be unavailable to offset future income tax liabilities, if any. Under the TaxAct, net operating losses incurred in 2018 and in future years may be carried forward indefinitely, but the deductibility of suchnet operating losses is limited to 80% of current year taxable income. We continue to examine the impact that this provision ofthe Tax Act, among other provisions, may have on our business.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Provisions of our charter documents or Delaware law coulddelay or prevent an acquisition of our company, even if the acquisition would be beneficial to our stockholders, and could makeit more difficult to change management.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Provisions of our certificate of incorporationand bylaws may discourage, delay or prevent a merger, acquisition or other change in control that stockholders might otherwiseconsider favorable, including transactions in which stockholders might otherwise receive a premium for their shares. In addition,these provisions may frustrate or prevent any attempt by our stockholders to replace or remove our current management by makingit more difficult to replace or remove our board of directors. These provisions include:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 10%">          </td>          <td style="width: 2%; font-size: 10pt">           •          </td>          <td style="width: 88%; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            limitations on our stockholders’ ability to call special meetings of stockholders;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           •          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            an advance notice requirement for stockholder proposals and nominations for members of our Board;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           •          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the authority of our Board to determine the number of director seats on our Board;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           •          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the authority of our Board to fill vacancies occurring on the Board;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           •          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the authority of our Board to issue preferred stock with such terms as our Board may determine.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        In addition, because we are governed byDelaware law, we are subject to the provisions of Section 203 of the Delaware General Corporation Law, which prohibits a publiclyheld Delaware corporation from engaging in a business combination with an interested stockholder, generally a person who, togetherwith its affiliates, owns or within the last three years has owned 15% of our voting stock, for a period of three years after thedate of the transaction in which the person became an interested stockholder, unless the business combination is approved in aprescribed manner.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          We face competition from entities that have developedor may develop therapeutic candidates for our target disease indications, including companies developing novel treatments and technologyplatforms based on modalities and technology that may be similar to ours. If these companies develop technologies, including deliverytechnologies, or therapeutic candidates more rapidly than we do, or their technologies are more effective, our ability to developand successfully commercialize therapeutic candidates may be adversely affected.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        While we believe that our DNAbilize        <sup>         ®        </sup>        technology is the only delivery method of its type, the area of cancer treatment research is rapidly progressing, with many stakeholders,including for-profit and nonprofit institutions, conducting preclinical and clinical studies of various types of therapeutic productsfor the same or similar indications for use as our drug candidates. We expect that such work by others will continue, which maymake it difficult for us to effectively recruit and enroll a satisfactory number of participants in clinical trials.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Our success will partially depend on ourability to develop therapeutics that are safer and more effective than competing therapeutics. Our commercial opportunity and successwill be reduced or eliminated if competing therapeutics are safer, more effective, or less expensive than the therapeutics we develop,or if any are granted exclusive marketing approval by the FDA that precludes the marketing of our drug candidates for a periodof time. If our lead drug candidates are approved for the indications we are currently pursuing, they will compete with a rangeof therapeutic treatments that are either in development or currently marketed. For example, the FDA has recently approved a numberof drugs indicated for treatment of AML, some of which may have target patient populations similar to that of our drug candidates.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 35; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            33            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Many of our competitors may have significantlygreater financial, technical, manufacturing, marketing, sales and supply resources or experience than we do. If we successfullyobtain FDA approval for any drug candidate, we will face competition based on many different factors, including the safety andeffectiveness of our products, the ease with which our products can be administered, the timing and scope of regulatory approvals(if we are able to obtain any) for these drug candidates, the availability and cost of manufacturing, marketing and sales capabilities,price, reimbursement coverage and patent position. Competing therapeutics could present superior treatment alternatives, includingby being more effective, safer, less expensive or marketed and sold more effectively than any therapeutics we may develop. Competitivealternatives may make any drugs that we develop obsolete or noncompetitive before we recover the expense of developing and commercializingour drug candidates, if we are able to obtain regulatory approval to commercialize such drug candidates.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          We may be subject, directly or indirectly, to certainU.S. federal and state healthcare laws and regulations, such as anti-kickback, false claims laws, physician payment transparencylaws or similar fraud and abuse laws, which could expose us to potential criminal sanctions, civil penalties, contractual damages,reputational harm and diminished profits and future earnings         </i>         .        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Healthcare providers, physicians and otherswill play a primary role in the recommendation, ordering and utilization of any products for which we obtain regulatory approval.If we obtain FDA approval for any of our products and begin commercializing those products in the U.S., our operations may be subjectto various federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute, the federalFalse Claims Act, and physician payment transparency laws and regulations. These laws may impact, among other things, our potentialsales, marketing and education programs and our relationships with physicians, patients, and other persons or entities in a positionto refer, use, or recommend our future products. The laws that may affect our ability to operate could include, but are not limitedto:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 10%">          </td>          <td style="width: 2%; font-size: 10pt">           •          </td>          <td style="width: 88%; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the federal Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual, or the purchase, lease, order or recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           •          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            federal civil and criminal false claims laws and civil monetary penalty laws, including the False Claims Act, which may be pursued through civil whistleblower or qui tam actions, impose criminal and civil penalties against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment or approval from Medicare, Medicaid or other third-party payors that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           •          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            federal criminal statutes under the Health Insurance Portability and Accountability Act of 1996, which prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters;           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin: 0">       </p>       <p style="margin: 0">       </p>       <!-- Field: Page; Sequence: 36; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            34            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="margin: 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 10%">          </td>          <td style="font-size: 10pt; width: 2%">           •          </td>          <td style="font-size: 10pt; width: 88%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the federal transparency requirements under The Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act (known collectively as the “Affordable Care Act”), including the provision commonly referred to as the Physician Payments Sunshine Act, which requires manufacturers of drugs, biologics, devices and medical supplies for which payment is available under Medicare, Medicaid or the Children’s Health Insurance Program to report annually to the Centers for Medicare and Medicaid Services information related to payments or other transfers of value made to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; and           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           •          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            State law equivalents of each of the healthcare laws described above, some of which may be broader in scope and apply regardless of the type of payor, such as state anti-kickback statutes and false claims acts, and state pricing, marketing, and transparency statutes that require us to adopt compliance programs, report pricing information, or disclose payments or other transfers of value to physicians or other covered recipients.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Because of the breadth of these laws andthe narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities couldbe subject to challenge under one or more of such laws once our products are commercialized. In addition, healthcare reform legislationhas strengthened these laws and additional laws or requirements may be implemented in the future. For example, the Affordable CareAct, among other things, amended the intent requirement of the federal Anti-Kickback and criminal healthcare fraud statutes. Asa result of such amendment, a person or entity no longer needs to have actual knowledge of these statutes or specific intent toviolate them in order to have committed a violation. Moreover, the Affordable Care Act provides that the government may assertthat a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false orfraudulent claim for purposes of the False Claims Act.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Efforts to ensure that our business arrangementscomply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authoritieswill conclude that our existing or future business practices do not comply with current or future statutes, regulations or caselaw involving applicable fraud and abuse or other healthcare laws and regulations. Any such actions instituted against us couldhave a significant adverse impact on our business, including the imposition of civil, criminal and administrative penalties, damages,disgorgement, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs,contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of whichcould adversely affect our ability to operate our business and our results of operations. Even if we are successful in defendingagainst such actions, we may nonetheless be subject to substantial costs, reputational harm and adverse effects on our abilityto operate our business.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        If any of our employees, agents, or thephysicians or other providers or entities with whom we expect to do business are found to have violated applicable laws, we maybe subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs, or,if we are not subject to such actions, we may suffer reputational harm for conducting business with persons or entities found,or accused of being, in violation of such laws. Any such events could adversely affect our ability to operate our business andour results of operations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Inadequate funding for the FDA, the SEC and other governmentagencies, or a work slowdown or stoppage at those agencies as part of a broader federal government shutdown, could hindertheir ability to hire and retain key leadership and other personnel, prevent new products and services from being developed orcommercialized in a timely manner, or otherwise prevent those agencies from performing normal business functions on which the operationof our business may rely, which could negatively impact our business.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The ability of the FDA to review and approvenew products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retainkey personnel and accept the payment of user fees, and statutory, regulatory and policy changes. Average review times at the agencyhave fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on whichour operations may rely, including those that fund research and development activities, is subject to the political process, whichis inherently fluid and unpredictable.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 37; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            35            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Disruptions at the FDA and other agenciesmay also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which could adverselyaffect our business. For example, over the last several years, including December 22, 2018 to January 25, 2019, the U.S.government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough employeesand stop critical activities. If a prolonged government shutdown or a series of shutdowns occurs, it could significantly affectthe ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on ourbusiness. Further, future government shutdowns could impact our ability to gain access to the public markets and obtain necessarycapital in order to properly capitalize and continue our operations, which could have a material adverse effect on our businessand financial condition.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Risks Related to the Development ofOur Drug Candidates        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          We must complete extensive clinical trials to demonstratethe safety and efficacy of our drug candidates. If we are unable to demonstrate the safety and efficacy of our drug candidates,we will not be successful.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        To date, none of our drug candidateshave been approved for sale in the U.S. or any foreign country. While antisense therapeutics have been in development forover 20 years, only a limited number of antisense drugs have been successfully developed to date. Further, the development ofliposomal antisense therapeutics, which comprise our drug therapeutics technology, has faced many challenges and generallyremains unproven in the treatment of cancers. The success of our business depends primarily on our ability to develop andcommercialize our drug candidates successfully. Our drug candidates must satisfy rigorous standards of safety and efficacybefore they can be approved for sale. To satisfy these standards, we must engage in expensive and lengthy testing of our drugcandidates.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        We may not be able to obtain authority fromthe FDA or other equivalent foreign regulatory agencies to move on to further efficacy segments of our ongoing clinicaltrials or commence and complete any other clinical trials for any of our drug candidates. Positive results in preclinical studiesof a drug candidate may not be predictive of similar results in human clinical trials, and promising results from early clinicaltrials of a drug candidate may not be replicated in later clinical trials. A number of companies in the pharmaceutical and biotechnologyindustries have suffered significant setbacks in late-stage clinical trials even after achieving promising results in early-stagedevelopment. Accordingly, the results from the preclinical tests or clinical trials for our drug candidates may not be predictiveof the results we may obtain in later stage trials. The failure of clinical trials to demonstrate safety and efficacy of one ormore of our drug candidates will have a material adverse effect on our business and financial condition.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 38; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            36            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Delays in the commencement of clinical trials of our drugcandidates could result in increased costs to us and delay our ability to generate revenues.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Our drug candidates will require continuedextensive clinical trials prior to the submission of a regulatory application for commercial sales. Because of the nature of clinicaltrials, we do not know whether future planned clinical trials will begin on time, if at all. Delays in the commencement of clinicaltrials could significantly increase our drug development costs and delay any commercialization of our drug candidates. In addition,many of the factors that may cause, or lead to, a delay in the commencement of clinical trials may also ultimately lead to denialof regulatory approval of a drug candidate.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The commencement of clinical trials canbe delayed for a variety of reasons, including delays in:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 10%">          </td>          <td style="width: 2%; font-size: 10pt">           •          </td>          <td style="width: 88%; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            demonstrating sufficient safety and efficacy in past clinical trials to obtain regulatory approval to commence a further clinical trial;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           •          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            convincing the FDA that we have selected valid endpoints for use in proposed clinical trials;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           •          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            reaching agreements on acceptable terms with prospective contract manufacturers for manufacturing sufficient quantities of our drug candidates; and           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           •          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            obtaining institutional review board approval to conduct a clinical trial at a prospective site.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        In addition, the commencement of clinicaltrials may be delayed due to insufficient patient enrollment, which is a function of many factors, including the size of the patientpopulation, the nature of the protocol, the proximity of patients to clinical sites, the availability of effective treatments forthe relevant disease and the eligibility criteria for the clinical trial.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Delays in the completion of, or the termination of, clinicaltrials of our drug candidates could result in increased costs to us and could delay or prevent us from generating revenues.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Once a clinical trial has begun, it maybe delayed, suspended or terminated by us or the FDA or other regulatory authorities due to a number of factors, including:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 10%">          </td>          <td style="width: 2%; font-size: 10pt">           •          </td>          <td style="width: 88%; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            regulators or institutional review boards may not authorize us to commence or conduct a clinical trial at a prospective trial site;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           •          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            our preclinical tests or clinical trials may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional preclinical testing or clinical trials or we may abandon projects that we expect may not be promising;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           •          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            we might have to suspend or terminate our clinical trials if the participating patients are being exposed to unacceptable health risks;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           •          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            regulators or institutional review boards may require that we hold, suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           •          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the cost of our clinical trials may be greater than we currently anticipate and we may lack adequate funding to continue the clinical trial;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           •          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the timing of our clinical trials may be longer than we currently anticipate;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           •          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner (including delays or inability to manufacture or obtain sufficient quantities of materials for use in clinical trials);           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin: 0">       </p>       <p style="margin: 0">       </p>       <!-- Field: Page; Sequence: 39; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            37            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="margin: 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 10%">          </td>          <td style="font-size: 10pt; width: 2%">           •          </td>          <td style="font-size: 10pt; width: 88%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            inadequacy of or changes in our manufacturing process or compound formulation;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           •          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            slower than expected rates of patient recruitment and enrollment or lower than expected patient retention rates;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           •          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the effects of our drug candidates may not be the desired effects or may include undesirable side effects or our drug candidates may have other unexpected characteristics;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           •          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            changes in applicable regulatory policies and regulations;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           •          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            delays in identifying and reaching agreement on acceptable terms with prospective clinical trial sites;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           •          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            uncertainty regarding proper dosing;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           •          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            failure of our clinical research organizations to comply with all regulatory and contractual requirements or otherwise fail to perform their services in a timely or acceptable manner;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           •          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            scheduling conflicts with participating clinicians and clinical institutions;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           •          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            failure to construct appropriate clinical trial protocols;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           •          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            insufficient data to support regulatory approval;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           •          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            inability or unwillingness of medical investigators to follow our clinical protocols; and           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           •          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the timing of discussions and meetings with the FDA or other regulatory authorities regarding the scope or design of our clinical trials.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Many of these factors that may lead to adelay, suspension or termination of clinical trials of our drug candidates may also ultimately lead to denial of regulatory approvalof our drug candidates.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        From time to time, we may publicly announceour expected timing of completing certain milestones relating to various scientific, clinical, regulatory, development and otherobjectives related to our business. For example, these milestones may include the commencement or completion of scientific studiesor clinical trials or the submission or approval of regulatory filings. Our estimates for completion of these milestones are basedon a variety of assumptions, some of which may be out of our control.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        If we experience delays in the completionof, or termination of, clinical trials of any drug candidates in the future, or if we do not meet our milestones within the estimatedtimeframes that we have publicly announced, our business, financial condition and the commercial prospects for our drug candidatescould be materially adversely affected, and our ability to generate product revenues could be delayed or eliminated. In addition,our stock price could decline.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 40; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            38            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          If we are unable to obtain U.S. and/or foreign regulatoryapproval, we will be unable to commercialize our drug candidates.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Our drug candidates are subject to extensivegovernmental regulations relating to, among other things, research, testing, development, manufacturing, safety, efficacy, recordkeeping, labeling, marketing and distribution of drugs. Rigorous preclinical testing and clinical trials and an extensive regulatoryapproval process are required in the U.S. and in many foreign jurisdictions prior to the commercial sale of our drug candidates.Satisfaction of these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays.It is possible that none of the drug candidates we are developing will obtain marketing approval. In connection with the clinicaltrials for our drug candidates, we face risks that:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 10%">          </td>          <td style="width: 2%; font-size: 10pt">           •          </td>          <td style="width: 88%; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the drug candidate may not prove to be efficacious;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           •          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the drug candidate may not prove to be safe;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           •          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the drug candidate may not be readily co-administered or combined with other drugs or drug candidates;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           •          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the results may not confirm the positive results from earlier preclinical studies or clinical trials;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           •          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the results may not meet the level of statistical significance required by the FDA or other regulatory agencies; and           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           •          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the FDA or other regulatory agencies may require us to carry out additional studies.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        We have limited experience in conductingand managing later stage clinical trials necessary to obtain regulatory approvals, including approval by the FDA. However, thisrisk would be mitigated in the event the Company is successful entering into a co-development agreement with a pharma partner forlate stage clinical development. The time required to complete clinical trials and for the FDA and other countries’ regulatoryreview processes is uncertain and typically takes many years. Our analysis of data obtained from preclinical and clinical trialsis subject to confirmation and interpretation by regulatory authorities, which could delay, limit or prevent regulatory approval.We may also encounter unanticipated delays or increased costs due to government regulation from future legislation or administrativeaction or changes in FDA policy during the period of product development, clinical trials, and FDA regulatory review.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Any regulatory approval to market a productmay be subject to limitations on the indicated uses for which we may market the product and affect reimbursement by third-partypayors. These limitations may limit the size of the market for the product. We may also become subject to numerous foreign regulatoryrequirements governing the conduct of clinical trials, manufacturing and marketing authorization, pricing and third-party reimbursement.The foreign regulatory approval process includes all of the risks associated with FDA approval described above as well as risksattributable to the satisfaction of foreign regulations. Approval by the FDA does not ensure approval by regulatory authoritiesoutside the U.S. Foreign jurisdictions may have different approval procedures than those required by the FDA and may impose additionaltesting requirements for our drug candidates.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          In addition to regulations in the U.S., we may be subjectto a variety of regulations in other jurisdictions governing, among other things, clinical trials and any commercial sales anddistribution of our products, if approved.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Whether or not we obtain FDA approval fora drug candidate, we must obtain the requisite approvals from regulatory authorities in non-U.S. countries prior to the commencementof clinical trials or marketing of our products in those countries. Certain countries outside of the U.S. have a process that requiresthe submission of a clinical trial application, much like an IND, prior to the commencement of human clinical trials. In the E.U.,for example, a CTA must be submitted to the competent national health authority and to independent ethics committees in each countryin which a company intends to conduct clinical trials. Once the CTA is approved in accordance with a country’s requirements,clinical trial development may proceed in that country.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The requirements and process governing theconduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, the clinicaltrials must be conducted in accordance with GCP and other applicable regulatory requirements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        To obtain regulatory approval of an investigationaldrug under E.U. regulatory systems, we must submit a marketing authorization application. This application is similar to the NDAin the U.S., with the exception of, among other things, country-specific document requirements. Drugs can be authorized in theE.U. by using (i) the centralized authorization procedure, (ii) the mutual recognition procedure, (iii) the decentralizedprocedure or (iv) national authorization procedures.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 41; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            39            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The EMA implemented the centralized procedurefor the approval of human drugs to facilitate marketing authorizations that are valid throughout the E.U. This procedure resultsin a single marketing authorization granted by the European Commission that is valid across the E.U., as well as in Iceland, Liechtensteinand Norway. The centralized procedure is compulsory for certain human drugs including those that are: (i) derived from biotechnologyprocesses, such as genetic engineering, or (ii) contain a new active substance indicated for the treatment of certain diseases.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Changes in existing laws and regulations affecting thehealthcare industry could increase our costs and otherwise adversely affect our business.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Our research and development activities,preclinical studies and clinical trials, and the manufacturing, marketing and labeling of any products we may develop, are subjectto extensive regulation by the FDA and other regulatory authorities in the U.S. and other countries. Changes in existing federal,state and foreign laws and agency regulations may be established that could prevent or delay regulatory approval of our drug candidatesor materially increase our costs, including:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 10%">          </td>          <td style="width: 2%; font-size: 10pt">           •          </td>          <td style="width: 88%; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            changes in the FDA and foreign regulatory processes for new therapeutics that may delay or prevent the approval of any of our drug candidates;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           •          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            new laws, regulations, or judicial decisions related to healthcare availability or the payment for healthcare products and services, including prescription drugs, that would make it more difficult for us to market and sell products once they are approved by the FDA or foreign regulatory agencies;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           •          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            changes in FDA and foreign regulations that may require additional safety monitoring prior to or after the introduction of new products to market, which could materially increase our costs of doing business; and           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           •          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            changes in FDA and foreign current cGMP that would make it more difficult for us to manufacture our drug candidates in accordance with cGMP.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Delays in obtaining or preventing our obtainingregulatory approval of our drug candidates could materially adversely affect our ability to commercialize any of our drug candidatesand our ability to receive product revenues or to receive milestone payments or royalties from any product rights we might licenseto others.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          We rely on third parties to conduct clinical trials forour drug candidates, and their failure to timely and properly perform their obligations may result in costs and delays that preventus from obtaining regulatory approval or successfully commercializing our drug candidates.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        We rely on independent contractors, includingclinical research organizations, in certain areas that are particularly relevant to our research and drug development plans, suchas for data management for the conduct of clinical trials. The competition for these relationships is intense, and we may not beable to maintain our relationships with them on acceptable terms. Independent contractors generally may terminate their engagementsat any time, subject to notice. As a result, we can control their activities only within certain limits, and they will devote onlya certain amount of their time conducting research on and trials of our drug candidates and assisting in developing them. If theydo not successfully carry out their duties under their agreements with us, fail to inform us if these trials fail to comply withclinical trial protocols or fail to meet expected deadlines, our clinical trials may need to be extended, delayed or terminated.We may not be able to enter into replacement arrangements without undue delays or excessive expenditures. If there are delays intesting or regulatory approvals as a result of the failure to perform by our independent contractors or other outside parties,our drug candidate development costs will increase and we may not be able to attain regulatory approval for or successfully commercializeour drug candidates.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        In addition, we have no control over thefinancial health of our independent contractors. Several of our independent contractors are in possession of valuable and sensitiveinformation relating to the safety and efficacy of our drug candidates, and several others provide services to a significant percentageof the patients enrolled in our clinical trials in which such independent contractors participate. Should one or more of theseindependent contractors become insolvent, or otherwise are not able to continue to provide services to us, the clinical trial inwhich such contractor participates could become significantly delayed and we may be materially adversely affected as a result ofthe delays and additional expenses associated with such event.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 42; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            40            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          We may not be able to obtain or maintain orphan drug exclusivityfor our product candidates.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Prexigebersen has received orphan drug designationsfor the treatment of AML in the U.S. Orphan designation is available to drugs intended to treat, diagnose or prevent a rare diseaseor condition that affects fewer than 200,000 people in the U.S. at the time of application for orphan designation. Orphan drugdesignation must be requested before submitting an application for marketing authorization. Orphan designation qualifies the sponsorof the product for a tax credit and marketing incentives. The first sponsor to receive FDA marketing approval for a drug with anorphan designation is entitled to a seven-year exclusive marketing period in the U.S. for that product for that indication and,typically, a waiver of the prescription drug user fee for its marketing application. However, a drug that the FDA considers tobe clinically superior to, or different from, the approved orphan drug, even though for the same indication, may also obtain approvalin the U.S. during the seven-year exclusive marketing period. Orphan drug exclusive marketing rights may also be lost if the FDAlater determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficientquantity of the drug.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        In October 2016, prexigebersen alsoreceived orphan drug designation for AML in the E.U. from the EMA. To receive orphan drug designation from the EMA, a therapy mustbe intended for the treatment of a life-threatening or chronically debilitating rare condition with a prevalence of less than fivein 10,000 in the E.U. Orphan drug designation provides incentives designed to facilitate development, including fee reductionsfor protocol assistance, scientific advice and importantly, may provide up to ten years of market exclusivity in the E.U. followingproduct approval.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        There is no guarantee that any of our otherdrug candidates will receive orphan drug designation or that, even if such drug candidate is granted such status, the drug candidate’sclinical development and regulatory approval process will not be delayed or will be successful.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Risks Related to Manufacturing Our DrugCandidates        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          We rely on third parties for manufacturing of our clinicaldrug supplies; our dependence on these manufacturers may impair the development of our drug candidates.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        We have no ability to internally manufacturethe drug candidates that we need to conduct our clinical trials. For the foreseeable future, we expect to continue to rely on third-partymanufacturers and other third parties to produce, package and store sufficient quantities of our drug candidates and any futuredrug candidates for use in our clinical trials. We have entered into agreements with our third-party manufacturer for the manufactureof our drug requirements, including an agreement for the manufacture of prexigebersen for use in our Phase 2 clinical trial forAML and third-party manufacture of our drug requirements agreement for BP1002. To date, we have made steady progress with our currentthird-party manufacturers, overcoming challenges associated with scaling up manufacturing to develop their capabilities to supplyus with our necessary quantities of drug supplies for our clinical trials. However, we may face various risks and uncertaintiesin connection with our reliance on third-party manufacturers, including:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 10%">          </td>          <td style="width: 2%; font-size: 10pt">           •          </td>          <td style="width: 88%; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            reliance on third-party manufacturers for regulatory compliance and quality assurance;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           •          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the possibility of breach of the manufacturing agreement by the third-party manufacturer because of factors beyond our control;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           •          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the possibility of termination or nonrenewal of our manufacturing agreement by the third-party manufacturer at a time that is costly or inconvenient for us;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           •          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the potential that third-party manufacturers will develop know-how owned by such third-party manufacturer in connection with the production of our drug candidates that is necessary for the manufacture of our drug candidates; and           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           •          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            reliance on third-party manufacturers to assist us in preventing inadvertent disclosure or theft of our proprietary knowledge.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 43; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            41            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Our drug candidates are complicated andexpensive to manufacture. If our third-party manufacturers fail to deliver our drug candidates for clinical use on a timely basis,with sufficient quality, and at commercially reasonable prices, we may be required to delay or suspend clinical trials or otherwisediscontinue development of our drug candidates. While we may be able to identify replacement third-party manufacturers or developour own manufacturing capabilities for these drug candidates, this process would likely cause a delay in the availability of ourdrug candidates and an increase in costs. In addition, third-party manufacturers may have a limited number of facilities in whichour drug candidates can be manufactured, and any interruption of the operation of those facilities due to events such as equipmentmalfunction or failure or damage to the facility by natural disasters could result in the cancellation of shipments, loss of productin the manufacturing process or a shortfall in available drug candidates.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        We may in the future elect to manufacturecertain of our drug candidates in our own manufacturing facilities. If we do so, we will require substantial additional funds andneed to recruit qualified personnel in order to build or lease and operate any manufacturing facilities.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          There are underlying risks associated with the manufactureof our drug candidates, which have never been manufactured in large scale. Furthermore, we anticipate continued reliance on third-partymanufacturers if we are successful in obtaining marketing approval from the FDA or other regulatory agencies for any of our drugcandidates.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        To date, our drug candidates have been manufacturedin relatively small quantities for preclinical testing and clinical trials by third-party manufacturers, and have never been manufacturedin large scale. Additionally, as in the development of any new compound, there are underlying risks associated with their manufacture.These risks include, but are not limited to, cost, process scale-up, process reproducibility, construction of a suitable processplant, timely availability of raw materials, as well as regulatory issues associated with the manufacture of an active pharmaceuticalagent. Any of these risks may prevent us from successfully developing our drug candidates. Our failure, or the failure of our third-partymanufacturers to achieve and maintain these high manufacturing standards, including the incidence of manufacturing errors and reliableproduct packaging for diverse environmental conditions, could result in patient injury or death, product recalls or withdrawals,delays or failures in product testing or delivery, cost overruns or other problems that could materially adversely affect our businessand financial condition.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        If the FDA or other regulatory agenciesapprove any of our drug candidates for commercial sale, we expect that we would continue to rely, at least initially, on third-partymanufacturers to produce commercial quantities of such approved drug candidates. These manufacturers may not be able to successfullyincrease the manufacturing capacity for any of our approved drug candidates in a timely or economic manner, or at all. Significantscale-up of manufacturing may require additional validation studies, which the FDA or other regulatory authorities must reviewand approve. If our third-party manufacturers are unable to successfully increase the manufacturing capacity for a drug candidate,or we are unable to establish our own manufacturing capabilities, the commercial launch of any approved products may be delayedor there may be a shortage in supply.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Identification of previously unknown problems with respectto a drug candidate, manufacturer or facility may result in restrictions on the drug candidate, manufacturer or facility.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The FDA stringently applies regulatory standardsfor the manufacturing of our drug candidates. Identification of previously unknown problems with respect to a drug candidate, manufactureror facility may result in restrictions on the drug candidate, manufacturer or facility, including warning letters, suspensionsof regulatory approvals, operating restrictions, delays in obtaining new product approvals, withdrawal of the product from themarket, product recalls, fines, injunctions and criminal prosecution. Any of the foregoing could have a material adverse effecton our business and financial condition.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 44; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            42            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          We may experience delays in the development of our drugcandidates if the third-party manufacturers of our drug candidates cannot meet FDA requirements relating to current Good ManufacturingPractices.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Our third-party manufacturers are requiredto produce our drug candidates under FDA cGMP in order to meet acceptable standards for our preclinical testing and clinical trials.If such standards change, the ability of third-party manufacturers to produce our drug candidates on the schedule we require forour preclinical tests and clinical trials may be affected. In addition, third-party manufacturers may not perform their obligationsunder their agreements with us or may discontinue their business before the time required by us to gain approval for or commercializeour drug candidates. Any difficulties or delays in the manufacturing and supply of our drug candidates could increase our costsor cause us to lose revenue or postpone or cancel clinical trials.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The FDA also requires that we demonstratestructural and functional comparability of a drug candidate produced by different third-party manufacturers. Because we may usemultiple sources to manufacture our drug candidates, we may need to conduct comparability studies to assess whether manufacturingchanges have affected the safety, identity, purity or potency of any drug candidate compared to the drug candidate produced byanother manufacturer. If we are unable to demonstrate comparability, the FDA could require us to conduct additional clinical trials,which would be expensive and significantly delay commercialization of our drug candidates.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Risks Related to Commercialization        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          If we are unable to establish sales and marketing capabilitiesor enter into agreements with third parties to market and sell our drug candidates, we may not generate product revenue.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        We have no commercial products, and we donot currently have an organization for the sales and marketing of pharmaceutical products. In order to successfully commercializeany drug candidates that may be approved in the future by the FDA or comparable foreign regulatory authorities, we must build oursales and marketing capabilities or make arrangements with third parties to perform these services. For certain drug candidatesin selected indications where we believe that an approved product could be commercialized by a specialty sales force that callson a limited but focused group of physicians, we may commercialize these products ourselves. However, in therapeutic indicationsthat require a large sales force selling to a large and diverse prescribing population, we may enter into arrangements with othercompanies for commercialization. If we are unable to establish adequate sales, marketing and distribution capabilities, whetherindependently or with third parties, we may not be able to generate product revenue and may not become profitable.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          If our future drugs do not achieve market acceptance,we may be unable to generate significant revenue, if any.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Even if our drug candidates obtain regulatoryapproval, they may not gain market acceptance among physicians, health care payors, patients and the medical community. Factorsthat we believe could materially affect market acceptance of our drug candidates include:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 10%">          </td>          <td style="width: 2%; font-size: 10pt">           •          </td>          <td style="width: 88%; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the timing of market introduction of competitive drugs;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           •          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the demonstrated clinical safety and efficacy of our drug candidates compared to other drugs and other drug candidates;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           •          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the suitability of our drug candidates to be co-administered or combined with other drugs or drug candidates;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           •          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the durability of our drug candidates in their ability to prevent the emergence of drug-resistant viral mutants;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           •          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the convenience and ease of administration of our drug candidates;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           •          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the existence, prevalence and severity of adverse side effects;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           •          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            other potential advantages of alternative treatment methods;           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin: 0">       </p>       <p style="margin: 0">       </p>       <!-- Field: Page; Sequence: 45; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            43            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="margin: 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 10%">          </td>          <td style="font-size: 10pt; width: 2%">           •          </td>          <td style="font-size: 10pt; width: 88%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the effectiveness of marketing and distribution support;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           •          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the cost-effectiveness of our drug candidates; and           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           •          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the availability of reimbursement from managed care plans, the government and other third-party payors.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        If our approved drug candidates fail toachieve market acceptance, we would not be able to generate significant revenue. In addition, even if our approved drug candidatesachieve market acceptance, we may not be able to maintain that market acceptance over time if:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 10%">          </td>          <td style="width: 2%; font-size: 10pt">           •          </td>          <td style="width: 88%; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            new products or technologies are introduced that are more favorably received than our products, are more cost effective or render our products obsolete;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           •          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            unforeseen complications arise with respect to the use of our products; or           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           •          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            sufficient third-party insurance coverage or reimbursement does not remain available.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          If third-party payors do not adequately reimburse patientsfor any of our drug candidates that are approved for marketing, they might not be purchased or used, and our revenues and profitswill not develop or increase.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Our revenues and profits will depend significantlyupon the availability of adequate reimbursement for the use of any approved drug candidates from governmental and other third-partypayors, both in the U.S. and in foreign markets. Reimbursement by a third party may depend upon a number of factors, includingthe third-party payor’s determination that use of an approved drug candidate is:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 10%; padding: 0.25pt">          </td>          <td style="width: 2%; padding: 0.25pt 0.25pt 8pt; font-size: 10pt">           •          </td>          <td style="width: 88%; padding: 0.25pt 0.25pt 8pt; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            a covered benefit under its health plan;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding: 0.25pt">          </td>          <td style="padding: 0.25pt 0.25pt 8pt; font-size: 10pt">           •          </td>          <td style="padding: 0.25pt 0.25pt 8pt; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            safe, effective and medically necessary;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding: 0.25pt">          </td>          <td style="padding: 0.25pt 0.25pt 8pt; font-size: 10pt">           •          </td>          <td style="padding: 0.25pt 0.25pt 8pt; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            appropriate for the specific patient;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding: 0.25pt">          </td>          <td style="padding: 0.25pt 0.25pt 8pt; font-size: 10pt">           •          </td>          <td style="padding: 0.25pt 0.25pt 8pt; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            cost effective; and           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding: 0.25pt">          </td>          <td style="padding: 0.25pt 0.25pt 8pt; font-size: 10pt">           •          </td>          <td style="padding: 0.25pt 0.25pt 8pt; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            neither experimental nor investigational.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The regulations that govern marketing approvals,pricing and reimbursement for new therapeutic and diagnostic products vary widely from country to country. Some countries requireapproval of the sale price of a drug candidate before it can be marketed. In many countries, the pricing review period begins aftermarketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subjectto continuing governmental control even after initial approval is granted. As a result, we might obtain regulatory approval fora drug candidate in a particular country, but then be subject to price regulations that delay our commercial launch of the approveddrug and negatively impact the revenues we are able to generate from the sale of the approved drug in that country. Adverse pricinglimitations may hinder our ability to recoup our investment in one or more drug candidates, even if our drug candidates obtainregulatory approval.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Obtaining reimbursement approval for anapproved drug from each third-party and government payor is a time-consuming and costly process that could require us to providesupporting scientific, clinical and cost-effectiveness data for the use of any approved drug candidates to each payor. We may notbe able to provide data sufficient to gain acceptance with respect to reimbursement. There also exists substantial uncertaintyconcerning third-party reimbursement for the use of any approved drug incorporating new technology, and even if determined eligible,coverage may be more limited than the purposes for which the drug is approved by the FDA. Moreover, eligibility for coverage doesnot imply that any approved drug will be reimbursed in all cases or at a rate that allows us to make a profit or even cover ourcosts. Interim payments for new products, if applicable, may also be insufficient to cover our costs and may not be made permanent.Reimbursement rates may vary according to the use of the approved drugs and the clinical setting in which it is used, may be basedon payments allowed for lower-cost products or combinations of products that are already reimbursed, may be incorporated into existingpayments for other products or services, and may reflect budgetary constraints and/or imperfections in Medicare or Medicaid dataused to calculate these rates. Net prices for products may be reduced by mandatory discounts or rebates required by governmenthealth care programs or by any future relaxation of laws that restrict imports of certain medical products from countries wherethey may be sold at lower prices than in the U.S.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 46; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            44            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        In the U.S., at both the federal and statelevels, the government regularly proposes legislation to reform health care and its cost, and such proposals have received increasingpolitical attention. While health care reform may increase the number of patients who have insurance coverage for the use of anyapproved drug, it may also include changes that adversely affect reimbursement for approved drugs. In addition, there has been,and we expect that there will continue to be, federal and state proposals to constrain expenditures for medical products and services,which may affect payments for any of our drug candidates that obtain approval. The Centers for Medicare and Medicaid Services frequentlychange product descriptors, coverage policies, product and service codes, payment methodologies and reimbursement values. Third-partypayors often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates and may have sufficientmarket power to demand significant price reductions. As a result of actions by these third-party payors, the health care industryis experiencing a trend toward containing or reducing costs through various means, including lowering reimbursement rates, limitingtherapeutic class coverage and negotiating reduced payment schedules with service providers for drug products.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Our inability to promptly obtain coverageand profitable reimbursement rates from government-funded and private payors for any of our drug candidates that obtain approvalcould have a material adverse effect on our business and financial condition.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Risks Related to Intellectual Property        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          If our patent position does not adequately protect ourdrug candidates, others could compete against us more directly, which would harm our business.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        We announced on September 25,2019 that the USPTO issued a patent for claims related to DNAbilize        <sup>         ®        </sup>        , including its use in the treatment ofcancers, autoimmune diseases and infectious diseases. Additionally, on February 10, 2021, we announced that the USPTOgranted U.S. Patent No. 10,898,506 titled, “P-ethoxy nucleic acids for liposomal formulation.” The newpatent builds on earlier patents granted that protect the platform technology for DNAbilize        <sup>         ®        </sup>        , theCompany’s novel RNAi nanoparticle drugs. Our patent portfolio currently includes three issued patents(No. 9,744,187, No. 10,335,428 and No. 10,898,506) in the U.S. for claims related toDNAbilize        <sup>         ®        </sup>        , as well as four additional pending patents for composition and methods of use of specific drugtargets. We announced on October 22, 2020 that the USPTO issued a Notice of Allowance for U.S. Patent ApplicationNo. 16/333,221 entitled “Combination Therapy with Liposomal Antisense Oligonucleotides.” Our success dependsin large part on our ability to obtain and maintain patent protection both in the U.S. and in other countries for our drugcandidates. Our ability to protect our drug candidates from unauthorized or infringing use by third parties depends insubstantial part on our ability to obtain and maintain valid and enforceable patents. Due to evolving legal standardsrelating to the patentability, validity and enforceability of patents covering pharmaceutical inventions and the scope ofclaims made under these patents, our ability to maintain, obtain and enforce patents is uncertain and involves complex legaland factual questions. Accordingly, rights under any issued patents may not provide us with sufficient protection for ourdrug candidates or provide sufficient protection to afford us a commercial advantage against competitive products orprocesses. We cannot guarantee that any patents will issue from any pending or future patent applications owned by orlicensed to us.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Even if patents have issued or will issue,we cannot guarantee that the claims of these patents are or will be valid or enforceable or will provide us with any significantprotection against competitive products or otherwise be commercially valuable to us. Patent applications in the U.S. are maintainedin confidence for up to 18 months after their filing. In some cases, however, patent applications remain confidential in the USPTOfor the entire time prior to issuance as a U.S. patent. Similarly, publication of discoveries in the scientific or patent literatureoften lags behind actual discoveries. Consequently, we cannot be certain that we or our licensors were the first to invent, orthe first to file patent applications on, our drug candidates. The costs of these proceedings could be substantial and it is possiblethat our efforts would be unsuccessful, resulting in a loss of our U.S. patent position. Furthermore, we may not have identifiedall U.S. and foreign patents or published applications that affect our business either by blocking our ability to commercializeour drugs or by covering similar technologies that affect our drug market.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 47; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            45            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The claims of the issued patents that arelicensed to us, and the claims of any patents which may issue in the future and be owned by or licensed to us, may not confer onus significant commercial protection against competing products. Additionally, our patents may be challenged by third parties,resulting in the patent being deemed invalid, unenforceable or narrowed in scope, or the third party may circumvent any such issuedpatents. Our patents might not contain claims that are sufficiently broad to prevent others from utilizing our technologies. Consequently,our competitors may independently develop competing products that do not infringe our patents or other intellectual property. Tothe extent a competitor can develop similar products using a different molecule, our patents may not prevent others from directlycompeting with us.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The laws of some foreign jurisdictions donot protect intellectual property rights to the same extent as in the U.S. and many companies have encountered significant difficultiesin protecting and defending such rights in foreign jurisdictions. If we encounter such difficulties in protecting or are otherwiseprecluded from effectively protecting our intellectual property rights in foreign jurisdictions, our business prospects could besubstantially harmed.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Because of the extensive time required fordevelopment, testing and regulatory review of a drug candidate, it is possible that, before any of our drug candidates can be commercialized,any related patent may expire or remain in force for only a short period following commercialization of our drug candidates, therebyreducing any advantages of the patent. To the extent our drug candidates based on that technology are not commercialized significantlyahead of the date of any applicable patent, or to the extent we have no other patent protection on such drug candidates, thosedrug candidates would not be protected by patents, and we would then rely solely on other forms of exclusivity, such as regulatoryexclusivity provided by the FDCA or trade secret protection.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The Leahy-Smith America Invents Act (the “America Invents Act”) was signed into law in September 2011, and many of the substantive changes became effectivein March 2013. The America Invents Act reforms U.S. patent law in part by changing the standard for patent approval from a “first to invent” standard to a “first to file” standard and developing a post-grant review system. Thislegislation changes U.S. patent law in a way that may weaken our ability to obtain patent protection in the U.S. for those applicationsfiled after March 2013.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          If any third-party owners of intellectual property wemay license in the future do not properly maintain or enforce the patents underlying such licenses, our competitive position andbusiness prospects will be harmed.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        We may enter into licenses for third-partyintellectual property in the future. Our success will depend in part on the ability of our licensors to obtain, maintain and enforcepatent protection for their intellectual property, in particular, those patents to which we have secured exclusive rights. If applicable,our licensors may not successfully prosecute the patent applications to which we are licensed. Even if patents issue in respectof any such patent applications, our licensors may fail to maintain these patents, may determine not to pursue litigation againstother companies that are infringing these patents, or may pursue such litigation less aggressively than we would. In addition,our licensors may terminate their agreements with us in the event we breach the applicable license agreement and fail to cure thebreach within a specified period of time. Without protection for the intellectual property we license, other companies might beable to offer substantially identical products for sale, which could materially adversely affect our competitive business position,business prospects and financial condition.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Because our research and development ofdrug candidates incorporates compounds and other information that is the intellectual property of third parties, we depend on continuedaccess to such intellectual property to conduct and complete our preclinical and clinical research and commercialize the drug candidatesthat result from this research. We expect that future licenses would impose, numerous obligations on us. For example, under ourexisting and future license agreements, we may be required to pay (i) annual maintenance fees until a drug candidate is soldfor the first time, (ii) running royalties on net sales of drug candidates, (iii) minimum annual royalties after a drugcandidate is sold for the first time, and (iv) one-time payments upon the achievement of specified milestones. We may alsobe required to reimburse patent costs incurred by the licensor, or we may be obligated to pay additional royalties, at specifiedrates, based on net sales of our drug candidates that incorporate the licensed intellectual property rights. We may also be obligatedunder some of these agreements to pay a percentage of any future sublicensing revenues that we may receive. Future license agreementsmay also include payment obligations such as milestone payments or minimum expenditures for research and development. We expectthat any future licenses would contain reporting, insurance and indemnification requirements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 48; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            46            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <!-- Field: Split-Segment; Name: 4 -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        We announced on September 25,2019 that the USPTO issued a patent for claims related to DNAbilize        <sup>         ®        </sup>        , including its use in the treatment ofcancers, autoimmune diseases and infectious diseases. Additionally, on February 10, 2021, we announced that the USPTOgranted U.S. Patent No. 10,898,506 titled, “P-ethoxy nucleic acids for liposomal formulation.” The newpatent builds on earlier patents granted that protect the platform technology for DNAbilize        <sup>         ®        </sup>        , theCompany’s novel RNAi nanoparticle drugs. Our patent portfolio currently includes three issued patents(No. 9,744,187, No. 10,335,428 and No. 10,898,506) in the U.S. for claims related toDNAbilize        <sup>         ®        </sup>        , as well as four additional pending patents for composition and methods of use of specific drugtargets. We announced on October 22, 2020 that the USPTO issued a Notice of Allowance for U.S. Patent ApplicationNo. 16/333,221 entitled “Combination Therapy with Liposomal Antisense Oligonucleotides.” We are activelyreviewing and preparing additional patent applications to expand our patent portfolio, but there can be no assurances thatpatents related to our existing patent applications or any applications we may file in the future will be issued or that anyissued patents will provide meaningful protection for our drug candidates, which could materially adversely affect ourcompetitive business position, business prospects and financial condition.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          If we infringe or are alleged to infringe intellectualproperty rights of third parties, our business could be harmed.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Our research, development and commercializationactivities, including any drug candidates resulting from these activities, may infringe or be claimed to infringe patents or otherproprietary rights owned by third parties and to which we do not hold licenses or other rights. There may be applications thathave been filed but not published that, if issued, could be asserted against us. If a patent infringement suit were brought againstus, we could be forced to stop or delay research, development or manufacturing of drug candidate that is the subject of the suit.Further, if we are found to have infringed a third- party patent, we could be obligated to pay royalties and/or other paymentsto the third party related to our drug candidates, which may be substantial, or we could be enjoined from selling our drug candidatesthat obtain approval.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        There has been substantial litigation andother proceedings regarding patent and other intellectual property rights in the pharmaceutical and biotechnology industries. Inaddition to infringement claims against us, we may become a party to other patent litigation and other proceedings, including interferenceproceedings declared by the USPTO and opposition proceedings in the European Patent Office, regarding intellectual property rightswith respect to our drug candidates and technology. Uncertainties resulting from the initiation and continuation of patent litigationor other proceedings could have a material adverse effect on our business and financial condition.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Litigation regarding patents, intellectual property andother proprietary rights may be expensive and time consuming. If we are involved in such litigation, it could cause delays in bringingdrug candidates to market and harm our ability to operate.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Our success will depend in part on our abilityto operate without infringing the proprietary rights of third parties. Although we are not currently aware of any litigation orother proceedings or third-party claims of intellectual property infringement related to our drug candidates, the pharmaceuticalindustry is characterized by extensive litigation regarding patents and other intellectual property rights. Other parties may obtainpatents in the future and allege that the use of our technologies infringes these patent claims or that we are employing theirproprietary technology without authorization. Likewise, third parties may challenge or infringe upon our existing or future patents.Proceedings involving our patents or patent applications or those of others could result in adverse decisions regarding:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.75in">          </td>          <td style="width: 0.25in; text-align: left">           •          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            thepatentability of our inventions relating to our drug candidates; and/or           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.75in">          </td>          <td style="width: 0.25in; text-align: left">           •          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            theenforceability, validity or scope of protection offered by our patents relating to our drug candidates.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 49; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            47            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Even if we are successful in these proceedings,we may incur substantial costs and divert management time and attention in pursuing these proceedings, which could have a materialadverse effect on us. If we are unable to avoid infringing the patent rights of others, we may be required to seek a license, defendan infringement action or challenge the validity of the patents in court. Patent litigation is costly and time consuming. We maynot have sufficient resources to bring these actions to a successful conclusion. In addition, if we do not obtain a license, developor obtain non-infringing technology, fail to defend an infringement action successfully or have infringed patents declared invalid,we may:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.75in">          </td>          <td style="width: 0.25in; text-align: left">           •          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            incursubstantial monetary damages;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.75in">          </td>          <td style="width: 0.25in; text-align: left">           •          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            encountersignificant delays in bringing our drug candidates to market; and/or           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.75in">          </td>          <td style="width: 0.25in; text-align: left">           •          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            beprecluded from participating in the manufacture, use or sale of our drug candidates or methods of treatment requiring licenses.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Furthermore, because of the substantialamount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidentialinformation could be compromised by disclosure during this type of litigation. In addition, during the course of this kind of litigation,there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If investorsperceive these results to be negative, the market price for our common stock could be significantly harmed.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Confidentiality agreements with employees and others maynot adequately prevent disclosure of trade secrets and other proprietary information and may not adequately protect our intellectualproperty.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        We rely on trade secrets to protect ourtechnology, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficultto protect. In order to protect our proprietary technology and processes, we also rely in part on confidentiality and intellectualproperty assignment agreements with our corporate partners, employees, consultants, outside scientific collaborators and sponsoredresearchers and other advisors. These agreements may not effectively prevent disclosure of confidential information nor resultin the effective assignment to us of intellectual property, and may not provide an adequate remedy in the event of unauthorizeddisclosure of confidential information or other breaches of the agreements. In addition, others may independently discover ourtrade secrets and proprietary information, and in such case we could not assert any trade secret rights against such party. Enforcinga claim that a party illegally obtained and is using our trade secrets is difficult, expensive and time-consuming, and the outcomeis unpredictable. In addition, courts outside the U.S. may be less willing to protect trade secrets. Costly and time-consuminglitigation could be necessary to seek to enforce and determine the scope of our proprietary rights, and failure to obtain or maintaintrade secret protection could materially adversely affect our business and financial condition.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Risks Related to Our Securities        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Raising additional capital may cause dilution to existingstockholders, restrict our operations or require us to relinquish rights. Additionally, sales of a substantial number of sharesof our common stock or other securities in the public market could cause our stock price to fall.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        We expect to seek the additional capitalnecessary to fund our operations through public or private equity offerings, collaboration agreements, debt financings or licensingarrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, existingstockholders’ ownership interests will be diluted and the terms may include liquidation or other preferences that adverselyaffect their rights as a stockholder. Debt financing, if available, may involve agreements that include covenants limiting or restrictingour ability to take specific actions such as incurring additional debt, making capital expenditures or declaring dividends. Ifwe raise additional funds through collaboration or licensing arrangements with third parties, we may have to relinquish valuablerights to our technologies or drug candidates, or grant licenses on terms that are not favorable to us. In addition, sales of asubstantial number of shares of our common stock or other securities in the public market could occur at any time. These sales,or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market priceof our common stock.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 50; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            48            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          We may issue additional shares of our common stock inaccordance with our equity incentive plans or upon exercise or conversion of outstanding securities that are exercisable for orconvertible into shares of our common stock, which may cause dilution to existing stockholders.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        As of December 31, 2020, there were274,008 shares of common stock reserved for issuance upon the exercise of outstanding options granted under our equity incentiveplans. As of December 31, 2020, there were 402,724 additional shares of common stock reserved for future issuance of awardsunder the Bio-Path Holdings, Inc. 2017 Stock Incentive Plan, as amended (the “2017 Stock Incentive Plan”). Inaddition, as of December 31, 2020, there were 858,699 shares of common stock reserved for issuance upon the exercise of outstandingwarrants that we have issued in connection with prior securities offerings. To the extent that outstanding stock options and warrantsare exercised, existing stockholders’ ownership interests may be diluted.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          The trading price of our common stock has been volatileand is likely to be volatile in the future.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The trading price of our common stock hasbeen highly volatile. On March 10, 2014, our common stock commenced trading on The Nasdaq Capital Market, and there is a limitedhistory on which to gauge the volatility of our stock price on The Nasdaq Capital Market. From January 1, 2018 through December 31,2020, our stock price has fluctuated from a low of $1.61 to a high of $73.52, after adjustment for reverse stock splits. The marketprice for our common stock will be affected by a number of factors, including:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.75in">          </td>          <td style="width: 0.25in; text-align: left">           •          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            thedenial or delay of regulatory approvals of our drug candidates or receipt of regulatory approval of competing products;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.75in">          </td>          <td style="width: 0.25in; text-align: left">           •          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ourability to accomplish clinical, regulatory and other drug development milestones;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.75in">          </td>          <td style="width: 0.25in; text-align: left">           •          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            theability of our drug candidates, if they receive regulatory approval, to achieve market success;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.75in">          </td>          <td style="width: 0.25in; text-align: left">           •          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            theperformance of third-party manufacturers and suppliers;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.75in">          </td>          <td style="width: 0.25in; text-align: left">           •          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            developmentswith respect to patents and other intellectual property rights;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.75in">          </td>          <td style="width: 0.25in; text-align: left">           •          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            salesof common stock or other securities by us or our stockholders in the future;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.75in">          </td>          <td style="width: 0.25in; text-align: left">           •          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            additionsor departures of key scientific or management personnel;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.75in">          </td>          <td style="width: 0.25in; text-align: left">           •          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            disputesor other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protectionfor our drug           </font>           candidates;          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.75in">          </td>          <td style="width: 0.25in; text-align: left">           •          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            tradingvolume of our common stock;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.75in">          </td>          <td style="width: 0.25in; text-align: left">           •          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            investorperceptions about us and our industry;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.75in">          </td>          <td style="width: 0.25in; text-align: left">           •          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            publicreaction to our press releases, other public announcements and SEC and other filings;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.75in">          </td>          <td style="width: 0.25in; text-align: left">           •          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            thefailure of analysts to cover us, or changes in analysts’ estimates or recommendations;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.75in">          </td>          <td style="width: 0.25in; text-align: left">           •          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            thefailure by us to meet analysts’ projections or guidance;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.75in">          </td>          <td style="width: 0.25in; text-align: left">           •          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            generalmarket conditions and other factors unrelated to our operating performance or the operating performance of our competitors; and           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.75in">          </td>          <td style="width: 0.25in; text-align: left">           •          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            theother factors described elsewhere in this “Item 1A. Risk Factors” or the section titled “Risk Factors”contained in our other public filings.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 51; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            49            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The stock prices of many companies in thebiotechnology industry have experienced wide fluctuations that have often been unrelated to the operating performance of thesecompanies. Following periods of volatility in the market price of a company’s securities, securities class action litigationoften has been initiated against a company. If any class action litigation is initiated against us, we may incur substantial costsand our management’s attention may be diverted from our operations, which could materially adversely affect our businessand financial condition.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Our common stock is thinly traded and in the future maycontinue to be thinly traded, and our stockholders may be unable to sell at or near asking prices or at all if they need to selltheir shares to raise money or otherwise desire to liquidate such shares.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        To date, we have a low volume of daily tradesin our common stock on The Nasdaq Capital Market. Our stockholders may be unable to sell their common stock at or near their askingprices or at all, which may result in substantial losses to our stockholders.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The market for our common stock may be characterizedby significant price volatility when compared to seasoned issuers, and we expect that our share price will be more volatile thana seasoned issuer for the foreseeable future. As noted above, our common stock may be sporadically and/or thinly traded. As a consequenceof this lack of liquidity, the trading of relatively small quantities of shares by our stockholders may disproportionately influencethe price of those shares in either direction.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Our certificate of incorporation grants our Board of Directorsthe power to designate and issue additional shares of common and/or preferred stock.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Our authorized capital consists of 200,000,000shares of common stock and 10,000,000 shares of preferred stock. Our preferred stock may be designated into series pursuant toauthority granted by our certificate of incorporation, and on approval from our Board of Directors (the “Board”). TheBoard, without any action by our stockholders, may designate and issue shares in such classes or series as the Board deems appropriateand establish the rights, preferences and privileges of such shares, including dividends, liquidation and voting rights. The rightsof holders of other classes or series of stock that may be issued could be superior to the rights of holders of our common shares.The designation and issuance of shares of capital stock having preferential rights could adversely affect other rights appurtenantto shares of our common stock.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          We do not anticipate paying cash dividends, and accordinglystockholders must rely on stock appreciation for any return on their investment in us.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        We anticipate that we will retain our earnings,if any, for future growth and therefore do not anticipate paying cash dividends in the future. As a result, only appreciation ofthe price of our common stock will provide a return to stockholders.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Our management is required to devote substantial timeand incur additional expense to comply with public company regulations.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        As a public reporting company, we are subjectto the Sarbanes-Oxley Act of 2002, as well as to the information and reporting requirements of the SEC and other federal securitieslaws. We are also subject to the rules of The Nasdaq Stock Market. As a result, we incur significant legal, accounting, andother expenses that we would not incur as a private company, including costs associated with our public company reporting requirementsand corporate governance requirements. Compliance with these public company obligations places significant additional demands onour limited number of finance and accounting staff and on our financial, accounting and information systems.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 52; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            50            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Our common stock may be delisted from The Nasdaq CapitalMarket which could negatively impact the price of our common stock and our ability to access the capital markets.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The listing standards of The Nasdaq CapitalMarket provide that a company, in order to qualify for continued listing, must maintain a minimum stock price of $1.00 and satisfystandards relative to minimum stockholders’ equity, minimum market value of publicly held shares and various additional requirements.If we fail to comply with all listing standards applicable to issuers listed on The Nasdaq Capital Market, our common stock maybe delisted. If our common stock is delisted, it could reduce the price of our common stock and the levels of liquidity availableto our stockholders. In addition, the delisting of our common stock could materially adversely affect our access to the capitalmarkets and any limitation on liquidity or reduction in the price of our common stock could materially adversely affect our abilityto raise capital. Delisting from The Nasdaq Capital Market could also result in other negative consequences, including the potentialloss of confidence by suppliers, customers and employees, the loss of institutional investor interest and fewer business developmentopportunities.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        In the past, we have received a notice ofnon-compliance from the Listing Qualifications Department of The Nasdaq Stock Market LLC with respect to the $1.00 minimum closingbid price requirement. Although we have regained compliance with the minimum closing bid price requirement after implementing reversestock splits, there can be no assurance that we will be able to meet the minimum closing bid price requirement or other listingrequirements in the future.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="text-transform: uppercase">         <b>          <a name="Seng_004">          </a>          ITEM 1B. UNRESOLVEDSTAFF COMMENTS         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        None.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="text-transform: uppercase">         <b>          <a name="Seng_005">          </a>          ITEM 2. PROPERTIES         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        In April 2014, we entered into a leaseagreement for approximately 3,000 square feet of office space for general and administrative purposes in Bellaire, Texas, whichis part of the Houston metropolitan area. The term of the lease began on August 1, 2014 and was scheduled to terminate onJuly 31, 2019. In May 2019, we entered into an amendment to the lease agreement to extend the term of the lease to October 31,2024.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        In April 2016, we entered into a leaseagreement for approximately 2,100 square feet of lab space located in Bellaire, Texas for research and development purposes. Theterm of the lease began on May 1, 2016 and was scheduled to terminate on April 30, 2019. In December 2018, we enteredinto an amendment to the lease agreement to extend the term of the lease to April 30, 2022.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        We do not own or lease any other real propertythat is materially important to our business. We believe that our current facilities are adequate for our current needs and thatadditional space will be available when and as needed.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="text-transform: uppercase">         <b>          <a name="Seng_006">          </a>          ITEM 3. LEGAL PROCEEDINGS         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        None.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="text-transform: uppercase">         <b>          <a name="Seng_007">          </a>          ITEM 4. MINE SAFETYDISCLOSURES         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Not applicable.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 53; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            51            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="text-transform: uppercase">         <b>          <u>           <a name="Seng_008">           </a>           PART II          </u>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="text-transform: uppercase">         <b>          <a name="Seng_009">          </a>          ITEM 5. MARKET FORREGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Our common stock is listed on The NasdaqCapital Market under the symbol “BPTH.”       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Holders        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        As of March 1, 2021, there were 6,947,912shares of our common stock outstanding and approximately 214 stockholders of record.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Dividends        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        We have not paid any cash dividends sinceour inception and do not anticipate or contemplate paying dividends in the foreseeable future.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Unregistered Sales of Equity Securitiesand Use of Proceeds        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        None.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Purchases of Equity Securities by theIssuer and Affiliated Purchasers        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        None.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="text-transform: uppercase">         <b>          <a name="Seng_010">          </a>          ITEM 6. [RESERVED]         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="text-transform: uppercase">         <b>          <a name="Seng_011">          </a>          ITEM 7. MANAGEMENT’SDISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        In addition to historical information, thisAnnual Report on Form 10-K contains forward-looking statements that involve significant risks and uncertainties, which maycause our actual results to differ materially from plans and results discussed in forward-looking statements. We encourage youto review the risks and uncertainties, discussed in “Item 1A. Risk Factors” and “Cautionary Note Regarding Forward-LookingStatements,” included elsewhere in this Annual Report on Form 10-K. The risks and uncertainties can cause actual resultsto differ significantly from those forecasted in forward-looking statements or implied in historical results and trends.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The following discussion of our financialcondition and results of operations should be read in conjunction with our financial statements and related notes included elsewherein this Annual Report on Form 10-K.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Overview        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        We are a clinical and preclinical stageoncology focused RNAi nanoparticle drug development company utilizing a novel technology that achieves systemic delivery for targetspecific protein inhibition for any gene product that is over-expressed in disease. Our drug delivery and antisense technology,called DNAbilize®, is a platform that uses P-ethoxy, which is a DNA backbone modification that is intended to protect the DNAfrom destruction by the body’s enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge.We believe this combination allows for high efficiency loading of antisense DNA into non-toxic, cell-membrane-like structures fordelivery of the antisense drug substance into cells. In vivo, the DNAbilize® delivered antisense drug substances are systemicallydistributed throughout the body to allow for reduction or elimination of target proteins in blood diseases and solid tumors. Throughtesting in numerous animal studies and treatment in over 80 patients, the Company’s DNAbilize® drug candidates have demonstratedan excellent safety profile. DNAbilize® is a registered trademark of the Company.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 54; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            52            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Using DNAbilize® as a platform for drugdevelopment and manufacturing, we currently have four drug candidates in development to treat at least five different cancer diseaseindications. Our lead drug candidate, prexigebersen (pronounced prex” i je ber’ sen), which targets growth factor receptor-boundprotein 2 (Grb2), initially started the efficacy portion of a Phase 2 clinical trial for untreated AML patients in combinationwith LDAC. The interim data released on March 6, 2019 showed that 11 (65%) of the 17 evaluable patients had a response, includingfive (29%) who achieved CR, including one CR        <sub>         i        </sub>        and one morphologic leukemia free state, and six (35%) stable diseaseresponses, including two patients who had greater than a 50% reduction in bone marrow blasts. However, DNA hypomethylating agentsare now the most frequently used agents in the treatment of elderly AML patients in the U.S. and Europe. As a result, Stage 2 ofthe Phase 2 trial in AML was amended to remove the combination treatment of prexigebersen and LDAC and replace it with the combinationtreatment prexigebersen and decitabine, a DNA hypomethylating agent, for treatment of a second cohort of untreated AML patients.Since decitabine is also used as a treatment for relapsed/refractory AML patients, a cohort of relapsed/refractory AML patientswas also added to the study.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The FDA recently granted approval of venetoclaxin combination with LDAC, decitabine or azacytidine (the latter two drugs are DNA hypomethylating agents) as frontline therapyfor newly diagnosed AML in adults who are 75 years or older, or who have comorbidities precluding intensive induction chemotherapy.We believe this recent approval of the frontline venetoclax and decitabine combination therapy provides an opportunity for combiningprexigebersen with the combination therapy for the treatment of        <i>         de novo        </i>        AML patients. Preclinical efficacy studies for thetriple combination treatment of prexigebersen, decitabine and venetoclax in AML have been successfully completed. In the preclinicalefficacy studies, four AML cancer cell lines were treated with three different combinations of decitabine, venetoclax and prexigebersen.Decrease in AML cell viability was the primary measure of efficacy. The triple combination of decitabine, venetoclax and prexigebersenshowed significant improvement in efficacy in three of the four AML cell lines. Based on these results, the Company believes thatadding prexigebersen to the treatment combination of decitabine and venetoclax could lead to improved efficacy in AML patients.Accordingly, the Company further amended Stage 2 of this Phase 2 clinical trial to add the triple combination treatment comprisedof prexigebersen, decitabine and venetoclax, which amendment has been approved by the FDA.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Bio-Path’s approved amended Stage2 for this Phase 2 clinical trial currently has three cohorts of patients. The first two cohorts will treat patients with the triplecombination of prexigebersen, decitabine and venetoclax. The first cohort will include untreated AML patients, and the second cohortwill include relapsed/refractory AML patients. Finally, the third cohort will treat relapsed/refractory AML patients who are venetoclax-resistantor -intolerant with the two-drug combination of prexigebersen and decitabine. The full trial design plans have approximately 98evaluable patients for the first cohort having untreated AML patients with a preliminary review performed after 19 evaluable patientsand a formal interim analysis after 38 evaluable patients. The full trial design plans have approximately 54 evaluable patientsfor each of the second cohort, having relapsed/refractory AML patients, and the third cohort, having AML patients who are venetoclax-resistantor -intolerant, in each case with a review performed after 19 evaluable patients. The study is anticipated to be conducted at tenclinical sites in the U.S., and Gail J. Roboz, MD will be the national coordinating Principal Investigator for the Phase 2 trial.Dr. Roboz is a professor of medicine and director of the Clinical and Translational Leukemia Program at the Weill MedicalCollege of Cornell University and the New York-Presbyterian Hospital in New York City. On August 13, 2020, we announced theenrollment and dosing of the first patient in this approved amended Stage 2 of the Phase 2 clinical study.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Our second drug candidate, BP1002, targetsthe protein Bcl-2, which is responsible for driving cell survival in up to 60% of all cancers. On November 21, 2019, we announcedthat the FDA cleared an IND application for BP1002. An initial Phase 1 clinical trial will evaluate the ability of BP1002 to treatrefractory/relapsed lymphoma and chronic lymphocytic leukemia patients. The Phase 1 clinical trial is being conducted at severalleading cancer centers, including MD Anderson, the Georgia Cancer Center and the Sarah Cannon Research Institute. Ian W. Flynn,MD will be the national coordinating Principal Investigator for the Phase 1 trial. Dr. Flynn serves as the director of lymphomaresearch at the Sarah Cannon Research Institute. On November 19, 2020, we announced the enrollment and dosing of the firstpatient in the Phase 1 clinical trial.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 55; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            53            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Our third drug candidate, BP1003, targetsthe STAT3 protein and is currently in IND enabling studies as a potential treatment of pancreatic cancer, NSCLC and AML. Preclinicalmodels have shown BP1003 to inhibit cell viability and STAT3 protein expression in NSCLC and AML cell lines. Further, BP1003 successfullypenetrated pancreatic tumors and significantly enhanced the efficacy of gemcitabine, a treatment for patients with advanced pancreaticcancer, in a pancreatic cancer patient derived tumor model. Our lead indication for BP1003 is pancreatic cancer due to the severityof this disease and the lack of effective, life-extending treatments. For example, pancreatic adenocarcinoma is projected to bethe second most lethal cancer behind lung cancer by 2030. Typical survival for a metastatic pancreatic cancer patient is aboutthree to six months from diagnosis. We expect to complete several IND enabling studies of BP1003 in 2021. If those studies aresuccessful, our goal is to file an IND in 2021 for the first-in-humans Phase 1 study of BP1003 in patients with refractory, metastaticsolid tumors, including pancreatic cancer and NSCLC.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        In addition, a modified product named prexigebersen-A,Bio-Path’s fourth drug candidate, has shown to enhance chemotherapy efficacy in preclinical solid tumor models. Prexigebersen-Aincorporates the same drug substance as prexigebersen but has a slightly modified formulation designed to enhance nanoparticleproperties. In late 2019, we filed an IND application to initiate a Phase 1 clinical trial of prexigebersen-A in patients withsolid tumors, including ovarian, endometrial, pancreatic and breast cancer. Ovarian cancer is one of the most common type of gynecologicmalignancies, with approximately 50% of all cases occurring in women older than 63 years. This trial is expected to commence afterthe IND has been cleared by the FDA, which we currently anticipate being in 2021.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Our DNAbilize® technology-based productsare available for out-licensing or partnering. We intend to apply our drug delivery technology template to new disease-causingprotein targets to develop new nanoparticle antisense RNAi drug candidates. We have a new product identification template in placeto define a process of scientific, preclinical, commercial and intellectual property evaluation of potential new drug candidatesfor inclusion into our drug product development pipeline. As we expand, we will look at indications where a systemic delivery isneeded and antisense RNAi nanoparticles can be used to slow, reverse or cure a disease, either alone or in combination with anotherdrug. On September 25, 2019, we announced that the USPTO issued a patent for claims related to DNAbilize®, including itsuse in the treatment of cancers, autoimmune diseases and infectious diseases. On October 22, 2020, we announced that the USPTOissued a Notice of Allowance for U.S. Patent Application No. 16/333,221 entitled “Combination Therapy with LiposomalAntisense Oligonucleotides.” In addition, on February 10, 2021, we announced that the USPTO granted U.S. Patent No. 10,898,506titled, “P-ethoxy nucleic acids for liposomal formulation.” The new patent builds on earlier patents granted that protectthe platform technology for DNAbilize        <sup>         ®        </sup>        , the Company’s novel RNAi nanoparticle drugs. The new patent is thethird patent in our family of platform intellectual property and offers expanded defense of our DNAbilize        <sup>         ®        </sup>        platformtechnology..       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        We have certain intellectual property asthe basis for our current drug products in clinical development, prexigebersen, prexigebersen-A, BP1002 and BP1003. We are developingRNAi antisense nanoparticle drug candidates based on our own patented technology to treat cancer and autoimmune disorders wheretargeting a single protein may be advantageous and result in reduced patient adverse effects as compared to small molecule inhibitorswith off-target and non-specific effects. We have composition of matter and method of use intellectual property for the designand manufacture of antisense RNAi nanoparticle drug products.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        As of December 31, 2020, we had anaccumulated deficit of $67.2 million. Our net loss was $10.9 million and $8.6 million for the years ended December 31, 2020and 2019, respectively. We expect to continue to incur significant operating losses, and we anticipate that our losses may increasesubstantially as we expand our drug development programs and commercialization efforts. To achieve profitability, we must enterinto license or development agreements with third parties, or successfully develop and obtain regulatory approval for one or moreof our drug candidates and effectively commercialize any drug candidates we develop. In addition, if we obtain regulatory approvalof one or more of our drug candidates, we expect to incur significant commercialization expenses related to product sales, marketing,manufacturing and distribution. Even if we succeed in developing and commercializing one or more of our drug candidates, we maynot be able to generate sufficient revenue and we may never be able to achieve or sustain profitability. We expect to finance ourforeseeable cash requirements through cash on hand, cash from operations, debt financings and public or private equity offerings.We may seek to access the public or private equity markets whenever conditions are favorable; however, there can be no assurancethat we will be able to raise additional capital when needed or on terms that are favorable to us, if at all. Additionally, wemay seek collaborations and license arrangements for our drug candidates. We currently have no lines of credit or other arrangedaccess to debt financing.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 56; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            54            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Financial Operations Overview        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">        <b>         <i>          Revenue         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        We have not generated significant revenuesto date. Our ability to generate revenues from our drug candidates, which we do not expect will occur for many years, if ever,will depend heavily on the successful development and eventual commercialization of our drug candidates.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        In the future, we may generate revenue froma combination of product sales, third-party grants, service agreements, strategic alliances and licensing arrangements. We expectthat any revenue we generate will fluctuate due to the timing and amount of services performed, milestones achieved, license feesearned and payments received upon the eventual sales of our drug candidates, in the event any are successfully commercialized.If we fail to complete the development of any of our drug candidates or obtain regulatory approval for them, our ability to generatefuture revenue will be adversely affected.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">        <b>         <i>          Research and development expenses         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Research and development expenses consistof costs associated with our research activities, including the development of our drug candidates. Our research and developmentexpenses consist of:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.75in">          </td>          <td style="width: 0.25in; text-align: left">           •          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            expensesrelated to research and development personnel, including salaries and benefits, travel and stock-based compensation;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.75in">          </td>          <td style="width: 0.25in; text-align: left">           •          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            externalresearch and development expenses incurred under arrangements with third parties, such as contract research organizations, clinicalinvestigative sites, laboratories, manufacturing organizations and consultants; and           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.75in">          </td>          <td style="width: 0.25in; text-align: left">           •          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            costsof materials used during research and development activities.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Costs and expenses that can be clearly identifiedas research and development are charged to expense as incurred. Advance payments, including nonrefundable amounts, for goods orservices that will be used or rendered for future research and development activities are deferred and capitalized. Such amountswill be recognized as an expense as the related goods are delivered or the related services are performed. If the goods will notbe delivered, or services will not be rendered, then the capitalized advance payment is charged to expense.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        We expect research and development expensesassociated with the completion of the associated clinical trials to be substantial and to increase over time. The successful developmentof our drug candidates is highly uncertain. At this time, we cannot reasonably estimate or know the nature, timing and estimatedcosts of the efforts that will be necessary to complete development of our drug candidates or the period, if any, in which materialnet cash inflows from our drug candidates may commence. This is due to the numerous risks and uncertainties associated with developingdrugs, including the uncertainty of:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.75in">          </td>          <td style="width: 0.25in; text-align: left">           •          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            therate of progress, results and costs of completion of ongoing clinical trials of our drug candidates;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.75in">          </td>          <td style="width: 0.25in; text-align: left">           •          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            thesize, scope, rate of progress, results and costs of completion of any potential future clinical trials and preclinical tests ofour drug candidates that we may initiate;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.75in">          </td>          <td style="width: 0.25in; text-align: left">           •          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            competingtechnological and market developments;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.75in">          </td>          <td style="width: 0.25in; text-align: left">           •          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            theperformance of third-party manufacturers and suppliers;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.75in">          </td>          <td style="width: 0.25in; text-align: left">           •          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            theability of our drug candidates, if they receive regulatory approval, to achieve market success;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.75in">          </td>          <td style="width: 0.25in; text-align: left">           •          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            disputesor other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protectionfor our drug candidates; and           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.75in">          </td>          <td style="width: 0.25in; text-align: left">           •          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            theimpact, risks and uncertainties related to COVID-19 and actions taken by governmental authorities or others in connection therewith.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 57; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            55            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        A change in the outcome of any of thesevariables with respect to the development of a drug candidate could mean a significant change in the costs and timing associatedwith the development of that drug candidate. For example, if the FDA or other regulatory authority were to require us to conductclinical trials beyond those which we currently anticipate will be required for the completion of clinical development of a drugcandidate or if we experience significant delays in enrollment in any clinical trials, we could be required to expend significantadditional financial resources and time on the completion of clinical development.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">        <b>         <i>          General and administrative expenses         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Our general and administrative expensesconsist primarily of salaries and benefits for management and administrative personnel, professional fees for legal, accountingand other services, travel costs and facility-related costs such as rent, utilities and other general office expenses.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Results of Operations        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">        <b>         <i>          Comparisons of the Year Ended December 31,2020 to the Year Ended December 31, 2019         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <i>         Revenue        </i>        . We had no revenue for eachof the years ended December 31, 2020 and 2019.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <i>         Research and Development Expenses        </i>        .Our research and development expense was $6.6 million for the year ended December 31, 2020, an increase of $2.0 million comparedto the year ended December 31, 2019. The increase in research and development expense was primarily due to increased enrollmentfor our Phase 2 clinical trial of prexigebersen in AML, startup costs related to our Phase 1 clinical trials for BP1002 in lymphomaand prexigebersen-A in solid tumors, increased preclinical expenses for BP1003 and increased drug material manufacturing activities.The following table sets forth our research and development expenses (in thousands):       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">           Year ended          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           December 31,          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           2020          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           2019          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; width: 72%; text-align: left">           Research and development expense          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">           6,477          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">           4,488          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Non-cash stock-based compensation expense          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           101          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           97          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Total research and development expense          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           6,578          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           4,585          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <i>         General and Administrative Expenses        </i>        .Our general and administrative expense was $4.3 million for the year ended December 31, 2020, an increase of $0.2 millioncompared to the year ended December 31, 2019. The increase in general and administrative expense was primarily due to increasedfranchise tax expense, which was partially offset by a decrease in stock-based compensation expense. The following table sets forthour general and administrative expenses (in thousands):       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">           Year ended          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           December 31,          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           2020          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           2019          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; width: 72%; text-align: left">           General and administrative expense          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">           3,854          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">           3,521          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Non-cash stock-based compensation expense          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           476          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           587          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Total general and administrative expense          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           4,330          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           4,108          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <i>         Net Operating Loss.        </i>        Our net lossfrom operations was $10.9 million for the year ended December 31, 2020, an increase of $2.2 million compared to the year endedDecember 31, 2019.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <i>         Net Loss        </i>        . Our net loss was $10.9million for the year ended December 31, 2020, an increase of $2.3 million compared to the year ended December 31, 2019.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 58; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            56            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <i>         Net Loss per Share.        </i>        Net loss pershare, both basic and diluted, was $2.83 per share for the year ended December 31, 2020, compared to $3.24 per share for theyear ended December 31, 2019. Net loss per share is calculated using the weighted average number of shares of common stockoutstanding during the applicable periods and excludes stock options and warrants because they are antidilutive.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Liquidity and Capital Resources        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">        <b>         <i>          Overview         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        We have not generated significant revenuesto date. Since our inception, we have funded our operations primarily through public and private offerings of our capital stockand other securities. We expect to finance our foreseeable cash requirements through cash on hand, cash from operations, debt financingsand public or private equity offerings. We may seek to access the public or private equity markets whenever conditions are favorable;however, there can be no assurance that we will be able to raise additional capital when needed or on terms that are favorableto us, if at all. Additionally, we may seek collaborations and license arrangements for our drug candidates. We currently haveno lines of credit or other arranged access to debt financing.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        We had a cash balance of $13.8 million atDecember 31, 2020, a decrease of $6.7 million compared to December 31, 2019. We believe that our available cash at December 31,2020, together with the net proceeds received from the 2021 Registered Direct Offering and sales of our common stock under theOffering Agreement, each as described below, in addition to net proceeds received from warrant exercises subsequent to December 31,2020, will be sufficient to meet obligations and fund our liquidity and capital expenditure requirements for at least the next12 months from the date of this Annual Report on Form 10-K.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">        <b>         <i>          Cash Flows         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <i>         For the Year Ended December 31,2020        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <i>         Operating Activities        </i>        . Net cash usedin operating activities for the year ended December 31, 2020 was $11.0 million. Excluding non-cash stock-based compensationexpense of $0.6 million and depreciation and amortization expenses of $0.2 million, net cash used in operating activities consistedprimarily of the net loss for the period of $10.9 million, an increase in current assets of $0.6 million and a decrease in operatingliabilities of $0.2 million.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <i>         Financing Activities        </i>        . Net cash providedby financing activities for the year ended December 31, 2020 consisted primarily of net proceeds of $4.3 million from theoffer and sale of shares of our common stock under the Offering Agreement, as described below.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">        <i>         For the Year Ended December 31, 2019        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <i>         Operating Activities        </i>        . Net cash usedin operating activities for the year ended December 31, 2019 was $8.4 million. Excluding non-cash stock-based compensationexpense of $0.7 million and amortization and depreciation expenses of $0.2 million, net cash used in operating activities consistedprimarily of the net loss for the period of $8.6 million, an increase in current assets of $0.4 million and a decrease in currentliabilities of $0.2 million.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <i>         Financing Activities        </i>        . Net cash providedby financing activities for the year ended December 31, 2019 consisted primarily of net proceeds of $26.7 million from the2019 Underwritten Offering, the January 2019 Registered Direct Offering and January 2019 Private Placement, the March 2019Registered Direct Offering and the November 2019 Registered Direct Offering, each as described below, as well as net proceedsof $1.1 million from the exercise of warrants to purchase shares of our common stock.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 59; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            57            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">        <b>         <i>          2019 Shelf Registration Statement         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        On May 16, 2019, we filed a shelf registrationstatement on Form S-3 with the SEC, which was declared effective by the SEC on June 5, 2019 (File No. 333-231537)(the “2019 Shelf Registration Statement”), at which time the offering of unsold securities under a previous shelf registrationstatement on Form S-3 filed with the SEC, which was declared effective by the SEC on January 9, 2017 (File No. 333-215205)(the “2017 Shelf Registration Statement”), was deemed terminated pursuant to Rule 415(a)(6) under the SecuritiesAct. The 2019 Shelf Registration Statement was filed to register the offering, issuance and sale of (i) up to $125.0 millionof our common stock, preferred stock, warrants to purchase common stock or preferred stock or any combination thereof, either individuallyor in units, and (ii) up to 5,149 shares of our common stock pursuant to the exercise of warrants that were issued in connectionwith a registered direct offering in 2016. Because our public float is less than $75 million, our ability to offer and sell anysecurities under the 2019 Shelf Registration Statement is currently limited pursuant to Instruction I.B.6 to Form S-3. Forso long as the Company's public float is less than $75 million, the aggregate market value of securities sold by the Company underthe 2019 Shelf Registration Statement pursuant to Instruction I.B.6 to Form S-3 during any 12 consecutive months may not exceedone-third of the Company’s public float. The foregoing does not constitute an offer to sell or the solicitation of an offerto buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitationor sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <b>         <i>          2019 Underwritten Offering         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        On January 14, 2019, we entered intoan underwriting agreement with H. C. Wainwright &amp; Co., LLC (“Wainwright”) relating to an underwritten publicoffering of 429,616 shares of our common stock for gross proceeds of approximately $1.1 million under the 2017 Shelf RegistrationStatement (the “2019 Underwritten Offering”). The offering price to the public in the 2019 Underwritten Offering was$2.60 per share, and Wainwright agreed to purchase the shares in the 2019 Underwritten Offering from the Company pursuant to theunderwriting agreement at a price of $2.418 per share. Additionally, we issued warrants to purchase up to 25,777 shares of ourcommon stock in a private placement to Wainwright as compensation for its services as underwriter in connection with the 2019 UnderwrittenOffering. The 2019 Underwritten Offering closed on January 17, 2019. The net proceeds to the Company from the 2019 UnderwrittenOffering, after deducting the underwriting discounts and commissions and expenses and the Company’s offering expenses, andexcluding the proceeds, if any, from the exercise of the underwriter warrants, were approximately $0.9 million.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <b>         <i>          January 2019 Registered DirectOffering and January 2019 Private Placement         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        On January 18, 2019, we entered intoa securities purchase agreement with certain investors pursuant to which we agreed to sell, in a registered direct offering, anaggregate of 648,233 shares of our common stock for gross proceeds of approximately $1.7 million under the 2017 Shelf RegistrationStatement (the “January 2019 Registered Direct Offering”). In a concurrent private placement, we also agreedpursuant to the securities purchase agreement to issue to such investors Series A warrants to purchase up to 324,117 sharesof our common stock (the “January 2019 Private Placement”). Additionally, we issued warrants to purchase up to38,894 shares of our common stock in a private placement to Wainwright as compensation for its services as a placement agent inconnection with the January 2019 Registered Direct Offering and the January 2019 Private Placement. The January 2019Registered Direct Offering and the January 2019 Private Placement closed on January 23, 2019. The net proceeds to theCompany from the offerings, after deducting the placement agent’s fees and expenses and the Company’s offering expenses,and excluding the proceeds, if any, from the exercise of the warrants issued in the offerings, were approximately $1.5 million.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <b>         <i>          March 2019 Registered DirectOffering         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        On March 12, 2019, we entered intoa securities purchase agreement with certain investors pursuant to which we agreed to sell, in a registered direct offering, anaggregate of 712,910 shares of our common stock for gross proceeds of approximately $18.5 million under the 2017 Shelf RegistrationStatement (the “March 2019 Registered Direct Offering”). Additionally, we issued warrants to purchase up to 42,775shares of our common stock in a private placement to Wainwright as compensation for its services as a placement agent in connectionwith the March 2019 Registered Direct Offering. The March 2019 Registered Direct Offering closed on March 14, 2019.The net proceeds to the Company from the offerings, after deducting the placement agent’s fees and expenses and the Company’soffering expenses, and excluding the proceeds, if any, from the exercise of the warrants issued in the offerings, were approximately$17.0 million.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 60; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            58            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <b>         <i>          November 2019 Registered DirectOffering         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        On November 21, 2019, we entered intoa securities purchase agreement with certain investors pursuant to which we agreed to sell, in a registered direct offering, anaggregate of 808,080 shares of our common stock and warrants to purchase up to 606,060 shares of our common stock for gross proceedsof approximately $8.0 million under the 2019 Shelf Registration Statement (the “November 2019 Registered Direct Offering”).Additionally, we issued warrants to purchase up to 48,485 shares of our common stock to Wainwright as compensation for its servicesas a placement agent in connection with the November 2019 Registered Direct Offering, which warrants and the common stockissuable upon exercise of such warrants were registered under the 2019 Shelf Registration Statement. The November 2019 RegisteredDirect Offering closed on November 25, 2019. The net proceeds to the Company from the offerings, after deducting the placementagent’s fees and expenses, and the Company’s offering expenses, and excluding the proceeds, if any, from the exerciseof the warrants issued in the offerings, were approximately $7.3 million.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <b>         <i>          At-The-Market Offering Agreement         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        On July 13, 2020, we entered into anAt-The-Market Offering Agreement (the “Offering Agreement”) with Wainwright, as sales agent and/or principal, pursuantto which we may offer and sell, from time to time, through or to Wainwright, shares of our common stock. Sales of shares of commonstock under the Offering Agreement will be made pursuant to the 2019 Shelf Registration Statement and a related prospectus supplementfiled with the SEC on July 14, 2020, for an aggregate offering price of up to $7.0 million, provided that we may be limitedin the amount of securities that we can sell under the Offering Agreement pursuant to Instruction I.B.6 to Form S-3 for solong as our public float remains less than $75.0 million. Under the Offering Agreement, Wainwright may sell shares by any methoddeemed to be an “at the market” offering as defined in Rule 415 under the Securities Act. We will pay Wainwrighta commission of 3% of the aggregate gross proceeds from each sale of shares under the Offering Agreement and have agreed to provideWainwright with customary indemnification and contribution rights. We have also agreed to reimburse Wainwright for certain specifiedexpenses. As of December 31, 2020, we had offered and sold 850,000 shares of our common stock under the Offering Agreementfor gross proceeds of approximately $4.6 million. The net proceeds to the Company from the offering, after deducting commissionsand the Company’s offering expenses, were approximately $4.3 million. Subsequent to December 31, 2020, we offered andsold 278,800 shares of our common stock under the Offering Agreement for gross proceeds of approximately $2.3 million. The netproceeds to the Company from the offering, after deducting commissions and the Company’s offering expenses, were approximately$2.2 million.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <b>         <i>          2021 Registered Direct Offering         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        On February 16, 2021, we entered intoa placement agency agreement with Roth Capital Partners, LLC relating to a public offering of 1,710,600 shares of our common stockfor gross proceeds of approximately $13.0 million under the 2019 Shelf Registration Statement (the “2021 Registered DirectOffering”). In addition, on February 16, 2021, we entered into a securities purchase agreement with certain institutionalinvestors pursuant to which we agreed to sell an aggregate of 1,650,000 shares of our common stock in the 2021 Registered DirectOffering to such investors. The 2021 Registered Direct Offering closed on February 18, 2021. The net proceeds to the Companyfrom the offerings, after deducting the placement agent’s fees and expenses and the Company’s offering expenses, wereapproximately $12.2 million.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">        <b>         <i>          Future Capital Requirements         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        We expect to continue to incur significantoperating expenses in connection with our ongoing activities, including conducting clinical trials, manufacturing and seeking regulatoryapproval of our drug candidates, prexigebersen, prexigebersen-A, BP1002 and BP1003. Accordingly, we will continue to require substantialadditional capital to fund our projected operating requirements. Such additional capital may not be available when needed or onterms favorable to us. In addition, we may seek additional capital due to favorable market conditions or strategic considerations,even if we believe we have sufficient funds for our current and future operating plan. There can be no assurance that we will beable to continue to raise additional capital through the sale of our securities in the future. Our future capital requirementsmay change and will depend on numerous factors, which are discussed in detail in “Item 1A. Risk Factors” of this AnnualReport on Form 10-K.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 61; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            59            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Off-Balance Sheet Arrangements        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        As of December 31, 2020, we did nothave any material off-balance sheet arrangements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Critical Accounting Policies        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Our management’s discussion and analysisof our financial condition and results of operations are based on our financial statements, which have been prepared in conformitywith GAAP in the U.S. The preparation of such financial statements has required our management to make assumptions, estimates andjudgments that affect the amounts reported in the financial statements, including the notes thereto, and related disclosures ofcommitments and contingencies, if any. We consider our critical accounting policies to be those that require the more significantjudgments and estimates in the preparation of financial statements, including the following:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <b>         <i>          Research and Development Costs -         </i>        </b>        Costsand expenses that can be clearly identified as research and development are charged to expense as incurred. Advance payments, includingnonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are deferredand capitalized. Such amounts will be recognized as an expense as the related goods are delivered or the related services are performed.If the goods will not be delivered, or services will not be rendered, then the capitalized advance payment is charged to expense.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The Company estimates its clinical trialexpense accrual each period based on a cost per patient calculation which is derived from estimated start-up costs, clinical trialcosts based on the number of patients and length of treatment and clinical study report costs. These services are performed bythe Company’s third-party clinical research organizations, laboratories and clinical investigative sites. The expense accrualis recorded in research and development expense each period. Amounts that have been prepaid in advance of work performed are recordedin other current assets.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        For the year ended December 31, 2020and 2019, we had $6.6 million and $4.6 million, respectively, of costs classified as research and development expense.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="text-transform: uppercase">         <b>          <a name="Seng_012">          </a>          ITEM 7A. QUANTITATIVEAND QUALITATIVE DISCLOSURES ABOUT MARKET RISK         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Not applicable.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="text-transform: uppercase">         <b>          <a name="Seng_013">          </a>          ITEM 8. FINANCIALSTATEMENTS AND SUPPLEMENTARY DATA         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Our consolidated financial statements, togetherwith the report of our independent registered public accounting firm, are set forth beginning on page F-1 of this Annual Reporton Form 10-K.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="text-transform: uppercase">         <b>          <a name="Seng_014">          </a>          ITEM 9. CHANGES ANDDISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        None.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="text-transform: uppercase">         <b>          <a name="Seng_015">          </a>          ITEM 9A. CONTROLSAND PROCEDURES         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Evaluation of Disclosure Controls andProcedures        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        It is management’s responsibilityto establish and maintain adequate disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) underthe Exchange Act. Disclosure controls and procedures are controls and other procedures of a company that are designed to ensurethat information required to be disclosed by the company in the reports that it files or submits under the Exchange Act is recorded,processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controlsand procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosedby a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to management, includingthe company’s principal executive and principal financial officers, as appropriate, to allow timely decisions regarding requireddisclosure.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 62; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            60            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Our management, including our Chief ExecutiveOfficer (who is also our Chief Financial Officer), has reviewed and evaluated the effectiveness of our disclosure controls andprocedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, as of the end of the period coveredby this Annual Report on Form 10-K. Following this review and evaluation, our management determined that as of the end ofthe period covered by this Annual Report on Form 10-K, our disclosure controls and procedures were effective to ensure thatinformation required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarizedand reported within the time periods specified in SEC rules and forms, and is accumulated and communicated to management,including our Chief Executive Officer and our Chief Financial Officer, as appropriate, to allow timely decisions regarding requireddisclosure.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Management’s Report on InternalControl over Financial Reporting        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Our management is responsible for establishingand maintaining adequate internal control over financial reporting. Internal control over financial reporting, as defined in Rule 13a-15(f) underthe Exchange Act, is a process designed by, or under the supervision of, our principal executive officer and our principal financialofficer, and effected by our Board, management, and other personnel, to provide reasonable assurance regarding the reliabilityof financial reporting and the preparation of financial statements for external purposes in accordance with GAAP and includes thosepolicies and procedures that:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.75in">          </td>          <td style="width: 0.25in; text-align: left">           •          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Pertainto the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and disposition of ourassets;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.75in">          </td>          <td style="width: 0.25in; text-align: left">           •          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Providereasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance withGAAP, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors;and           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0.75in">          </td>          <td style="width: 0.25in; text-align: left">           •          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Providereasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets thatcould have a material effect on our financial statements.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Because of its inherent limitations, internalcontrol over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to futureperiods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliancewith the policies or procedures may deteriorate. All internal control systems, no matter how well designed, have inherent limitations.Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statementpreparation and presentation. The scope of management’s assessment of the effectiveness of internal control over financialreporting includes our consolidated subsidiary.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Management’s assessment of the effectivenessof our internal controls is based principally on our financial reporting as of December 31, 2020. In making our assessmentof internal control over financial reporting, management used the criteria set forth in        <i>         Internal Control - Integrated Framework        </i>        (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Our management, with the participationof our Chief Executive Officer (who is also our Chief Financial Officer), has evaluated the effectiveness of our internal controlover financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, as of December 31,2020. Based on this evaluation, management believes that, as of December 31, 2020, our internal control over financial reportingwas effective.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Changes in Internal Control over FinancialReporting        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        There were no changes in our internal controlover financial reporting that occurred during the fourth fiscal quarter of 2020 that have materially affected, or are reasonablylikely to materially affect, our internal control over financial reporting.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <a name="Seng_016">         </a>         ITEM 9B. OTHER INFORMATION        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        None.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 63; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            61            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Split-Segment; Name: 5 -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="text-transform: uppercase">         <b>          <a name="Seng_017">          </a>          <u>           PART III          </u>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="text-transform: uppercase">         <b>          <a name="Seng_018">          </a>          ITEM 10. DIRECTORS,EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Identification of Directors and ExecutiveOfficers        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Our current directors and officers are setforth below:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr>          <td style="border-bottom: black 1pt solid; text-align: left; vertical-align: bottom; padding-top: 0.25pt; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Name            </b>           </font>          </td>          <td style="vertical-align: bottom; padding: 0.25pt 0.25pt 1.25pt">          </td>          <td style="border-bottom: black 1pt solid; vertical-align: bottom; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: center; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Age            </b>           </font>          </td>          <td style="vertical-align: bottom; padding: 0.25pt 0.25pt 1.25pt">          </td>          <td style="border-bottom: black 1pt solid; vertical-align: bottom; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: center; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Position - Committee            </b>           </font>          </td>         </tr>         <tr style="background-color: #CCEEFF">          <td style="vertical-align: top; width: 20%; padding-top: 0.25pt; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Peter H. Nielsen           </font>          </td>          <td style="vertical-align: bottom; width: 1%; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">          </td>          <td style="vertical-align: top; width: 8%; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 3.25pt; text-align: center; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            72           </font>          </td>          <td style="vertical-align: bottom; width: 1%; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">          </td>          <td style="vertical-align: bottom; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 3.25pt; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Chief Executive Officer; President; Chief Financial Officer; Treasurer; Chairman of the Board; Director – Business Development Committee           </font>          </td>         </tr>         <tr style="background-color: white">          <td style="vertical-align: top; padding-top: 0.25pt">          </td>          <td style="vertical-align: bottom; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">          </td>          <td style="vertical-align: top; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 3.25pt">          </td>          <td style="vertical-align: bottom; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">          </td>          <td style="vertical-align: bottom; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 3.25pt">          </td>         </tr>         <tr style="background-color: #CCEEFF">          <td style="vertical-align: top; padding-top: 0.25pt; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Heath W. Cleaver, CPA           </font>          </td>          <td style="vertical-align: bottom; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">          </td>          <td style="vertical-align: top; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 3.25pt; text-align: center; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            47           </font>          </td>          <td style="vertical-align: bottom; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">          </td>          <td style="vertical-align: bottom; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 3.25pt; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Director – Audit Committee (Chair); Compensation Committee; Nominating/Corporate Governance Committee (Chair)           </font>          </td>         </tr>         <tr style="background-color: white">          <td style="vertical-align: top; padding-top: 0.25pt">          </td>          <td style="vertical-align: bottom; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">          </td>          <td style="vertical-align: top; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 3.25pt">          </td>          <td style="vertical-align: bottom; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">          </td>          <td style="vertical-align: bottom; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 3.25pt">          </td>         </tr>         <tr style="background-color: #CCEEFF">          <td style="vertical-align: top; padding-top: 0.25pt; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Paul D. Aubert           </font>          </td>          <td style="vertical-align: bottom; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">          </td>          <td style="vertical-align: top; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 3.25pt; text-align: center; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            51           </font>          </td>          <td style="vertical-align: bottom; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">          </td>          <td style="vertical-align: bottom; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 3.25pt; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Director – Audit Committee; Compensation Committee (Chair); Nominating/Corporate Governance Committee           </font>          </td>         </tr>         <tr style="background-color: white">          <td style="vertical-align: top; padding-top: 0.25pt">          </td>          <td style="vertical-align: bottom; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">          </td>          <td style="vertical-align: top; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 3.25pt">          </td>          <td style="vertical-align: bottom; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">          </td>          <td style="vertical-align: bottom; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 3.25pt">          </td>         </tr>         <tr style="background-color: #CCEEFF">          <td style="vertical-align: top; padding-top: 0.25pt; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Martina Molsbergen           </font>          </td>          <td style="vertical-align: bottom; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">          </td>          <td style="vertical-align: top; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 3.25pt; text-align: center; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            55           </font>          </td>          <td style="vertical-align: bottom; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">          </td>          <td style="vertical-align: bottom; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 3.25pt; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Director – Audit Committee; Compensation Committee; Nominating/Corporate Governance Committee; Business Development Committee (Chair)           </font>          </td>         </tr>         <tr style="background-color: white">          <td style="vertical-align: top; padding-top: 0.25pt">          </td>          <td style="vertical-align: bottom; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">          </td>          <td style="vertical-align: top; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 3.25pt">          </td>          <td style="vertical-align: bottom; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">          </td>          <td style="vertical-align: bottom; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 3.25pt">          </td>         </tr>         <tr style="background-color: #CCEEFF">          <td style="vertical-align: top; padding-top: 0.25pt; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Douglas P. Morris           </font>          </td>          <td style="vertical-align: bottom; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">          </td>          <td style="vertical-align: top; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 3.25pt; text-align: center; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            65           </font>          </td>          <td style="vertical-align: bottom; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">          </td>          <td style="vertical-align: bottom; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 3.25pt; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Director – Business Development Committee; Director of Investor Relations; Secretary           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Our current directors will serve until thenext annual meeting of stockholders or until their successors are elected or appointed and qualified.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Background Information        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <b>         <i>          Peter H. Nielsen.         </i>        </b>        Mr. Nielsenco-founded Bio-Path and has served as Bio-Path’s President, Chief Executive Officer, Chief Financial Officer/Treasurer andChairman of the Board since 2008. At the time of Bio-Path’s establishment in 2007, Mr. Nielsen licensed technology andtargets from The University of Texas, MD Anderson Cancer Center and coordinated preclinical development, optimization and manufacturingof Bio-Path’s lead drug candidate, prexigebersen. Since that time, Mr. Nielsen has led the clinical advancement of prexigeberseninto Phase 2 studies, the introduction of additional pipeline candidates and the Company’s public market debut. Prior toco-founding Bio-Path, Mr. Nielsen worked with several other companies, leading turnarounds and developing and executing onstrategies for growth. Mr. Nielsen previously served as a director of Synthecon, Inc., a company developing 3D cell culturetechnology. Before entering the biotechnology sector, Mr. Nielsen was a lieutenant in the U.S. Naval Nuclear Power programwhere he was director of the physics department and was employed at Ford Motor Company in product development. Mr. Nielsenhas a broad background in senior management and has significant negotiating experience. He holds engineering, mathematics and M.B.A.finance degrees from the University of California at Berkeley.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <b>         <i>          Heath W. Cleaver, CPA.         </i>        </b>        Mr. Cleaverhas served as a director of Bio-Path since 2014. Since February 2020, Mr. Cleaver has served as the President and ChiefFinancial Officer of Compressor Engineering Corporation (“CECO”), a privately-held independent manufacturer of engineand compressor replacement parts. Prior to his current roles, Mr. Cleaver served as Chief Financial Officer of CECO from July 2017to February 2020. Mr. Cleaver was previously a consultant providing turn-around management and capital raising servicesto companies in the oil and gas service sector from 2016 to 2017. From 2015 to 2016, Mr. Cleaver served as the Chief FinancialOfficer of Global Fabrication Services, Inc. In 2014, Mr. Cleaver served as Chief Financial Officer at Tarka Resources, Inc.From 2011 until 2014, Mr. Cleaver served as Chief Financial Officer of Porto Energy Corp. From 2010 until 2011, Mr. Cleaverserved as Chief Accounting Officer of Porto Energy Corp. Mr. Cleaver served as Corporate Controller and then as Vice Presidentand Chief Accounting Officer for BPZ Energy from 2006 to 2010. Beginning in 1997 through 2004, Mr. Cleaver served in variousaccounting roles, including Financial Controller, at Horizon Offshore Contractors, Inc. Mr. Cleaver is a Certified PublicAccountant in the state of Texas and holds a Bachelor’s Degree in Business Administration - Accounting from Texas A&amp;MUniversity.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 64; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            62            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <b>         <i>          Paul D. Aubert         </i>        </b>        . Mr. Aubertwas appointed to the Board on February 1, 2018. Mr. Aubert is currently Senior Vice President &amp; General Counselof Anthem Holdings Company and its subsidiaries, positions he has held since March 2018. From June 2014 to March 2018,he practiced law in a solo law practice and also served as part-time General Counsel to his current employers. From February 2012through May 2014, Mr. Aubert served as General Counsel of Pernix Therapeutics Holdings, Inc., a Nasdaq-listed specialtypharmaceutical company. Before that, he was a Shareholder in the Corporate and Securities practice group at Winstead PC, a nationallaw firm headquartered in Dallas, Texas, from 2007 to 2012. Mr. Aubert also served as an attorney in the Corporate and Securitiespractice groups of several national and international law firms prior to joining Winstead in 2004, including at Andrews Kurth LLPfrom 1999 to 2004, Weil, Gotshal &amp; Manges LLP from 1998 to 1999 and Jones Walker LLP from 1996 to 1998. Mr. Aubertholds a Juris Doctor and an M.B.A. from Tulane University in New Orleans, Louisiana and a B.A. in History from Louisiana StateUniversity - Baton Rouge.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <b>         <i>          Martina Molsbergen.         </i>        </b>        Ms. Molsbergenwas appointed to the Board on October 11, 2019. Ms. Molsbergen has more than 25 years of business development and marketingexperience, including more than 15 years of business development expertise in cutting edge technology tools and products for biotherapeutics,immunotherapies and regenerative medicine. Since October 2009, Ms. Molsbergen has served as the Chief Executive Officerof C14 Consulting Group, LLC, a private consulting company focused on providing business development support for the biotech, VCand pharmaceutical communities. From 2007 to October 2009, Ms. Molsbergen served as Vice President of Business Developmentof Crucell Holland BV, a biotechnology company specializing in vaccines and biopharmaceutical technologies. From 2004 to 2007,Ms. Molsbergen served as Vice President of Business Development of Biowa, Inc. Ms. Molsbergen served as Vice Presidentof Business Development of Zetiq Technologies Ltd. from 2002 to 2003 and as Vice President of Pharmaceutical Development Services &amp;Business Development of Patheon Inc. from 1997 to 2001. Ms. Molsbergen holds a B.S. in Chemical Engineering from Drexel University.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <b>         <i>          Douglas P. Morris         </i>        </b>        . Mr. Morrisis a co-founder of Bio-Path and has served as a director of Bio-Path since 2007 and served as an officer from 2007 to June 2014.Mr. Morris also currently serves as the Director of Investor Relations and the Secretary of Bio-Path. Mr. Morris previouslyserved as a co-founder, Managing Member, and Secretary of nCAP Holdings, LLC (nCAP), a privately held technology based companyfrom September 2013 to January 2016. Between 1993 and 2010, Mr. Morris was an officer and director of Celtic Investment, Inc.,a financial services company. Mr. Morris owned and operated Hyacinth Resources, LLC (“Hyacinth”), a business-consultingfirm, from 1990 until September 2018, and is also a Managing Member of Sycamore Ventures, LLC, a privately held consultingfirm. Mr. Morris has a B.A. from Brigham Young University, and attended the University of Southern California Master’sprogram in public administration.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Board of Directors        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Our operations are managed under the broadsupervision of the Board, which has ultimate responsibility for the establishment and implementation of our general operating philosophy,objectives, goals and policies. Our Board is currently comprised of three independent directors and two non-independent directors.The Board has determined that current directors Heath W. Cleaver, Paul D. Aubert and Martina Molsbergen are “independent”as independence is defined under the listing standards for The Nasdaq Stock Market. The Board based these determinations primarilyon a review of the responses our directors provided to questions regarding employment and compensation history, affiliations andfamily and other relationships.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Codes of Ethics        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        We have adopted the Employee Code of BusinessConduct and Ethics, which applies to all of our employees, including our executive officers, and the Code of Business Conductand Ethics for Members of the Board, which applies to members of the Board.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 65; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            63            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Board Committees        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The Board has a standing audit committee(the “Audit Committee”), compensation committee (the “Compensation Committee”) and nominating/corporategovernance committee (the “Nominating/Corporate Governance Committee”), each of which is governed by a charter. TheBoard may also establish other committees from time to time as necessary to facilitate the management of the business and affairsof the Company. The Board recently formed a business development committee (the “Business Development Committee”) thatassists the Board by advising management on its plans for business development, licensing opportunities and business partnershipopportunities. In addition to these committees, we also have a Scientific Advisory Board that serves an advisory role to managementand the Board. The information below summarizes the functions of each of the committees and the Scientific Advisory Board.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">        <b>         <i>          Audit Committee         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The Audit Committee has been structuredto comply with the requirements of Section 3(a)(58)(A) of the Exchange Act. The Board has determined that the Audit Committeemembers have the appropriate level of financial understanding and industry specific knowledge to be able to perform the dutiesof the position and are financially literate and have the requisite financial sophistication as required by the applicable listingstandards of The Nasdaq Stock Market.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The Audit Committee, as permitted by, andin accordance with, its charter, is responsible to periodically assess the adequacy of procedures for the public disclosure offinancial information and review on behalf of the Board, and report to the Board, the results of its review and its recommendationregarding all material matters of a financial reporting and audit nature, including, but not limited to, the following main subjectareas:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 10%; padding: 0.25pt">          </td>          <td style="width: 2%; padding: 0.25pt 0.25pt 8pt; font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="width: 88%; padding: 0.25pt 0.25pt 8pt; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            financial statement, including management’s discussion and analysis thereof;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding: 0.25pt">          </td>          <td style="padding: 0.25pt 0.25pt 8pt; font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="padding: 0.25pt 0.25pt 8pt; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            financial information in any annual information form, proxy statement, prospectus or other offering document, material change report, or business acquisition report;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding: 0.25pt">          </td>          <td style="padding: 0.25pt 0.25pt 8pt; font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="padding: 0.25pt 0.25pt 8pt; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            press releases regarding annual and interim financial results or containing earnings guidance;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding: 0.25pt">          </td>          <td style="padding: 0.25pt 0.25pt 8pt; font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="padding: 0.25pt 0.25pt 8pt; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            internal controls;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding: 0.25pt">          </td>          <td style="padding: 0.25pt 0.25pt 8pt; font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="padding: 0.25pt 0.25pt 8pt; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            audits and reviews our financial statements; and           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            filings with securities regulators containing financial information, including our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The Audit Committee appoints and sets thecompensation for the independent registered public accounting firm annually and reviews and evaluates such external auditor. Thisexternal auditor reports directly to the Audit Committee. The Audit Committee establishes our hiring policies regarding currentand former partners and employees of the external auditor. In addition, the Audit Committee pre-approves all audit and non-auditservices undertaken by the external auditor.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The Audit Committee has direct responsibilityfor overseeing the work of the external auditor engaged for the purpose of preparing or issuing an auditor’s report or performingother audit, review or attest services, including the resolution of disagreements between the external auditor and management.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The Audit Committee is comprised of Messrs. Cleaverand Aubert and Ms. Molsbergen. Mr. Cleaver currently serves as the chair of the Audit Committee. The Board has determinedthat Mr. Cleaver qualifies as an “audit committee financial expert” under the Exchange Act and that each memberof the Audit Committee is an independent director. The Audit Committee meets at least once per fiscal quarter to fulfill its responsibilitiesunder its charter and in connection with the review of the Company’s quarterly and annual financial statements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 66; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            64            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">        <b>         <i>          Compensation Committee         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The Compensation Committee’s roleis to assist the Board in fulfilling its responsibilities relating to all forms of compensation of the Company's executive officers,administering the Company's incentive compensation plan and other benefits plans, including a deferred compensation plan, if applicable,and producing any required report on executive compensation for use in the Company's proxy statement or other public disclosure.The Compensation Committee operates under a written charter adopted by the Board. The Compensation Committee periodically assessescompensation of our executive officers in relation to companies of comparable size, industry and complexity, taking the performanceof the Company and such other companies into consideration. All decisions with respect to the compensation of our Chief ExecutiveOfficer are determined and approved either solely by the Compensation Committee or together with other independent directors, asdirected by the Board. All decisions with respect to non-CEO executive compensation, and incentive-compensation and equity-basedplans are first approved by the Compensation Committee and then submitted, together with the Compensation Committee’s recommendation,to the members of the Board for final approval. In addition, the Compensation Committee will, as appropriate, review and approvepublic or regulatory disclosure respecting compensation, including required disclosures regarding executive compensation underItem 402 of Regulation S-K, and the basis on which performance is measured. The Compensation Committee has the authority to retainand compensate any outside adviser as it determines necessary to permit it to carry out its duties. The Compensation Committeehas not to date engaged the services of any executive compensation consultant. The Compensation Committee may not form or delegateauthority to subcommittees without the prior approval of the Board.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The Compensation Committee is comprisedof Messrs. Aubert and Cleaver and Ms. Molsbergen, each of whom are independent under the rules of The Nasdaq StockMarket. The Compensation Committee meets as necessary. Mr. Aubert is the chair of the Compensation Committee.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">        <b>         <i>          Nominating/Corporate Governance Committee         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The Nominating/Corporate Governance Committee’scharter provides that the responsibilities of such committee include:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 10%; padding: 0.25pt">          </td>          <td style="width: 2%; padding: 0.25pt 0.25pt 8pt; font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="width: 88%; padding: 0.25pt 0.25pt 8pt; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            evaluating, identifying and recommending nominees to the Board;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding: 0.25pt">          </td>          <td style="padding: 0.25pt 0.25pt 8pt; font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="padding: 0.25pt 0.25pt 8pt; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            considering written recommendations from our stockholders for nominees to the Board;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding: 0.25pt">          </td>          <td style="padding: 0.25pt 0.25pt 8pt; font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="padding: 0.25pt 0.25pt 8pt; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            recommending directors to serve as committee members and chairs;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding: 0.25pt">          </td>          <td style="padding: 0.25pt 0.25pt 8pt; font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="padding: 0.25pt 0.25pt 8pt; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            reviewing and developing corporate governance guidelines, policies and procedures for the Board;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding: 0.25pt">          </td>          <td style="padding: 0.25pt 0.25pt 8pt; font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="padding: 0.25pt 0.25pt 8pt; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            reviewing disclosure by the Company of matters within the Nominating/Corporate Governance Committee’s mandate; and           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            reviewing and evaluating the Nominating/Corporate Governance Committee’s charter and efficacy.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The Nominating/Corporate Governance Committeeis responsible for, among other things, identifying and recommending potential candidates for nomination to the Board. The Nominating/CorporateGovernance Committee receives advice from the Board and will consider written recommendations from the stockholders of the Companyrespecting individuals best suited to serve as directors, and, when necessary, develops its own list of appropriate candidatesfor directorships. For a description of the procedures to be followed by stockholders of the Company in submitting recommendationsto be considered by the Nominating/Corporate Governance Committee, see the discussion set forth below under the heading titled, “Stockholder Nominations for Directors.”       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The Nominating/Corporate Governance Committeeis comprised of Messrs. Cleaver and Aubert and Ms. Molsbergen, each of whom are independent under the rules of TheNasdaq Stock Market. The Nominating/Corporate Governance Committee meets at least annually, and otherwise as necessary. Mr. Cleaveris the chair of the Nominating/Corporate Governance Committee.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <b>         <i>          Business Development Committee         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The Business Development Committee assiststhe Board by advising management on its plans for business development, licensing opportunities and business partnership opportunities.The Business Development Committee also performs other duties as directed by the Board from time to time and operates under a writtencharter adopted by the Board. The Business Development Committee is currently comprised of Ms. Molsbergen and Messrs. Nielsenand Morris. Ms. Molsbergen currently serves as the chair of the Business Development Committee.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 67; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            65            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">        <b>         <i>          Scientific Advisory Board         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The Scientific Advisory Board assists managementand the Board on an advisory basis with respect to the research, development, clinical, regulatory and commercial plans and activitiesrelating to research, manufacture, use and/or sale of our drug candidates and products. The Scientific Advisory Board meets onan        <i>         ad hoc        </i>        basis and may attend meetings of the Board at the Board’s request. The current members of the ScientificAdvisory Board are Jorge Cortes, M.D, who serves as chairman, D. Craig Hooper, Ph.D., and Jason Fleming, M.D.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Availability of Committee Charters andOther Information        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The charters for our Audit Committee, CompensationCommittee, and Nominating/Corporate Governance Committee, as well as our Corporate Governance Guidelines, Employee Code of BusinessConduct and Ethics and Code of Business Conduct and Ethics for Members of the Board, are available under the section titled “CorporateGovernance” on the Investors page of the Company’s website,        <i>         www.biopathholdings.com        </i>        . We intend to discloseany changes to or waivers from the Employee Code of Business Conduct and Ethics that would otherwise be required to be disclosedunder Item 5.05 of Form 8-K on our website. The information on our website is not, and shall not be deemed to be, a part ofthis Annual Report on Form 10-K or incorporated into any other filings we make with the SEC.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        We also make available on our website, freeof charge, access to our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-Kand any amendments to those reports, as well as other documents that we file with or furnish to the SEC pursuant to Sections 13(a) or15(d) of the Exchange Act, as soon as reasonably practicable after such documents are filed with, or furnished to, the SEC.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Nomination Process        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        It is our Board’s responsibility tonominate members for election to the Board and to fill vacancies on the Board that may occur between annual meetings of stockholders.The Nominating/Corporate Governance Committee assists the Board by identifying and reviewing potential candidates for Board membershipconsistent with criteria approved by the Board. The Nominating/Corporate Governance Committee also annually recommends qualifiedcandidates (which may include existing directors) for approval by the Board of a slate of nominees to be proposed for electionto the Board at the annual meeting of stockholders.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        In the event of a vacancy on the Board betweenannual meetings of our stockholders, the Board may request that the Nominating/Corporate Governance Committee identify, reviewand recommend qualified candidates for Board membership for Board consideration to fill such vacancies, if the Board determinesthat such vacancies will be filled. Our First Amended and Restated Bylaws (the “Bylaws”) allow for up to fifteen directors.The Board is permitted by the Bylaws to change the number of directors by a resolution adopted by the Board.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        When formulating its recommendations forpotential Board nominees, the Nominating/Corporate Governance Committee seeks and considers advice and recommendations from management,other members of the Board and may seek or consider advice and recommendations from consultants, outside counsel, accountants orother advisors as the Nominating/Corporate Governance committee or the Board may deem appropriate.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Board membership criteria are determinedby the Board, with input from the Nominating/Corporate Governance Committee. The Board is responsible for periodically determiningthe appropriate skills, perspectives, experiences and characteristics required of Board candidates, taking into account our needsand current make-up of the Board. This assessment should include appropriate knowledge, experience, and skills in areas deemedcritical to understanding the Company and our business; personal characteristics, such as integrity and judgment; and the candidate’scommitments to the boards of other companies. Each Board member is expected to ensure that other existing and planned future commitmentsdo not materially interfere with the member’s service as a director and that he or she devotes the time necessary to dischargehis or her duties as a director.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 68; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            66            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Stockholder Nominations for Directors        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The Nominating/Corporate Governance Committeewill consider candidates for director nominees that are recommended by our stockholders in the same manner as Board recommendednominees, in accordance with the procedures set forth in our Bylaws. Any such nominations should be submitted to the Nominating/CorporateGovernance Committee c/o Secretary, Bio-Path Holdings, Inc., 4710 Bellaire Boulevard, Suite 210, Bellaire, Texas 77401before the deadline set forth in the Bylaws and should be accompanied by the following information:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 10%; padding: 0.25pt">          </td>          <td style="width: 2%; padding: 0.25pt 0.25pt 8pt; font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="width: 88%; padding: 0.25pt 0.25pt 8pt; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            appropriate biographical information, a statement as to the qualifications of the nominee and any other information relating to such nominee that is required to be disclosed pursuant to Regulation 14A under the Exchange Act (including such person’s written consent to being named in the proxy statement as a nominee and to serving as a director if elected); and           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the Proposing Stockholder Information (as defined in the Bylaws).           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Involvement in Certain Legal Proceedings        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        There have been no events under any bankruptcyact, no criminal proceedings and any judgments or injunctions material to the evaluation of the ability and integrity of any directoror executive officer during the last ten years.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Section 16(a) Beneficial OwnershipReporting Compliance        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">        Section 16(a) of the ExchangeAct requires our directors and officers, and persons who own more than 10% of our common stock, to file initial reports of ownershipand reports of changes in ownership (Forms 3, 4, and 5) of common stock with the SEC. Officers, directors and greater than 10%stockholders are required by SEC regulation to furnish us with copies of all such forms that they file.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        To our knowledge, based solely on our reviewof the copies of such reports received by us and on written representations by certain reporting persons that no reports on Form 5were required, we believe that during the fiscal year ended December 31, 2020, all Section 16(a) filing requirementsapplicable to our officers, directors and 10% stockholders were complied with in a timely manner.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="text-transform: uppercase">         <b>          <a name="Seng_019">          </a>          ITEM 11. EXECUTIVECOMPENSATION         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The Compensation Committee oversees ourcompensation programs for executives and all employees. The Compensation Committee understands that for the Company and its stockholdersto achieve long-term success, the compensation programs need to attract, retain, develop and motivate a strong leadership team.As a result, our executive compensation programs are designed to pay for performance, enable talent attraction, retain top talentand closely align the interests of our executives with those of our stockholders. All decisions with respect to the compensationof our Chief Executive Officer are determined and approved either solely by the Compensation Committee or together with other independentdirectors, as directed by the Board. All decisions with respect to non-CEO executive compensation, incentive-compensation and equity-basedplans are first approved by the Compensation Committee and then submitted, together with the Compensation Committee’s recommendation,to the members of the Board for final approval.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        This section provides important informationon our executive compensation programs and explains the compensation decisions made during 2020 by the Compensation Committee forour named executive officers (“NEOs”). In the fiscal year ended December 31, 2020, our only NEO was Peter H. Nielsen,Chairman of the Board, Chief Executive Officer, Chief Financial Officer and President.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 69; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            67            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">        <b>         <i>          Compensation Philosophy         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Our primary objective with respect to executivecompensation is to design a reward system that will align executive compensation with our overall business strategies and attractand retain highly qualified executives. We intend to stay competitive in the marketplace with companies of comparable size, industryand complexity. Our compensation philosophy for executives is guided by the following principles:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 11%; font-size: 10pt">          </td>          <td style="width: 3%; font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="width: 86%; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <i>             Pay for    Performance            </i>            . In making compensation decisions, we consider annual and long-term Company performance and consider    the compensation of our executive officers in relation to companies of comparable size, industry and complexity, taking the    performance of the Company  into consideration.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 11%; font-size: 10pt">          </td>          <td style="width: 3%; font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="width: 86%; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <i>             Reviewed Annually            </i>            . The Compensation Committee annually reviews compensation levels to ensure we remain competitive and continue to attract, retain and motivate top-tier talent.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 11%; font-size: 10pt">          </td>          <td style="width: 3%; font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="width: 86%; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <i>             Alignment with Stockholder Interests            </i>            . Our compensation is intended to closely align the interests of our NEOs with those of our stockholders in an effort to create long-term stockholder value. In developing our compensation philosophy, the Compensation Committee has considered the most recent stockholder advisory vote on executive compensation in which an overwhelmingly positive percentage of the votes cast were in favor of our executive compensation. The Compensation Committee is continuously mindful of stockholders’ views on executive compensation and remains focused on ensuring proper alignment with stockholder interests.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Our compensation philosophy rewards demonstratedperformance and encourages behavior that is in the long-term best interests of the Company and its stockholders.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">        <b>         <i>          Elements and Mix of our 2020 Compensation Program         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The following elements made up the fiscalyear 2020 compensation program for our NEOs:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: bottom">          <td style="border-bottom: black 1pt solid; width: 17%; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Element            </b>           </font>          </td>          <td style="width: 1%; padding-right: 3pt; padding-left: 3pt; text-align: justify; font-size: 10pt">          </td>          <td style="border-bottom: black 1pt solid; width: 21%; padding-right: 3pt; padding-left: 3pt; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Form of Compensation            </b>           </font>          </td>          <td style="width: 1%; padding-right: 3pt; padding-left: 3pt; text-align: justify; font-size: 10pt">          </td>          <td style="border-bottom: black 1pt solid; width: 60%; padding-right: 3pt; padding-left: 3pt; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Purpose, Basis and Performance Criteria            </b>           </font>          </td>         </tr>         <tr style="background-color: #CCEEFF">          <td style="vertical-align: top; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Base Salary           </font>          </td>          <td style="vertical-align: bottom; padding-right: 3pt; padding-left: 3pt; text-align: justify; font-size: 10pt">          </td>          <td style="vertical-align: top; padding-right: 3pt; padding-left: 3pt; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Cash           </font>          </td>          <td style="vertical-align: bottom; padding-right: 3pt; padding-left: 3pt; text-align: justify; font-size: 10pt">          </td>          <td style="vertical-align: top; padding-right: 3pt; padding-left: 3pt">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 19.8pt; text-indent: -9.9pt">            <font style="font-family: Symbol">             ·            </font>            <font style="font-family: Times New Roman, Times, Serif">             Base salary is intended to provide a market competitive level        of fixed compensation in recognition of responsibilities, skills, capabilities, experience and leadership.            </font>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 19.8pt; text-indent: -9.9pt">           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 19.8pt; text-indent: -9.9pt">            <font style="font-family: Symbol">             ·            </font>            <font style="font-family: Times New Roman, Times, Serif">             Base salary is not generally performance based, but reflective        of competencies and experience.            </font>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 19.8pt; text-indent: -9.9pt">           </p>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #FEFEFE">          <td style="text-align: justify; font-size: 10pt">          </td>          <td style="padding-right: 3pt; padding-left: 3pt; text-align: justify; font-size: 10pt">          </td>          <td style="padding-right: 3pt; padding-left: 3pt; text-align: justify; font-size: 10pt">          </td>          <td style="padding-right: 3pt; padding-left: 3pt; text-align: justify; font-size: 10pt">          </td>          <td style="padding-right: 3pt; padding-left: 3pt; text-align: justify; font-size: 10pt">          </td>         </tr>         <tr style="background-color: #CCEEFF">          <td style="vertical-align: top; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Annual Performance Incentive Awards (considered “at-risk” compensation)           </font>          </td>          <td style="vertical-align: bottom; padding-right: 3pt; padding-left: 3pt; text-align: justify; font-size: 10pt">          </td>          <td style="vertical-align: top; padding-right: 3pt; padding-left: 3pt; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Cash           </font>          </td>          <td style="vertical-align: bottom; padding-right: 3pt; padding-left: 3pt; text-align: justify; font-size: 10pt">          </td>          <td style="vertical-align: top; padding-right: 3pt; padding-left: 3pt">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 19.8pt; text-indent: -9.9pt">            <font style="font-family: Symbol">             ·            </font>            <font style="font-family: Times New Roman, Times, Serif">             Annual cash performance incentive awards are intended to        motivate and reward performance achievement.            </font>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 19.8pt; text-indent: -9.9pt">           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 19.8pt; text-indent: -9.9pt">            <font style="font-family: Symbol">             ·            </font>            <font style="font-family: Times New Roman, Times, Serif">             Payments are discretionary and approved annually by the Compensation        Committee.            </font>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 19.8pt; text-indent: -9.9pt">           </p>          </td>         </tr>         <tr style="background-color: #FEFEFE">          <td style="vertical-align: top; font-size: 10pt">          </td>          <td style="vertical-align: bottom; padding-right: 3pt; padding-left: 3pt; text-align: justify; font-size: 10pt">          </td>          <td style="vertical-align: top; padding-right: 3pt; padding-left: 3pt; text-align: justify; font-size: 10pt">          </td>          <td style="vertical-align: bottom; padding-right: 3pt; padding-left: 3pt; text-align: justify; font-size: 10pt">          </td>          <td style="vertical-align: top; padding-right: 3pt; padding-left: 3pt; font-size: 10pt">          </td>         </tr>         <tr style="background-color: #CCEEFF">          <td style="vertical-align: top; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Long-Term Incentive Awards (considered “at-risk” compensation)           </font>          </td>          <td style="vertical-align: bottom; padding-right: 3pt; padding-left: 3pt; text-align: justify; font-size: 10pt">          </td>          <td style="vertical-align: top; padding-right: 3pt; padding-left: 3pt; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Stock Options           </font>          </td>          <td style="vertical-align: bottom; padding-right: 3pt; padding-left: 3pt; text-align: justify; font-size: 10pt">          </td>          <td style="vertical-align: top; padding-right: 3pt; padding-left: 3pt">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 19.8pt; text-indent: -9.9pt">            <font style="font-family: Symbol">             ·            </font>            <font style="font-family: Times New Roman, Times, Serif">             Long-term incentive awards are intended to recognize and        reward the achievement of long-term corporate goals and objectives, recognize promotions, motivate retention of our leadership        talent and align executives’ interests with our stockholders.            </font>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 19.8pt; text-indent: -9.9pt">           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 19.8pt; text-indent: -9.9pt">            <font style="font-family: Symbol">             ·            </font>            <font style="font-family: Times New Roman, Times, Serif">             The Compensation Committee determines the amount of long-term        incentive awards to be granted to each NEO. The Compensation Committee also may make isolated awards to recognize promotions, new        hires or individual performance achievements.            </font>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 19.8pt; text-indent: -9.9pt">           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 19.8pt; text-indent: -9.9pt">            <font style="font-family: Symbol">             ·            </font>            <font style="font-family: Times New Roman, Times, Serif">             In 2020, the long-term incentive awards included time-vested        equity awards that vest over a four-year period.            </font>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 19.8pt; text-indent: -9.9pt">           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 19.8pt; text-indent: -9.9pt">            <font style="font-family: Symbol">             ·            </font>            <font style="font-family: Times New Roman, Times, Serif">             The Compensation Committee provides time-vested long-term        incentives (i) to build a consistent ownership stake and retention incentive, (ii) to create a meaningful tie to the        Company’s relative long-term stockholder returns and (iii) to motivate consistent improvement over a longer-term horizon.            </font>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 19.8pt; text-indent: -9.9pt">           </p>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #FEFEFE">          <td style="text-align: justify; font-size: 10pt">          </td>          <td style="padding-right: 3pt; padding-left: 3pt; text-align: justify; font-size: 10pt">          </td>          <td style="padding-right: 3pt; padding-left: 3pt; text-align: justify; font-size: 10pt">          </td>          <td style="padding-right: 3pt; padding-left: 3pt; text-align: justify; font-size: 10pt">          </td>          <td style="padding-right: 3pt; padding-left: 3pt; font-size: 10pt">          </td>         </tr>         <tr style="background-color: #CCEEFF">          <td style="vertical-align: top; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Change of Control Severance           </font>          </td>          <td style="vertical-align: bottom; padding-right: 3pt; padding-left: 3pt; text-align: justify; font-size: 10pt">          </td>          <td style="vertical-align: top; padding-right: 3pt; padding-left: 3pt; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Eligible to receive severance payments and post-termination health benefits in connection with involuntary termination within three months before or twelve months after a change of control           </font>          </td>          <td style="vertical-align: bottom; padding-right: 3pt; padding-left: 3pt; text-align: justify; font-size: 10pt">          </td>          <td style="vertical-align: top; padding-right: 3pt; padding-left: 19.8pt; text-indent: -9.9pt; font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Employment agreements are intended to provide financial security and an industry-competitive compensation package for NEOs. This additional security helps ensure that NEOs remain focused on our performance and the continued creation of stockholder value throughout any change of control transaction rather than on the potential uncertainties associated with their own employment.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 70; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            68            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">        <b>         <i>          Evaluation Process, Compensation Consultant,Peer Comparisons and Officers         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <i>         Evaluation Process        </i>        . The CompensationCommittee oversees the administration of the compensation programs applicable to our employees, including our NEOs. The CompensationCommittee generally makes its decisions regarding the annual compensation of our NEOs at its regularly-scheduled meeting in thefirst quarter of each year. These decisions include adjustments to base salary, grants of annual incentive awards and grants oflong-term incentive awards. The Compensation Committee also makes compensation adjustments as necessary at other times during theyear, such as in the case of promotions, changes in employment status and for competitive purposes.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Each year for the Compensation Committeemeeting, our CEO prepares an evaluation of each of the other executive officers, if any, and makes compensation recommendationsto the Compensation Committee based upon our performance against our corporate performance metrics and the individual’s performance. In addition to considering the CEO’s recommendations, the Compensation Committee assesses the applicableexecutive officer’s impact during the year and his or her overall value to the Company, specifically by considering the individualleadership skills, impact on strategic initiatives, performance in his or her primary area of responsibility, his or her role insuccession planning and development, and other intangible qualities that contribute to corporate and individual success. During2020, our CEO was our only executive officer.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <i>         Compensation Consultant and PeerComparisons.        </i>        For the 2020 performance period, the Compensation Committee did not engage an external compensationconsultant to review the compensation of our executive officers. For comparison purposes, the Compensation Committee reliedupon peer executive compensation data from proxies and compensation surveys of the Industry Peer Group (as defined below)prepared by our executive compensation counsel based on parameters set by the Compensation Committee. The CompensationCommittee reviewed executive compensation data from the Industry Peer Group to consider competitive pay levels andcompensation practices. Such data included components such as total direct compensation, considered as the sum of base salaryand annual cash performance incentive award, as well as total compensation, including long-term incentive awards.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        While executive compensation data from the Industry Peer Group provides a point of reference for measurement, it is not the determinativefactor for compensation decisions. The Compensation Committee does not target the compensation of our executive officers to a specificpercentile of compensation provided to officers in comparable positions in our Industry Peer Group. The purpose of the comparison is notto supplant the analyses of our corporate performance and the individual performance of our executive officers that the Compensation Committeeconsiders when making compensation decisions. Because the compensation data is just one of the several analytic tools that are used insetting executive compensation, the Compensation Committee has discretion in determining the nature and extent of its use.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The Compensation Committee establishedour current Industry Peer Group in 2020. With the assistance of our executive compensation counsel, the CompensationCommittee reviews the composition of the peer group annually to ensure that companies are relevant for comparative purposes.In identifying companies to include in the Industry Peer Group, the Compensation Committee considered, among other things,the following:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 15%; padding-right: 3pt; text-align: justify; font-size: 10pt">          </td>          <td style="width: 5%; padding-right: 3pt; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            •           </font>          </td>          <td style="width: 80%; padding-right: 3pt; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the industry of the companies;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">       </p>       <!-- Field: Page; Sequence: 71; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            69            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 15%; padding-right: 3pt; padding-bottom: 8pt; padding-left: 3pt; font-size: 10pt">          </td>          <td style="width: 5%; padding-right: 3pt; padding-bottom: 8pt; padding-left: 3pt; font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="width: 80%; padding-right: 3pt; padding-bottom: 8pt; padding-left: 3pt; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the annual revenue, market capitalization and total assets of the companies;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 15%; padding-right: 3pt; padding-bottom: 8pt; padding-left: 3pt; font-size: 10pt">          </td>          <td style="width: 5%; padding-right: 3pt; padding-bottom: 8pt; padding-left: 3pt; font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="width: 80%; padding-right: 3pt; padding-bottom: 8pt; padding-left: 3pt; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the number of full-time employees of the companies;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 15%; padding-right: 3pt; padding-bottom: 8pt; padding-left: 3pt; font-size: 10pt">          </td>          <td style="width: 5%; padding-right: 3pt; padding-bottom: 8pt; padding-left: 3pt; font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="width: 80%; padding-right: 3pt; padding-bottom: 8pt; padding-left: 3pt; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the market data sources that are available with respect to the companies; and           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 15%; font-size: 10pt">          </td>          <td style="width: 5%; font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="width: 80%; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the number of peers included in the Industry Peer Group.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        For 2020, our Industry Peer Group consistedof the following companies (the “Industry Peer Group”):       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 15%; padding-right: 3pt; padding-bottom: 8pt; padding-left: 3pt; font-size: 10pt">          </td>          <td style="width: 5%; padding-right: 3pt; padding-bottom: 8pt; padding-left: 3pt; font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="width: 80%; padding-right: 3pt; padding-bottom: 8pt; padding-left: 3pt; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Actinium Pharmaceuticals Inc. (ATNM)           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 15%; padding-right: 3pt; padding-bottom: 8pt; padding-left: 3pt; font-size: 10pt">          </td>          <td style="width: 5%; padding-right: 3pt; padding-bottom: 8pt; padding-left: 3pt; font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="width: 80%; padding-right: 3pt; padding-bottom: 8pt; padding-left: 3pt; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Cellectar Biosciences, Inc. (CLRB)           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 15%; padding-right: 3pt; padding-bottom: 8pt; padding-left: 3pt; font-size: 10pt">          </td>          <td style="width: 5%; padding-right: 3pt; padding-bottom: 8pt; padding-left: 3pt; font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="width: 80%; padding-right: 3pt; padding-bottom: 8pt; padding-left: 3pt; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Citius Pharmaceuticals (CXTR)           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 15%; padding-right: 3pt; padding-bottom: 8pt; padding-left: 3pt; font-size: 10pt">          </td>          <td style="width: 5%; padding-right: 3pt; padding-bottom: 8pt; padding-left: 3pt; font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="width: 80%; padding-right: 3pt; padding-bottom: 8pt; padding-left: 3pt; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Cyclacel Pharmaceuticals Inc. (CYCC)           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 15%; padding-right: 3pt; padding-bottom: 8pt; padding-left: 3pt; font-size: 10pt">          </td>          <td style="width: 5%; padding-right: 3pt; padding-bottom: 8pt; padding-left: 3pt; font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="width: 80%; padding-right: 3pt; padding-bottom: 8pt; padding-left: 3pt; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Dare Bioscience, Inc. (DARE)           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 15%; padding-right: 3pt; padding-bottom: 8pt; padding-left: 3pt; font-size: 10pt">          </td>          <td style="width: 5%; padding-right: 3pt; padding-bottom: 8pt; padding-left: 3pt; font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="width: 80%; padding-right: 3pt; padding-bottom: 8pt; padding-left: 3pt; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Diffusion Pharmaceuticals, Inc. (DFFN)           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 15%; padding-right: 3pt; padding-bottom: 8pt; padding-left: 3pt; font-size: 10pt">          </td>          <td style="width: 5%; padding-right: 3pt; padding-bottom: 8pt; padding-left: 3pt; font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="width: 80%; padding-right: 3pt; padding-bottom: 8pt; padding-left: 3pt; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Neurobo Pharmaceuticals Inc. (NRBO)           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 15%; padding-right: 3pt; padding-bottom: 8pt; padding-left: 3pt; font-size: 10pt">          </td>          <td style="width: 5%; padding-right: 3pt; padding-bottom: 8pt; padding-left: 3pt; font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="width: 80%; padding-right: 3pt; padding-bottom: 8pt; padding-left: 3pt; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Novus Therapeutics, Inc. (NVUS)           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 15%; padding-right: 3pt; padding-bottom: 8pt; padding-left: 3pt; font-size: 10pt">          </td>          <td style="width: 5%; padding-right: 3pt; padding-bottom: 8pt; padding-left: 3pt; font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="width: 80%; padding-right: 3pt; padding-bottom: 8pt; padding-left: 3pt; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Oncova Therapeutics Inc. (ONTX)           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 15%; padding-right: 3pt; padding-bottom: 8pt; padding-left: 3pt; font-size: 10pt">          </td>          <td style="width: 5%; padding-right: 3pt; padding-bottom: 8pt; padding-left: 3pt; font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="width: 80%; padding-right: 3pt; padding-bottom: 8pt; padding-left: 3pt; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Rexahn Pharmaceuticals Inc. (RNN)           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 15%; font-size: 10pt">          </td>          <td style="width: 5%; font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="width: 80%; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Xenetic Biosciences Inc. (XBIO)           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <i>         Role of the Chief Executive Officer        </i>        .Annually, our CEO provides the Compensation Committee with an evaluation of his performance that is based, in large part, uponperformance of the Company and as our lead representative to the investment community. The Compensation Committee evaluates ourCEO on these and other criteria. The total compensation package for our CEO is based on the Compensation Committee’s evaluation,and reflects his performance, the performance of the Company and competitive industry practices.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <i>         Role of Other Executive Officers        </i>        .Our CEO makes recommendations to the Compensation Committee on all compensation actions (other than his own compensation) affectingour other executive officers, if any. In developing his recommendation for an executive officer, our CEO considers the self-evaluationprepared by the executive officer, the recommendations of his executive team, as well as his own evaluation. Our CEO’s evaluationincludes an assessment of the impact that the executive officer has had on the Company during the award year and their overallvalue to the Company as a senior leader. The Compensation Committee is provided with our CEO’s evaluation of each executiveofficer’s performance and contributions to the Company. The Compensation Committee considers the information and recommendationsprovided by our CEO and provides a recommendation to the Board for non-CEO executive officer base salary, annual cash incentiveawards and grants of long-term incentive awards, which are subject to Board approval. During 2020, our CEO was our only executiveofficer.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 72; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            70            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">        <b>         <i>          2020 Performance Analysis and Compensation Decisions         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        In its meeting in the first quarter of eachyear, the Compensation Committee determines base salaries for the current year, the annual performance incentive awards for prior-yearperformance and the long-term incentive awards for the current year. Each element is reviewed annually, as well as at the timeof a promotion, other change in responsibilities, other significant corporate events or a material change in market conditions.Variances in the amount of compensation awarded to each executive officer generally reflect differences in individual responsibilityand experience.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <i>         Base Salary        </i>        . In recent years, theCompensation Committee has adjusted executive base salaries with the goal of providing a stable base of competitive cash compensationwhile rewarding corporate and individual performance through annual performance incentive awards. During 2020, the annual basesalary for Mr. Nielsen was $510,000, compared to $490,000 during 2019.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <i>         Annual Performance Incentive Awards        </i>        .During 2020, the Compensation Committee approved a discretionary annual cash performance incentive award for Mr. Nielsen inthe amount of $150,000.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <i>         Long-term Incentive Awards        </i>        . TheCompensation Committee believes that long-term incentive awards should provide for a retention incentive with a strong tie torelative long-term stockholder return. Accordingly, the Compensation Committee grants stock option awards that typically vestover a four-year period. During 2020, the Board approved a long-term incentive award in the form of stock options toMr. Nielsen based on recommendations from the Compensation Committee. Specifically, in March 2020, Mr. Nielsenwas awarded a time-vested stock option award to purchase 15,000 shares of our common stock. In June 2020,Mr. Nielsen was awarded a time-vested stock option award to purchase 85,000 shares of our common stock. The terms of thestock option grants require, among other things, that Mr. Nielsen continue to provide services over the vesting periodof the options. The stock options vest over a four-year period from the date of the grant, with one-fourth (1/4) of the stockoptions vesting on the first anniversary of each such grant, and the remaining stock options vesting thereafter in equalmonthly increments equal to one-forty-eighth (1/48) of the stock options over the next three years, based on continuingservice to the Company.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Summary Compensation Table        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The following table sets forth informationwith respect to the compensation of our sole NEO for the fiscal years ended December 31, 2020 and 2019.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           Name and           <br/>           Principal           <br/>           Position          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           Year          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           Salary ($)          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           Bonus ($)          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           Option           <br/>           Awards           <br/>           ($)(1)          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           All Other           <br/>           Compensation           <br/>           ($)          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           Total ($)          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: left">           Peter H. Nielsen, CEO,          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: center">           2020          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">           510,000          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">           150,000          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">           427,332          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">           170          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">           (2)          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">           1,087,502          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           CFO, President, Chairman, Director          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">           2019          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           490,000          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           244,570          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           164          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           (2)          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           734,734          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="padding: 0.25pt; width: 24px">          </td>          <td style="padding: 0.25pt 0.25pt 8pt; font-size: 10pt; width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (1)           </font>          </td>          <td style="text-align: left; padding: 0.25pt 0.25pt 8pt; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The amounts reported in this column reflect the aggregate grant date fair value of equity awards granted during the year computed in accordance with FASB ASC Topic 718. See Note 9 to our consolidated financial statements included in this Annual Report on Form 10-K for assumptions made by us in such valuation.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (2)           </font>          </td>          <td style="text-align: left; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The amounts reported represent life insurance premiums paid by the Company for Mr. Nielsen.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 73; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            71            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Grants of Plan-Based Awards Table        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The following table contains informationabout grants of plan-based stock options to our sole NEO during fiscal year 2020:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: bottom">          <td style="white-space: nowrap; text-align: center; font-size: 10pt">          </td>          <td style="white-space: nowrap; font-size: 10pt">          </td>          <td style="white-space: nowrap; text-align: center; font-size: 10pt">          </td>          <td style="white-space: nowrap; font-size: 10pt">          </td>          <td colspan="10" style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: center; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Estimated Future Payouts Under Non-Equity             <br/>             Incentive Plan Awards            </b>           </font>          </td>          <td style="white-space: nowrap; font-size: 10pt">          </td>          <td style="white-space: nowrap; font-size: 10pt">          </td>          <td colspan="2" style="white-space: nowrap; text-align: center; font-size: 10pt">          </td>          <td style="white-space: nowrap; font-size: 10pt">          </td>          <td style="white-space: nowrap; font-size: 10pt">          </td>          <td colspan="2" style="white-space: nowrap; text-align: center; font-size: 10pt">          </td>          <td style="white-space: nowrap; font-size: 10pt">          </td>          <td style="white-space: nowrap; font-size: 10pt">          </td>          <td colspan="2" style="white-space: nowrap; text-align: center; font-size: 10pt">          </td>          <td style="white-space: nowrap; font-size: 10pt">          </td>          <td style="white-space: nowrap; font-size: 10pt">          </td>          <td colspan="2" style="white-space: nowrap; text-align: center; font-size: 10pt">          </td>          <td style="white-space: nowrap; font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: center; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Name            </b>           </font>          </td>          <td style="white-space: nowrap; font-size: 10pt">          </td>          <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: center; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Grant             <br/>             Date            </b>           </font>          </td>          <td style="white-space: nowrap; font-size: 10pt">          </td>          <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: center; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Threshold             <br/>             ($)            </b>           </font>          </td>          <td style="white-space: nowrap; font-size: 10pt">          </td>          <td style="white-space: nowrap; font-size: 10pt">          </td>          <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: center; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Target             <br/>             ($)            </b>           </font>          </td>          <td style="white-space: nowrap; font-size: 10pt">          </td>          <td style="white-space: nowrap; font-size: 10pt">          </td>          <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: center; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Maximum             <br/>             ($)            </b>           </font>          </td>          <td style="white-space: nowrap; font-size: 10pt">          </td>          <td style="white-space: nowrap; font-size: 10pt">          </td>          <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: center; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             All Other             <br/>             Stock             <br/>             Awards:             <br/>             Number of             <br/>             Shares of             <br/>             Stock or             <br/>             Units (#)            </b>           </font>          </td>          <td style="white-space: nowrap; font-size: 10pt">          </td>          <td style="white-space: nowrap; font-size: 10pt">          </td>          <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: center; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             All Other             <br/>             Option             <br/>             Awards:             <br/>             Number of             <br/>             Securities             <br/>             Underlying             <br/>             Options (#)            </b>           </font>          </td>          <td style="white-space: nowrap; font-size: 10pt">          </td>          <td style="white-space: nowrap; font-size: 10pt">          </td>          <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: center; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Exercise or             <br/>             Base             <br/>             Price of             <br/>             Option             <br/>             Awards             <br/>             ($/Sh)            </b>           </font>          </td>          <td style="white-space: nowrap; font-size: 10pt">          </td>          <td style="white-space: nowrap; font-size: 10pt">          </td>          <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: center; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Grant Date             <br/>             Fair Value             <br/>             of             <br/>             Stock             <br/>             Awards             <br/>             ($)(2)            </b>           </font>          </td>          <td style="white-space: nowrap; font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="white-space: nowrap; width: 6%; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Mr. Nielsen (1)           </font>          </td>          <td style="white-space: nowrap; width: 1%; font-size: 10pt">          </td>          <td style="white-space: nowrap; width: 29%; text-align: center; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            3/18/2020           </font>          </td>          <td style="white-space: nowrap; width: 1%; font-size: 10pt">          </td>          <td style="white-space: nowrap; width: 3%; font-size: 10pt">          </td>          <td style="white-space: nowrap; width: 5%; text-align: right; font-size: 10pt">          </td>          <td style="white-space: nowrap; width: 1%; font-size: 10pt">          </td>          <td style="white-space: nowrap; width: 1%; font-size: 10pt">          </td>          <td style="white-space: nowrap; width: 2%; font-size: 10pt">          </td>          <td style="white-space: nowrap; width: 3%; text-align: right; font-size: 10pt">          </td>          <td style="white-space: nowrap; width: 1%; font-size: 10pt">          </td>          <td style="white-space: nowrap; width: 1%; font-size: 10pt">          </td>          <td style="white-space: nowrap; width: 3%; font-size: 10pt">          </td>          <td style="white-space: nowrap; width: 5%; text-align: right; font-size: 10pt">          </td>          <td style="white-space: nowrap; width: 1%; font-size: 10pt">          </td>          <td style="white-space: nowrap; width: 1%; font-size: 10pt">          </td>          <td style="white-space: nowrap; width: 3%; font-size: 10pt">          </td>          <td style="white-space: nowrap; width: 4%; text-align: right; font-size: 10pt">          </td>          <td style="white-space: nowrap; width: 1%; font-size: 10pt">          </td>          <td style="white-space: nowrap; width: 1%; font-size: 10pt">          </td>          <td style="white-space: nowrap; width: 2%; font-size: 10pt">          </td>          <td style="white-space: nowrap; width: 7%; text-align: right; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            15,000           </font>          </td>          <td style="white-space: nowrap; width: 1%; font-size: 10pt">          </td>          <td style="white-space: nowrap; width: 1%; font-size: 10pt">          </td>          <td style="white-space: nowrap; width: 2%; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="white-space: nowrap; width: 5%; text-align: right; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            3.25           </font>          </td>          <td style="white-space: nowrap; width: 1%; font-size: 10pt">          </td>          <td style="white-space: nowrap; width: 1%; font-size: 10pt">          </td>          <td style="white-space: nowrap; width: 2%; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="white-space: nowrap; width: 4%; text-align: right; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2.83           </font>          </td>          <td style="white-space: nowrap; width: 1%; font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="white-space: nowrap; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Mr. Nielsen (1)           </font>          </td>          <td style="white-space: nowrap; font-size: 10pt">          </td>          <td style="white-space: nowrap; text-align: center; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            6/16/2020           </font>          </td>          <td style="white-space: nowrap; font-size: 10pt">          </td>          <td style="white-space: nowrap; font-size: 10pt">          </td>          <td style="white-space: nowrap; text-align: right; font-size: 10pt">          </td>          <td style="white-space: nowrap; font-size: 10pt">          </td>          <td style="white-space: nowrap; font-size: 10pt">          </td>          <td style="white-space: nowrap; font-size: 10pt">          </td>          <td style="white-space: nowrap; text-align: right; font-size: 10pt">          </td>          <td style="white-space: nowrap; font-size: 10pt">          </td>          <td style="white-space: nowrap; font-size: 10pt">          </td>          <td style="white-space: nowrap; font-size: 10pt">          </td>          <td style="white-space: nowrap; text-align: right; font-size: 10pt">          </td>          <td style="white-space: nowrap; font-size: 10pt">          </td>          <td style="white-space: nowrap; font-size: 10pt">          </td>          <td style="white-space: nowrap; font-size: 10pt">          </td>          <td style="white-space: nowrap; text-align: right; font-size: 10pt">          </td>          <td style="white-space: nowrap; font-size: 10pt">          </td>          <td style="white-space: nowrap; font-size: 10pt">          </td>          <td style="white-space: nowrap; font-size: 10pt">          </td>          <td style="white-space: nowrap; text-align: right; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            85,000           </font>          </td>          <td style="white-space: nowrap; font-size: 10pt">          </td>          <td style="white-space: nowrap; font-size: 10pt">          </td>          <td style="white-space: nowrap; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="white-space: nowrap; text-align: right; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            5.21           </font>          </td>          <td style="white-space: nowrap; font-size: 10pt">          </td>          <td style="white-space: nowrap; font-size: 10pt">          </td>          <td style="white-space: nowrap; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="white-space: nowrap; text-align: right; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            4.53           </font>          </td>          <td style="white-space: nowrap; font-size: 10pt">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 7%; padding-right: 3pt; padding-bottom: 8pt; padding-left: 3pt; text-align: justify; font-size: 10pt">          </td>          <td style="width: 7%; padding-right: 3pt; padding-bottom: 8pt; padding-left: 3pt; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (1)           </font>          </td>          <td style="width: 86%; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Reflects a time-vested stock option awarded under the 2017 Stock Incentive Plan. The option vests over a four-year period from the date of grant, with one-fourth (1/4) of the options vesting on the first anniversary of each such grant, and the remaining options vesting thereafter in equal monthly increments equal to one-forty-eighth (1/48) of the options over the next three years.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 7%; text-align: justify; font-size: 10pt">          </td>          <td style="width: 7%; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (2)           </font>          </td>          <td style="width: 86%; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The amounts in this column reflect the aggregate grant date fair value of equity awards granted during the year computed in accordance with FASB ASC Topic 718. See Note 9 to our consolidated financial statements included in this Annual Report on Form 10-K for assumptions made by us in such valuation.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Narrative Disclosures to Summary CompensationTable and Grants of Plan-Based Awards Table        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Please see the discussion under the heading “2020 Performance Analysis and Compensation Decisions” in this Annual Report on Form 10-K, above.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Outstanding Equity Awards at December 31,2020        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The following table sets forth certain informationwith respect to outstanding stock option awards of our sole NEO for the fiscal year ended December 31, 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: bottom">          <td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Name            </b>           </font>          </td>          <td>          </td>          <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Number of             <br/>             Securities             <br/>             Underlying             <br/>             Unexercised             <br/>             Options             <br/>             Exercisable             <br/>             (#)            </b>           </font>          </td>          <td>          </td>          <td>          </td>          <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Number of             <br/>             Securities             <br/>             Underlying             <br/>             Unexercised             <br/>             Options             <br/>             Unexercisable             <br/>             (#)            </b>           </font>          </td>          <td>          </td>          <td>          </td>          <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Equity             <br/>             Incentive             <br/>             Plan             <br/>             Awards:             <br/>             Number of             <br/>             Securities             <br/>             Underlying             <br/>             Unexercised             <br/>             Unearned             <br/>             Options (#)            </b>           </font>          </td>          <td>          </td>          <td>          </td>          <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Option             <br/>             Exercise             <br/>             Price ($)            </b>           </font>          </td>          <td>          </td>          <td>          </td>          <td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Option             <br/>             Expiration             <br/>             Date            </b>           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="width: 17%; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Mr. Nielsen (1)           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 14%; text-align: right; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            7,500           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 14%; text-align: right; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 14%; text-align: right; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="width: 14%; text-align: right; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            92.00           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 14%; text-align: center; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Aug 2023           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Mr. Nielsen (1)           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2,761           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            550.00           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: center; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            April 2026           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Mr. Nielsen (2)           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            4,333           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2,167           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            36.80           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: center; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            April 2028           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Mr. Nielsen (3)           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            6,562           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            8,438           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            18.40           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: center; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            March 2029           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Mr. Nielsen (4)           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            15,000           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            3.25           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: center; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            March 2030           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Mr. Nielsen (5)           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            85,000           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            5.21           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: center; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            June 2030           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="font-size: 10pt; width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (1)           </font>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            All of these options granted are fully vested.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (2)           </font>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            This option vests over a four-year period from the date of grant, April 11, 2018, with one-fourth (1/4) of the shares vesting on the first anniversary of such grant, and the remaining shares vesting thereafter in equal monthly increments equal to one-forty-eighth (1/48) of the shares over the next three years, based on continuing service to the Company.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (3)           </font>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            This option vests over a four-year period from the date of grant, March 28, 2019, with one-fourth (1/4) of the shares vesting on the first anniversary of such grant, and the remaining shares vesting thereafter in equal monthly increments equal to one-forty-eighth (1/48) of the shares over the next three years, based on continuing service to the Company.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (4)           </font>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            This option vests over a four-year period from the date of grant, March 28, 2020, with one-fourth (1/4) of the shares vesting on the first anniversary of such grant, and the remaining shares vesting thereafter in equal monthly increments equal to one-forty-eighth (1/48) of the shares over the next three years, based on continuing service to the Company.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (5)           </font>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            This option vests over a four-year period from the date of grant, June 16, 2020, with one-fourth (1/4) of the shares vesting on the first anniversary of such grant, and the remaining shares vesting thereafter in equal monthly increments equal to one-forty-eighth (1/48) of the shares over the next three years, based on continuing service to the Company.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 74; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            72            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Split-Segment; Name: 6 -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Employment Agreement and Potential PaymentsUpon Termination or Change of Control        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Bio-Path Subsidiary has entered into anemployment agreement with its Chief Executive Officer, Peter H. Nielsen, dated May 1, 2007 (the “Nielsen EmploymentAgreement”).       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The Nielsen Employment Agreement providesfor a base salary, as approved by the Compensation Committee, of $510,000. The Nielsen Employment Agreement provides that Mr. Nielsenis entitled to certain severance payments and benefits in the event he is terminated without Cause (as defined in the Nielsen EmploymentAgreement) or resigns for Good Reason (as defined in the Nielsen Employment Agreement), subject to Mr. Nielsen’s continuedcompliance with the Confidentiality Agreement (as defined in the Nielsen Employment Agreement) and execution of a general releaseof all claims against us. In addition, the Nielsen Employment Agreement also provides that Mr. Nielsen is entitled to certainseverance payments and benefits in the event he is terminated without Cause or resigns for Good Reason within three months beforeor 12 months following a Change in Control (as defined in the Nielsen Employment Agreement), subject to Mr. Nielsen’scontinued compliance with the Confidentiality Agreement and execution of a general release of all claims against us.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The severance payments and benefits includethe following in the event Mr. Nielsen is terminated without Cause or resigns for Good Reason: (i) any accrued but untakenvacation days of Mr. Nielsen will be paid to the extent not yet paid; (ii) the equivalent of Mr. Nielsen’sbase salary will be paid for a period of three months; and (iii) subject to certain restrictions, for three months after Mr. Nielsen’sdate of termination, the Company will continue its contributions toward Mr. Nielsen’s health care, dental, disabilityand life insurance benefits on the same basis as immediately prior to the date of termination.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The severance payments and benefits includethe following in the event Mr. Nielsen is terminated without Cause or resigns for Good Reason within three months before or12 months following a Change in Control: (i) any unvested stock or stock options awarded to Mr. Nielsen shall immediatelyvest upon the occurrence of Mr. Nielsen’s termination of employment; (ii) Mr. Nielsen’s base salarywill be paid through the termination date, and any accrued but untaken vacation days of Mr. Nielsen will be paid to the extentnot yet paid; (iii) Mr. Nielsen’s normal post-termination benefits will be paid in accordance with our retirement,insurance and other benefit plan arrangements (including non-qualified deferred compensation plans); (iv) the equivalent ofMr. Nielsen’s base salary will be paid for a period of three months; (v) subject to certain restrictions, for sixmonths after Mr. Nielsen’s date of termination, or such longer period as may be provided by the terms of the appropriateplan, program, practice of policy, Mr. Nielsen’s health care, dental, disability and life insurance benefits will beprovided on the same basis as immediately prior to the date of termination; and (vi) subject to certain restrictions and tothe extent not otherwise paid or provided, we will pay or provide any other amounts or benefits required to be paid or providedor which Mr. Nielsen is eligible to receive following his termination of employment under any of our plans, programs, policies,practices, contracts or agreements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 75; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            73            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Potential severance payments and benefitsto be paid pursuant to the Nielsen Employment Agreement assuming a termination or Change in Control occurred on December 31,2020 are set forth in the table below.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           Triggering Event          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">           Name          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">           Benefit          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           Termination           <br/>           without           <br/>           Cause or           <br/>           Resignation           <br/>           for Good           <br/>           Reason           <br/>           ($)          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           Termination           <br/>           without           <br/>           Cause or           <br/>           Resignation           <br/>           for           <br/>           Good Reason           <br/>           within 3           <br/>           Months Before or           <br/>           12           <br/>           Months Following           <br/>           a           <br/>           Change in Control           <br/>           ($)          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 32%; font: 10pt Times New Roman, Times, Serif; text-align: left">           Peter H. Nielsen          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 31%; font: 10pt Times New Roman, Times, Serif">           Market Value of Stock Vesting          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 15%; font: 10pt Times New Roman, Times, Serif; text-align: right">           3,750          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 15%; font: 10pt Times New Roman, Times, Serif; text-align: right">           3,750          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           (1)          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Accrued Vacation Days          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           47,077          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           47,077          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">           Three Months’ Base Salary          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           127,500          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           127,500          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">           Continuation of Benefits          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           8,816          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           17,631          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">           Total          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           187,143          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           195,958          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 7%; padding-right: 3pt; padding-bottom: 8pt; padding-left: 3pt; text-align: justify">          </td>          <td style="width: 7%; padding-right: 3pt; padding-bottom: 8pt; padding-left: 3pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (1)           </font>          </td>          <td style="width: 86%; padding-right: 3pt; padding-bottom: 8pt; padding-left: 3pt; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Mr. Nielsen’s stock option awards would immediately become vested, and the value of the acceleration would be equal to the vesting shares multiplied by the excess of the then current stock price over the exercise price of the options. For purposes of this table, we have calculated the value of the acceleration using the closing price of our common stock on December 31, 2020, or $3.50 per share.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         DIRECTOR COMPENSATION        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The following table presents summary informationfor the year ended December 31, 2020 regarding the compensation of the members of our Board (other than Mr. Nielsen).       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">           Name          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           Fees           <br/>           Earned           <br/>           or Paid           <br/>           in Cash          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           Option           <br/>           Awards          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           All Other           <br/>           Compensation          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           Total          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 48%; font: 10pt Times New Roman, Times, Serif; text-align: left">           Heath W. Cleaver          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           52,000          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           (1)          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           43,469          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           (2)          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           95,469          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Paul D. Aubert          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           42,000          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           (1)          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           43,469          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           (2)          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           750          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           (3)          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           86,219          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Martina Molsbergen          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           43,500          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           (1)          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           43,469          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           (2)          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           86,969          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Douglas P. Morris (4)          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           57,421          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           (5)          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           50,641          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           (6)          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           108,062          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (1)           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            These amounts reflect cash fees paid to or earned by our non-employee directors for attending Board or committee meetings during the year ended December 31, 2020.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (2)           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            In March 2020, our non-employee directors who were eligible at such time earned or received an annual grant of an option to purchase 10,000 shares of our common stock, which was the only grant received by such directors during 2020. The amounts in this column reflect the aggregate grant date fair value of equity awards granted during the year computed in accordance with FASB ASC Topic 718. See Note 9 to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K for assumptions made by us in such valuation.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (3)           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The amounts reported represent amounts earned for Board services performed beyond the normal scope of their Board or committee responsibilities.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (4)           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Mr. Morris was hired by the Company in 2016 as the Company’s Director of Investor Relations. Accordingly, Mr. Morris is not considered a non-employee director and does not receive compensation for his services as a member of the Board.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (5)           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Option awards granted to Mr. Morris reflect compensation received by Mr. Morris in his capacity as the Company’s Director of Investor Relations.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (6)           </font>          </td>          <td>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">            This amount reflects compensation received by Mr. Morrisin his capacity as the Company’s Director of Investor Relations, which includes base salary and certain other benefits.           </p>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 76; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            74            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The following table reflects the aggregatenumber of outstanding options (including unexercisable options) held by our directors (other than Mr. Nielsen) as of December 31,2020:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           Director          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           Number of           <br/>           shares           <br/>           underlying           <br/>           outstanding           <br/>           options          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 87%; font: 10pt Times New Roman, Times, Serif; text-align: left">           Heath W. Cleaver          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           12,500          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Paul D. Aubert          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           12,000          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Martina Molsbergen          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           10,000          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Douglas P. Morris (1)          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           18,640          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 32px">          </td>          <td style="width: 32px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (1)           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Mr. Morris’s outstanding options include 3,265 options earned while serving as an executive officer of the Company. Mr. Morris ceased serving in his officer capacities in June 2014. However, Mr. Morris was hired by the Company in 2016 as the Company’s Director of Investor Relations. Accordingly, Mr. Morris is not considered a non-employee director.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Narrative to Director Compensation Table        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        In 2020, our non-employee directors receivedcash and equity compensation in accordance with our non-employee director compensation structure. Directors who were also employedby the Company did not receive compensation for services as directors. We amended our compensation structure for all non-employeedirectors on March 27, 2020. We further amended our compensation structure for all non-employee directors on July 20,2020 in order to provide for the compensation of the members of the Business Development Committee. During 2020, our compensationstructure for all non-employee directors was as follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">        <b>         <i>          Cash Compensation Program         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Non-employee directors received as compensationthe following amounts: (i) an annual cash retainer in the amount of $20,000; (ii) $3,000 for each required meeting ofthe Board attended in person; (iii) $1,500 for each meeting of the Board conducted by telephonic or other electronic communicationsof duration of 15 minutes or longer; and (iv) $500 for each meeting of the Board of duration less than 15 minutes conductedby telephonic or other electronic communications. Board members must have attended meetings in person or by telephonic or otherelectronic communications to have received the applicable cash compensation.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The chairs of the respective Board committeesalso received as compensation the following amounts: (i) an annual cash retainer in the amount of $10,000 to the chair ofthe Audit Committee; (ii) an annual cash retainer in the amount of $5,000 to the chair of the Compensation Committee; (iii) anannual cash retainer in the amount of $5,000 to the chair of the Nominating/Corporate Governance Committee; and (iv) an annualcash retainer in the amount of $5,000 to the chair of the Business Development Committee.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 77; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            75            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Each non-employee director of the Boardwho was a member of a Board committee, including the chair of such committee, also received as compensation the following amounts:(i) $2,000 for each committee meeting attended in person; (ii) $1,500 for each committee meeting conducted by telephonicor other electronic communications of duration of 15 minutes or longer; and (iii) $500 for each committee meeting of durationless than 15 minutes conducted by telephonic or other electronic communications. Committee members must have attended meetingsin person or by telephonic or other electronic communications to have received the applicable compensation.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        In addition to the foregoing cash compensationfor Board and committee members, non-employee directors of the Board who spent significant time performing Board or committee servicebeyond the normal scope of their Board or committee responsibilities could receive up to $2,500 per diem at the discretion of theChief Executive Officer of the Company.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">        <b>         <i>          Equity Compensation Program         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Each non-employee director of the Boardalso received as compensation an annual stock option grant (a “Grant”) of 10,000 shares of our common stock (the “OptionShares”). The exercise price of the Option Shares was determined by the Board, and the Option Shares vest over a one-yearperiod from the date of the Grant, with the Option Shares vesting in equal monthly increments equal to one-twelfth (1/12) of theOption Shares, based on continuing service to the Company.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="text-transform: uppercase">         <b>          <a name="Seng_020">          </a>          ITEM 12. SECURITYOWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The following table sets forth informationregarding shares of our common stock beneficially owned at March 1, 2021 by: (i) our sole NEO and each director; (ii) allexecutive officers and directors as a group; and (iii) each person known by us to beneficially own 5% or more of the outstandingshares of our common stock. The information in this table is based solely on statements in filings with the SEC or other reliableinformation.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; border-bottom: Black 1pt solid">           Name of Beneficial Owner          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           Amount and           <br/>           Nature of           <br/>           Beneficial           <br/>           Ownership          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           Percent of           <br/>           Class          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 74%; font: 10pt Times New Roman, Times, Serif; text-align: justify">           Peter H. Nielsen (1) (2)          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           52,837          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            *           </font>          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           Douglas P. Morris (1) (3)          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           15,792          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            *           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           Heath W. Cleaver (1) (4)          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           12,252          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            *           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           Paul D. Aubert (1) (5)          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           11,764          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            *           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           Martina Molsbergen (1)(6)          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           10,000          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            *           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           All officers and directors as a group (7)          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           102,645          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1.48          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 56px">          </td>          <td style="width: 56px">          </td>          <td>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">            *Less than 1%           </p>          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (1)           </font>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            These are our NEOs and directors.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (2)           </font>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Includes 25,823 shares owned of record and 27,014 shares issuable upon the exercise of options that are exercisable within 60 days.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (3)           </font>          </td>          <td style="text-align: left; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Includes 8,050 shares held by Hyacinth Resources, LLC and 121 shares held by Sycamore Ventures, LLC. Mr. Morris disclaims beneficial ownership of the shares held by Sycamore Ventures, LLC except to the extent of his pecuniary interest therein. Also includes 7,621 shares issuable upon the exercise of options that are exercisable within 60 days.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (4)           </font>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            All 12,252 shares are issuable upon the exercise of options that are exercisable within 60 days.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (5)           </font>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            All 11,764 shares are issuable upon the exercise of options that are exercisable within 60 days.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (6)           </font>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            All 10,000 shares are issuable upon the exercise of options that are exercisable within 60 days.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (7)           </font>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Includes 33,994 shares owned of record and 68,651 shares issuable upon the exercise of options currently exercisable or will be exercisable within 60 days.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 78; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            76            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Equity Compensation Plan Information        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        There are no equity compensation plans thathave not been approved by our stockholders. The following table contains information about our equity compensation plans in effectas of December 31, 2020 (in thousands, except per share amount).       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; border-bottom: Black 1pt solid">           Plan Category          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           Number of           <br/>           shares of           <br/>           common stock to           <br/>           be issued           <br/>           upon exercise of           <br/>           outstanding           <br/>           options, warrants           <br/>           and rights (1)          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           Weighted-average           <br/>           exercise price           <br/>           of outstanding           <br/>           options, warrants           <br/>           and rights          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           Number of           <br/>           shares of           <br/>           common stock           <br/>           remaining           <br/>           available for           <br/>           future issuance           <br/>           under equity           <br/>           compensation           <br/>           plans (2)          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 61%; font: 10pt Times New Roman, Times, Serif; text-align: left">           Equity compensation plans approved by stockholders          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           274          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           20.57          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           403          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">           Equity compensation plans not approved by stockholders          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="font-size: 10pt; width: 48px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (1)           </font>          </td>          <td>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">            17 of the shares shown in this column as securitiesto be issued upon exercise of outstanding options, warrants and rights were subject to outstanding stock option awards as of December 31,2020 that were granted under the First Amended Bio-Path Holdings, Inc. 2007 Stock Incentive Plan, as amended (the “2007Stock Incentive Plan”). 257 of the shares shown in this column as securities to be issued upon exercise of outstanding options,warrants and rights were subject to outstanding stock option awards as of December 31, 2020 that were granted under the Bio-PathHoldings, Inc. 2017 Stock Incentive Plan, as amended (the “2017 Stock Incentive Plan”).           </p>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px; padding-bottom: 8pt; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (2)           </font>          </td>          <td style="padding-bottom: 8pt; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The shares shown in this column as remaining available for future issuance as of December 31, 2020 are all under the 2017 Stock Incentive Plan. The 2007 Stock Incentive Plan expired in January 2018.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="text-transform: uppercase">         <b>          <a name="Seng_021">          </a>          ITEM 13. CERTAINRELATIONSHIPS AND RELATED PARTY TRANSACTIONS, AND DIRECTOR INDEPENDENCE         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Related Party Transactions        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        It is our policy that we will not enterinto any transactions required to be disclosed under Item 404 of Regulation S-K promulgated by the SEC unless the Audit Committeefirst reviews and approves the transactions. The Audit Committee is required to review on an ongoing basis, and pre-approve allrelated party transactions before they are entered into, including those transactions that are required to be disclosed under Item404 of Regulation S-K. Related party transactions involving a director must also be approved by the disinterested members of theAudit Committee. It is the responsibility of our employees and directors to disclose any significant financial interest in a transactionbetween the Company and a third party, including an indirect interest. All related party transactions shall be disclosed in ourfilings with the SEC as required under SEC rules.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 79; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            77            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        In addition, pursuant to our codes of ethics,all employees, officers and directors of ours and our subsidiaries are prohibited from engaging in any relationship or financialinterest that is an actual or potential conflict of interest with us without approval. Employees and officers are required to providewritten disclosure to their supervisors as soon as they have any knowledge of a transaction or proposed transaction with an outsideindividual, business or other organization that would create a conflict of interest or the appearance of one. Directors are requiredto disclose such information to the Board or as otherwise required by law.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        For our last two fiscal years, there hasnot been nor is there currently proposed any transaction or series of similar transactions to which we were or are to be a partyin which the amount involved exceeds the lesser of $120,000 or 1% of the average of our total assets at the end of our last twofiscal years, and in which any of our directors, executive officers, persons who we know hold more than 5% of our common stock,or any member of the immediate family of any of the foregoing persons had or will have a direct or indirect material interest otherthan: (i) compensation agreements and other arrangements, which are described elsewhere in this Annual Report on Form 10-Kand (ii) the transactions described in the following paragraph.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        We have entered into indemnity agreementswith certain of our officers and directors which provide, among other things, that we will indemnify such officer or director,under the circumstances and to the extent provided for therein, for expenses, damages, judgments, fines and settlements he or shemay be required to pay in actions or proceedings which he or she is or may be made a party by reason of his or her position asa director, officer or other agent of the Company, and otherwise to the fullest extent permitted under applicable law, our Certificateof Incorporation and our Bylaws.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Director Independence        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The following members of the Board havebeen identified as independent under the standards of The Nasdaq Stock Market: Heath W. Cleaver, Paul D. Aubert and Martina Molsbergen.Presently, there are no directors on our Audit Committee, Nominating/Corporate Governance Committee or Compensation Committee whoare not independent under the standards of The Nasdaq Stock Market.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="text-transform: uppercase">         <b>          <a name="Seng_022">          </a>          ITEM 14. PRINCIPALACCOUNTING FEES AND SERVICES         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        On March 5, 2020, the Company, at thedirection of the Audit Committee, chose not to renew the engagement of BDO USA, LLP (“BDO”), which was then servingas the Company’s independent registered public accounting firm. The Company notified BDO on March 6, 2020 that it wouldbe dismissed as the Company’s independent registered public accounting firm, effective immediately. The decision to changeindependent registered public accounting firms was approved by the Audit Committee. On March 9, 2020, the Audit Committeeapproved the appointment of Ernst &amp; Young LLP (“EY”) as the Company’s new independent registered publicaccounting firm.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        For the fiscal year ended December 31,2019, and for the interim period from January 1, 2020 through March 6, 2020, BDO, as our independent registered publicaccounting firm during such time, billed the approximate fees set forth in the first table below. During the interim period fromMarch 9, 2020 through December 31, 2020, EY, as our independent registered public accounting firm during such time, billedthe approximate fees set forth in the second table below. The Board has considered the respective services provided by BDO andEY and has concluded that such services are compatible with the independence of BDO and EY as our principal accountants duringthe respective periods.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 80; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            78            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The table below sets forth the aggregatefees billed to the Company by BDO for services rendered in the fiscal year ended December 31, 2019 and in the interim periodfrom January 1, 2020 through March 6, 2020 (in thousands).       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           January 1,           <br/>           2020 –           <br/>           March 6,           <br/>           2020          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           December           <br/>           31,           <br/>           2019          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 74%; font: 10pt Times New Roman, Times, Serif; text-align: left">           Audit fees (1)          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           225          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Audit-related fees (2)          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Tax fees (3)          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">           All other fees (4)          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">           Total          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           225          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 56px">          </td>          <td style="font-size: 10pt; width: 56px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (1)           </font>          </td>          <td>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">            Audit fees consist of fees billed for professional services        rendered for the audit of our consolidated financial statements, reviews of the interim condensed consolidated financial statements        included in quarterly filings, services associated with equity offerings, including with respect to registration statements filed        by the Company, and services that are normally provided by BDO in connection with statutory and regulatory filings or engagements,        including consents, except those not required by statute or regulation.           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">           </p>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (2)           </font>          </td>          <td>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">            Audit-related fees consist of fees billed by BDO for assurance        and related services. These fees include services provided in conjunction with due diligence services and employee benefit plan        audits.           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">           </p>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (3)           </font>          </td>          <td>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">            Tax fees consist of fees billed for professional services rendered        by BDO for state and federal tax compliance and advice, and tax planning.           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">           </p>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (4)           </font>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            All other fees consist of fees billed by BDO for professional services other than those relating to audit fees, audit-related fees and tax fees.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The table below sets forth the aggregatefees billed to the Company by EY for services rendered in the interim period from March 9, 2020 through December 31,2020 (in thousands).       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           March 9,           <br/>           2020 –           <br/>           December 31,           <br/>           2020          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 87%; font: 10pt Times New Roman, Times, Serif; text-align: left">           Audit fees (1)          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           272          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Audit-related fees (2)          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Tax fees (3)          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">           All other fees (4)          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           —          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">           Total          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           272          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 56px">          </td>          <td style="font-size: 10pt; width: 56px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (1)           </font>          </td>          <td>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">            Audit fees consist of fees billed for professional services        rendered for the audit of our consolidated financial statements, reviews of the interim condensed consolidated financial statements        included in quarterly filings, services associated with equity offerings, including with respect to registration statements filed        by the Company, and services that are normally provided by EY in connection with statutory and regulatory filings or engagements,        including consents, except those not required by statute or regulation.           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">           </p>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (2)           </font>          </td>          <td>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">            Audit-related fees consist of fees billed by EY for assurance        and related services. These fees include services provided in conjunction with due diligence services and employee benefit plan        audits.           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">           </p>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (3)           </font>          </td>          <td>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">            Tax fees consist of fees billed for professional services rendered        by EY for state and federal tax compliance and advice, and tax planning.           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">           </p>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (4)           </font>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            All other fees consist of fees billed by EY for professional services other than those relating to audit fees, audit-related fees and tax fees.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Pre-Approval Policies and Procedures        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The Audit Committee has not adopted anyblanket pre-approval policies and procedures. Instead, the Audit Committee will pre-approve the provision of all audit or non-auditservices.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 81; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            79            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Split-Segment; Name: 7 -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">        <font style="text-transform: uppercase">         <b>          <u>           <a name="Seng_023">           </a>           PART IV          </u>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="text-transform: uppercase">         <b>          <a name="Seng_024">          </a>          ITEM 15. EXHIBITSAND FINANCIAL STATEMENT SCHEDULES         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        1.        <i>         Financial Statements        </i>        . The financialstatements and information required by “Item 8. Financial Statements and Supplementary Data” of this Annual Reporton Form 10-K appear on pages F-1 through F-17 of this report. The Index to Consolidated Financial Statements appearson page F-1.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        2.        <i>         Financial Statement Schedules        </i>        .All schedules are omitted because they are not applicable or the required information is shown in the financial statements or thenotes thereto.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        3.        <i>         Exhibits.        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr>          <td style="border-bottom: black 1pt solid; vertical-align: top; width: 8%; font-size: 10pt">           <font style="font-size: 10pt">            <b>             Exhibit             <br/>             Number            </b>           </font>          </td>          <td style="vertical-align: top; width: 2%">          </td>          <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 90%; font-size: 10pt">           <font style="font-size: 10pt">            <b>             Exhibit            </b>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000101619307000027/ex2-1.htm">            <font style="font-size: 10pt">             2.1            </font>           </a>          </td>          <td>          </td>          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000101619307000027/ex2-1.htm">            <font style="font-size: 10pt">             Agreement and Plan of Merger and Reorganization dated September 27, 2007, by and among the Company, Biopath Acquisition Corp., a Utah corporation and wholly owned subsidiary of the registrant, and Bio-Path, Inc., a Utah corporation (incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K filed on September 27, 2007).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420415000776/v398162_ex3-3.htm">            <font style="font-size: 10pt">             3.1            </font>           </a>          </td>          <td>          </td>          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420415000776/v398162_ex3-3.htm">            <font style="font-size: 10pt">             Certificate of Incorporation (incorporated by reference to Exhibit 3.3 to the Company’s Current Report on Form 8-K filed on January 6, 2015).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420418006765/tv485337_ex3-1.htm">            <font style="font-size: 10pt">             3.2            </font>           </a>          </td>          <td>          </td>          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420418006765/tv485337_ex3-1.htm">            <font style="font-size: 10pt">             Certificate of Amendment to the Certificate of Incorporation of Bio-Path Holdings, Inc. (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on February 9, 2018).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420417031532/v468617_ex3-1.htm">            <font style="font-size: 10pt">             3.3            </font>           </a>          </td>          <td>          </td>          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420419001872/tv511127_ex3-1.htm">            <font style="font-size: 10pt">             Certificate of Amendment to the Certificate of Incorporation of Bio-Path Holdings, Inc. (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on January 16, 2019).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420419001872/tv511127_ex3-1.htm">            <font style="font-size: 10pt">             3.4            </font>           </a>          </td>          <td>          </td>          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420417031532/v468617_ex3-1.htm">            <font style="font-size: 10pt">             First Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on June 7, 2017).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420415016335/v404039_ex4-1.htm">            <font style="font-size: 10pt">             4.1            </font>           </a>          </td>          <td>          </td>          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420415016335/v404039_ex4-1.htm">            <font style="font-size: 10pt">             Form of Common Stock Certificate (incorporated by reference to Exhibit 4.1 to the Company’s Annual Report on Form 10-K filed on March 16, 2015).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420414002956/v365601_ex4-1.htm">            <font style="font-size: 10pt">             4.2            </font>           </a>          </td>          <td>          </td>          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420414002956/v365601_ex4-1.htm">            <font style="font-size: 10pt">             Form of Warrant issued to Maxim Group LLC, Sabby Healthcare Volatility Master Fund, Ltd. and Sabby Volatility Warrant Master Fund, Ltd. (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K on January 21, 2014).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420416110666/v443292_ex4-1.htm">            <font style="font-size: 10pt">             4.3            </font>           </a>          </td>          <td>          </td>          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420416110666/v443292_ex4-1.htm">            <font style="font-size: 10pt">             Form of Warrant issued to certain investors (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on June 29, 2016).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420416117698/v445454_ex4-5.htm">            <font style="font-size: 10pt">             4.4            </font>           </a>          </td>          <td>          </td>          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420416117698/v445454_ex4-5.htm">            <font style="font-size: 10pt">             Form of Warrant issued to H.C. Wainwright &amp; Co., LLC and certain of its designees (incorporated by reference to Exhibit 4.5 to the Company’s Quarterly Report on Form 10-Q filed on August 9, 2016).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420417028733/v467559_ex4-1.htm">            <font style="font-size: 10pt">             4.5            </font>           </a>          </td>          <td>          </td>          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420417028733/v467559_ex4-1.htm">            <font style="font-size: 10pt">             Form of New Warrant (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on May 22, 2017).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420417056346/tv478543_ex4-1.htm">            <font style="font-size: 10pt">             4.6            </font>           </a>          </td>          <td>          </td>          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420417033064/v469208_ex4-1.htm">            <font style="font-size: 10pt">             Form of Warrant Amendment (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on June 19, 2017).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420417056346/tv478543_ex4-1.htm">            <font style="font-size: 10pt">             4.7            </font>           </a>          </td>          <td>          </td>          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420417056346/tv478543_ex4-1.htm">            <font style="font-size: 10pt">             Form of Warrant issued to certain investors (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on November 6, 2017).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420418018611/tv488319_ex4-9.htm">            <font style="font-size: 10pt">             4.8            </font>           </a>          </td>          <td>          </td>          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420418018611/tv488319_ex4-9.htm">            <font style="font-size: 10pt">             Form of Warrant issued to Roth Capital Partners, LLC (incorporated by reference to Exhibit 4.9 to the Company’s Annual Report on Form 10-K filed on April 2, 2018).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420418050410/tv503304_ex4-2.htm">            <font style="font-size: 10pt">             4.9            </font>           </a>          </td>          <td>          </td>          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420418050410/tv503304_ex4-2.htm">            <font style="font-size: 10pt">             Form of Series A Warrant issued to certain investors (incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K filed on September 21, 2018).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420418059966/tv506222_ex4-3.htm">            <font style="font-size: 10pt">             4.10            </font>           </a>          </td>          <td>          </td>          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420418059966/tv506222_ex4-3.htm">            <font style="font-size: 10pt">             Form of Warrant issued to H.C. Wainwright &amp; Co., LLC and certain of its designees (incorporated by reference to Exhibit 4.3 to the Company’s Quarterly Report on Form 10-Q filed on November 14, 2018).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420419001872/tv511127_ex4-1.htm">            <font style="font-size: 10pt">             4.11            </font>           </a>          </td>          <td>          </td>          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420419001872/tv511127_ex4-1.htm">            <font style="font-size: 10pt">             Form of Underwriter Warrant issued to H.C. Wainwright &amp; Co., LLC and certain of its designees (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on January 16, 2019).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420419002290/tv511350_ex4-1.htm">            <font style="font-size: 10pt">             4.12            </font>           </a>          </td>          <td>          </td>          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420419002290/tv511350_ex4-1.htm">            <font style="font-size: 10pt">             Form of Series A Warrant issued to certain investors (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on January 22, 2019).            </font>           </a>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 82; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            80            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 8%; font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420419014855/tv515879_ex4-15.htm">            <font style="font-size: 10pt">             4.13            </font>           </a>          </td>          <td style="width: 2%">          </td>          <td style="width: 90%; font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420419014855/tv515879_ex4-15.htm">            <font style="font-size: 10pt">             Form of Warrant issued to H.C. Wainwright &amp; Co., LLC and certain of its designees (incorporated by reference to Exhibit 4.15 to the Company’s Annual Report on Form 10-K filed on March 19, 2019).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420419013721/tv516100_ex4-1.htm">            <font style="font-size: 10pt">             4.14            </font>           </a>          </td>          <td>          </td>          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420419013721/tv516100_ex4-1.htm">            <font style="font-size: 10pt">             Form of Warrant issued to H.C. Wainwright &amp; Co., LLC and certain of its designees (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on March 13, 2019).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000110465919066713/tm1923708d2_ex4-1.htm">            <font style="font-size: 10pt">             4.1            </font>           </a>           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000110465919066713/tm1923708d2_ex4-1.htm">            <font style="font-size: 10pt">             5            </font>           </a>          </td>          <td>          </td>          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000110465919066713/tm1923708d2_ex4-1.htm">            <font style="font-size: 10pt">             Form of Warrant issued to certain investors (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on November 22, 2019).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000110465919066713/tm1923708d2_ex4-2.htm">            <font style="font-size: 10pt">             4.1            </font>           </a>           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000110465919066713/tm1923708d2_ex4-2.htm">            <font style="font-size: 10pt">             6            </font>           </a>          </td>          <td>          </td>          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000110465919066713/tm1923708d2_ex4-2.htm">            <font style="font-size: 10pt">             Form of Warrant issued to H.C. Wainwright &amp; Co., LLC and certain of its designees (incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K filed on November 22, 2019).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">           <a href="https://www.sec.gov/Archives/edgar/data/1133818/000110465920029711/tm205374d1_ex4-17.htm">            <font style="font-size: 10pt">             4.17            </font>           </a>          </td>          <td>          </td>          <td style="font-size: 10pt">           <a href="https://www.sec.gov/Archives/edgar/data/1133818/000110465920029711/tm205374d1_ex4-17.htm">            <font style="font-size: 10pt">             Description of Bio-Path Holdings, Inc.’s Securities Registered under Section 12 of the Securities Exchange Act of 1934 (incorporated by reference to Exhibit 4.17 to the Company's Annual Report on Form 10-K filed on March 5, 2020).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000093173108000021/ex10-1nielsen.htm">            <font style="font-size: 10pt">             10.1+            </font>           </a>          </td>          <td>          </td>          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000093173108000021/ex10-1nielsen.htm">            <font style="font-size: 10pt">             Employment Agreement – Peter H. Nielsen (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on February 19, 2008).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000101619308000054/ex4-1.htm">            <font style="font-size: 10pt">             10.2+            </font>           </a>          </td>          <td>          </td>          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000101619308000054/ex4-1.htm">            <font style="font-size: 10pt">             Amended 2007 Stock Incentive Plan (incorporated by reference to Exhibit 4.1 to the Company’s Registration Statement on Form S-8 filed on December 10, 2008).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420413045992/v352628_ex10-1.htm">            <font style="font-size: 10pt">             10.3+            </font>           </a>          </td>          <td>          </td>          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420413045992/v352628_ex10-1.htm">            <font style="font-size: 10pt">             First Amendment to First Amended 2007 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q filed on August 14, 2013).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420414002956/v365601_ex10-2.htm">            <font style="font-size: 10pt">             10.4            </font>           </a>          </td>          <td>          </td>          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420414002956/v365601_ex10-1.htm">            <font style="font-size: 10pt">             Form of Securities Purchase Agreement by and between the Company, Sabby Healthcare Volatility Master Fund, Ltd. and Sabby Volatility Warrant Master Fund, Ltd. (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on January 21, 2014).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420414002956/v365601_ex10-2.htm">            <font style="font-size: 10pt">             10.5            </font>           </a>          </td>          <td>          </td>          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420414002956/v365601_ex10-2.htm">            <font style="font-size: 10pt">             Form of Waiver, Consent and Amendment to that certain Securities Purchase Agreement by and between Sabby Healthcare Volatility Master Fund, Ltd. and Sabby Volatility Warrant Master Fund, Ltd. (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K on January 21, 2014).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420414017895/v372789_ex10-1.htm">            <font style="font-size: 10pt">             10.6+            </font>           </a>          </td>          <td>          </td>          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420414017895/v372789_ex10-1.htm">            <font style="font-size: 10pt">             First Amendment to Employment Agreement, dated March 26, 2014 – Peter H. Nielsen (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on March 26, 2014).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420414023522/v375097_ex10-1.htm">            <font style="font-size: 10pt">             10.7            </font>           </a>          </td>          <td>          </td>          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420414023522/v375097_ex10-1.htm">            <font style="font-size: 10pt">             Lease Agreement dated April 16, 2014 by and between the Company and Pin Oak North Parcel TT, LLC (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on April 18, 2014).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420415023271/v407464_ex10-1.htm">            <font style="font-size: 10pt">             10.8            </font>           </a>          </td>          <td>          </td>          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420415023271/v407464_ex10-1.htm">            <font style="font-size: 10pt">             Form of Indemnification Agreement (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on April 16, 2015).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420415039030/v413299_ex1-1.htm">            <font style="font-size: 10pt">             10.9            </font>           </a>          </td>          <td>          </td>          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420415039030/v413299_ex1-1.htm">            <font style="font-size: 10pt">             Controlled Equity OfferingSM Sales Agreement, dated June 24, 2015, by and between the Company and Cantor Fitzgerald &amp; Co. (incorporated by reference to Exhibit 1.1 to the Company’s Current Report on Form 8-K filed on June 25, 2015).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420416110666/v443292_ex10-1.htm">            <font style="font-size: 10pt">             10.10            </font>           </a>          </td>          <td>          </td>          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420416110666/v443292_ex10-1.htm">            <font style="font-size: 10pt">             Form of Securities Purchase Agreement by and between the Company and certain investors (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on June 29, 2016).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420417028733/v467559_ex10-1.htm">            <font style="font-size: 10pt">             10.11            </font>           </a>          </td>          <td>          </td>          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420417028733/v467559_ex10-1.htm">            <font style="font-size: 10pt">             Form of Warrant Exercise Agreement (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on May 22, 2017).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420417056346/tv478543_ex10-1.htm">            <font style="font-size: 10pt">             10.12            </font>           </a>          </td>          <td>          </td>          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420417056346/tv478543_ex10-1.htm">            <font style="font-size: 10pt">             Form of Securities Purchase Agreement by and between the Company and certain investors (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on November 6, 2017).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420417056346/tv478543_ex10-2.htm">            <font style="font-size: 10pt">             10.13            </font>           </a>          </td>          <td>          </td>          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420417056346/tv478543_ex10-2.htm">            <font style="font-size: 10pt">             Form of Leak-Out Agreement by and between the Company and certain investors (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed on November 6, 2017).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420417065489/tv482134_ex10-1.htm">            <font style="font-size: 10pt">             10.14+            </font>           </a>          </td>          <td>          </td>          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420417065489/tv482134_ex10-1.htm">            <font style="font-size: 10pt">             Bio-Path Holdings, Inc. 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on December 27, 2017).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420417065489/tv482134_ex10-2.htm">            <font style="font-size: 10pt">             10.15            </font>           </a>          </td>          <td>          </td>          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420417065489/tv482134_ex10-2.htm">            <font style="font-size: 10pt">             Form of Incentive Stock Option Award Agreement under 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed on December 27, 2017).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420417065489/tv482134_ex10-3.htm">            <font style="font-size: 10pt">             10.16            </font>           </a>          </td>          <td>          </td>          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420417065489/tv482134_ex10-3.htm">            <font style="font-size: 10pt">             Form of Non-Qualified Stock Option Award Agreement under 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K filed on December 27, 2017).            </font>           </a>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 83; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            81            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 8%; font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420417065489/tv482134_ex10-4.htm">            <font style="font-size: 10pt">             10.17            </font>           </a>          </td>          <td style="width: 2%">          </td>          <td style="width: 90%; font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420417065489/tv482134_ex10-4.htm">            <font style="font-size: 10pt">             Form of Restricted Share Unit Award Agreement (Time-Vested) under 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.4 to the Company’s Current Report on Form 8-K filed on December 27, 2017).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420417065489/tv482134_ex10-5.htm">            <font style="font-size: 10pt">             10.18            </font>           </a>          </td>          <td>          </td>          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420417065489/tv482134_ex10-5.htm">            <font style="font-size: 10pt">             Form of Restricted Share Unit Award Agreement (Performance-Based) under 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.5 to the Company’s Current Report on Form 8-K filed on December 27, 2017).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420417065489/tv482134_ex10-6.htm">            <font style="font-size: 10pt">             10.19            </font>           </a>          </td>          <td>          </td>          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420417065489/tv482134_ex10-6.htm">            <font style="font-size: 10pt">             Form of Restricted Share Award Agreement under 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.6 to the Company’s Current Report on Form 8-K filed on December 27, 2017).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420417065489/tv482134_ex10-7.htm">            <font style="font-size: 10pt">             10.20            </font>           </a>          </td>          <td>          </td>          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420417065489/tv482134_ex10-7.htm">            <font style="font-size: 10pt">             Form of Stock Appreciation Right Award Agreement under 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.7 to the Company’s Current Report on Form 8-K filed on December 27, 2017).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420418050410/tv503304_ex10-1.htm">            <font style="font-size: 10pt">             10.21            </font>           </a>          </td>          <td>          </td>          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420418050410/tv503304_ex10-1.htm">            <font style="font-size: 10pt">             Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on September 21, 2018).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420419002290/tv511350_ex10-1.htm">            <font style="font-size: 10pt">             10.22            </font>           </a>          </td>          <td>          </td>          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420419002290/tv511350_ex10-1.htm">            <font style="font-size: 10pt">             Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on January 22, 2019).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420419013721/tv516100_ex10-1.htm">            <font style="font-size: 10pt">             10.23            </font>           </a>          </td>          <td>          </td>          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420419013721/tv516100_ex10-1.htm">            <font style="font-size: 10pt">             Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on March 13, 2019).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420419029728/tv522895_ex10-1.htm">            <font style="font-size: 10pt">             10.24            </font>           </a>          </td>          <td>          </td>          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000114420419029728/tv522895_ex10-1.htm">            <font style="font-size: 10pt">             First Amendment to Lease Agreement dated April 16, 2014 by and between the Company and Pin Oak North Parcel TT, LLC (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on June 4, 2019).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000110465919066713/tm1923708d2_ex10-1.htm">            <font style="font-size: 10pt">             10.25            </font>           </a>          </td>          <td>          </td>          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000110465919066713/tm1923708d2_ex10-1.htm">            <font style="font-size: 10pt">             Form of Securities Purchase Agreement by and between the Company and certain investors (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on November 22, 2019).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000110465919075627/tm1926828d1_ex10-1.htm">            <font style="font-size: 10pt">             10.26            </font>           </a>          </td>          <td>          </td>          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000110465919075627/tm1926828d1_ex10-1.htm">            <font style="font-size: 10pt">             First Amendment to Bio-Path Holdings, Inc. 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on December 23, 2019).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">           <a href="https://www.sec.gov/Archives/edgar/data/1133818/000110465920061598/tm2014555d1_ex10-1.htm">            <font style="font-size: 10pt">             10.27            </font>           </a>          </td>          <td>          </td>          <td style="font-size: 10pt">           <a href="https://www.sec.gov/Archives/edgar/data/1133818/000110465920061598/tm2014555d1_ex10-1.htm">            <font style="font-size: 10pt">             Second Amendment to Bio-Path Holdings, Inc. 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q filed on May 14, 2020).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">           <a href="https://www.sec.gov/Archives/edgar/data/1133818/000110465920083224/tm2024604d1_ex10-1.htm">            <font style="font-size: 10pt">             10.28            </font>           </a>          </td>          <td>          </td>          <td style="font-size: 10pt">           <a href="https://www.sec.gov/Archives/edgar/data/1133818/000110465920083224/tm2024604d1_ex10-1.htm">            <font style="font-size: 10pt">             At-the-Market Offering Agreement, by and between the Company and H.C. Wainwright &amp; Co., LLC, dated July 13, 2020 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on July 14, 2020).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000110465919066713/tm1923708d2_ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             10.29            </font>           </a>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/1133818/000110465919066713/tm1923708d2_ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Form of Securities Purchase Agreement by and between the Company and certain investors (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on February 17, 2021).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">           <a href="https://www.sec.gov/Archives/edgar/data/1133818/000110465920029711/tm205374d1_ex21-1.htm">            <font style="font-size: 10pt">             21.1            </font>           </a>          </td>          <td>          </td>          <td style="font-size: 10pt">           <a href="https://www.sec.gov/Archives/edgar/data/1133818/000110465920029711/tm205374d1_ex21-1.htm">            <font style="font-size: 10pt">             Subsidiaries of Bio-Path Holdings, Inc. (incorporated by reference to Exhibit 21.1 to the Company's Annual Report on Form 10-K filed on March 5, 2020).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">           <a href="tm211142d1_ex23-1.htm">            <font style="font-size: 10pt">             23.1*            </font>           </a>          </td>          <td>          </td>          <td style="font-size: 10pt">           <a href="tm211142d1_ex23-1.htm">            Consent of Ernst &amp; Young LLP.           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">           <a href="tm211142d1_ex23-2.htm">            <font style="font-size: 10pt">             23.2*            </font>           </a>          </td>          <td>          </td>          <td style="font-size: 10pt">           <a href="tm211142d1_ex23-2.htm">            Consent of BDO, LLP.           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">           <a href="tm211142d1_ex31.htm">            <font style="font-size: 10pt">             31*            </font>           </a>          </td>          <td>          </td>          <td style="font-size: 10pt">           <a href="tm211142d1_ex31.htm">            <font style="font-size: 10pt">             Certification of Principal Executive Officer/Principal Financial Officer pursuant to Exchange Act Rules 13a-14 and 15d-14, as adopted pursuant to Section 302 Sarbanes Oxley Act of 2002.            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">           <a href="tm211142d1_ex32.htm">            <font style="font-size: 10pt">             32**            </font>           </a>          </td>          <td>          </td>          <td style="font-size: 10pt">           <a href="tm211142d1_ex32.htm">            <font style="font-size: 10pt">             Certification of Principal Executive Officer/Principal Financial Officer pursuant to Section 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002.            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">           <font style="font-size: 10pt">            101.INS*           </font>          </td>          <td>          </td>          <td style="font-size: 10pt">           <font style="font-size: 10pt">            XBRL Instance Document           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">           <font style="font-size: 10pt">            101.SCH*           </font>          </td>          <td>          </td>          <td style="font-size: 10pt">           <font style="font-size: 10pt">            XBRL Taxonomy Extension Schema Document           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">           <font style="font-size: 10pt">            101.CAL*           </font>          </td>          <td>          </td>          <td style="font-size: 10pt">           <font style="font-size: 10pt">            XBRL Taxonomy Extension Calculation Linkbase Document           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">           <font style="font-size: 10pt">            101.DEF*           </font>          </td>          <td>          </td>          <td style="font-size: 10pt">           <font style="font-size: 10pt">            XBRL Taxonomy Extension Definition Linkbase Document           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">           <font style="font-size: 10pt">            101.LAB*           </font>          </td>          <td>          </td>          <td style="font-size: 10pt">           <font style="font-size: 10pt">            XBRL Taxonomy Extension Label Linkbase Document           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">           <font style="font-size: 10pt">            101.PRE*           </font>          </td>          <td>          </td>          <td style="font-size: 10pt">           <font style="font-size: 10pt">            XBRL Taxonomy Extension Presentation Linkbase Document           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        * Filed herewith.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        ** Furnished herewith.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        + Management contract or compensatory plan.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="text-transform: uppercase">         <b>          <a name="Seng_025">          </a>          ITEM 16. FORM 10-KSUMMARY         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        None.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 84; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            82            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">        <u>         SIGNATURES        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Pursuant to the requirements of Section 13or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf bythe undersigned, thereunto duly authorized.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td>          </td>          <td colspan="2" style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            BIO-PATH HOLDINGS, INC.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="width: 50%">          </td>          <td style="width: 3%">          </td>          <td style="width: 47%">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Dated:    March 9, 2021           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            By:           </font>          </td>          <td style="border-bottom: black 1pt solid; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            /s/ Peter H. Nielsen           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Peter H. Nielsen           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            President           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Chief Executive Officer           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Chief Financial Officer           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Principal Accounting Officer           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Pursuant to the requirements of the SecuritiesExchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacitiesand on the dates indicated.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 18%; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Date            </b>           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 50%; text-align: center; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Title            </b>           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 30%; text-align: center; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Signature            </b>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr>          <td style="vertical-align: top; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            March 9,    2021           </font>          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: top; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            President/Chief    Executive Officer/ Chief Financial Officer/           </font>          </td>          <td style="vertical-align: top">          </td>          <td style="border-bottom: black 1pt solid; vertical-align: bottom; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            /s/    Peter H. Nielsen           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Principal Accounting    Officer/Director           </font>          </td>          <td>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Peter    H. Nielsen           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            March 9, 2021           </font>          </td>          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Director           </font>          </td>          <td>          </td>          <td style="border-bottom: black 1pt solid; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            /s/    Heath W. Cleaver           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Heath W. Cleaver           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            March 9, 2021           </font>          </td>          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Director           </font>          </td>          <td>          </td>          <td style="border-bottom: black 1pt solid; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            /s/    Paul D. Aubert           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Paul D. Aubert           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            March 9, 2021           </font>          </td>          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Director           </font>          </td>          <td>          </td>          <td style="border-bottom: black 1pt solid; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            /s/    Martina Molsbergen           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Martina Molsbergen           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            March 9, 2021           </font>          </td>          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Director           </font>          </td>          <td>          </td>          <td style="border-bottom: black 1pt solid; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            /s/    Douglas P. Morris           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Douglas P. Morris           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 85; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            83            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">        <u>         Index to Consolidated Financial Statements        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom; background-color: White">          <td style="border-bottom: Black 1pt solid; width: 87%; font: bold 10pt Times New Roman, Times, Serif; text-align: justify">           Bio-Path Holdings, Inc.    Financial Statements          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 10%; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Page            </b>           </font>          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: justify; padding-bottom: 1pt">           <a href="#Seng_026">            Reports    of Independent Registered Public Accounting Firms           </a>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; color: #0000ee; padding-bottom: 1pt">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; color: #0000ee; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           <a href="#Seng_026">            F-2           </a>          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; color: #0000ee; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: justify; padding-bottom: 1pt">           <a href="#Seng_027">            Consolidated    Balance Sheets           </a>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; color: #0000ee; padding-bottom: 1pt">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; color: #0000ee; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           <a href="#Seng_027">            F-4           </a>          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; color: #0000ee; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: justify; padding-bottom: 1pt">           <a href="#Seng_028">            Consolidated    Statements of Operations           </a>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; color: #0000ee; padding-bottom: 1pt">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; color: #0000ee; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           <a href="#Seng_028">            F-5           </a>          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; color: #0000ee; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: justify; padding-bottom: 1pt">           <a href="#Seng_029">            Consolidated    Statements of Cash Flows           </a>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; color: #0000ee; padding-bottom: 1pt">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; color: #0000ee; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           <a href="#Seng_029">            F-6           </a>          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; color: #0000ee; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: justify; padding-bottom: 1pt">           <a href="#Seng_030">            Consolidated    Statements of Shareholders’ Equity           </a>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; color: #0000ee; padding-bottom: 1pt">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; color: #0000ee; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           <a href="#Seng_030">            F-7           </a>          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; color: #0000ee; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">           <a href="#Seng_031">            Notes    to Consolidated Financial Statements           </a>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; color: #0000ee; padding-bottom: 1pt">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; color: #0000ee; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           <a href="#Seng_031">            F-8           </a>          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; color: #0000ee; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 86; Options: NewSection; Value: 1 -->       <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            1            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         <a name="Seng_026">         </a>         Report of Independent Registered Public Accounting Firm        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         To the Shareholders and the Board of Directors of Bio-PathHoldings, Inc.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Opinion on the Financial Statements        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We have audited the accompanying consolidated balance sheetof Bio-Path Holdings, Inc. (the Company) as of December 31, 2020, the related consolidated statements of operations, shareholders’equity and cash flows for the year then ended, and the related notes (collectively referred to as the “consolidated financialstatements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financialposition of the Company at December 31, 2020, and the results of its operations and its cash flows for the year then ended        <b>         ,        </b>        inconformity with U.S. generally accepted accounting principles.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Basis for Opinion        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        These financial statements are the responsibility of the Company’smanagement. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We area public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are requiredto be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules andregulations of the Securities and Exchange Commission and the PCAOB.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We conducted our audit in accordance with the standards of thePCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statementsare free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform,an audit of its internal control over financial reporting. As part of our audit we are required to obtain an understanding of internalcontrol over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internalcontrol over financial reporting. Accordingly, we express no such opinion.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Our audit included performing procedures to assess the risksof material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond tothose risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financialstatements. Our audit also included evaluating the accounting principles used and significant estimates made by management, aswell as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basisfor our opinion.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Critical Audit Matter        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The critical audit matter communicated below is a matter arisingfrom the current period audit of the financial statements that was communicated or required to be communicated to the audit committeeand that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especiallychallenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinionon the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providinga separate opinion on the critical audit matter or on the accounts or disclosure to which it relates.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 14%; padding-bottom: 10pt">          </td>          <td style="width: 2%; padding-right: 3.5pt; padding-bottom: 12pt">          </td>          <td style="width: 84%; padding-bottom: 12pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             <i>              Accrued and Prepaid Research and Development Expenses             </i>            </b>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding-bottom: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <i>             Description of the Matter            </i>           </font>          </td>          <td style="padding-right: 3.5pt; padding-bottom: 12pt">          </td>          <td>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.5pt 0pt 0">            During 2020, the Company incurred $6.6 million for        research and development expenses and as of December 31, 2020 recorded prepaid clinical trial expenses of $0.6 million and accrued        clinical trial expenses of $0.4 million. As disclosed in Note 2 to the consolidated financial statements, research and development        costs are charged to expense when the related goods are delivered or services are performed. The Company estimated its clinical        trial expense based on a cost per patient calculation, which is derived from estimated start-up costs, clinical trial costs based        on the number of patients, and length of treatment and clinical study report costs. The Company recorded an accrual or prepaid        based on its estimated clinical trial expense as compared to payments made to the Company’s third-party clinical research        organization, laboratories and clinical investigation sites.           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.5pt 0pt 0">           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.5pt 0pt 0">            Auditing the Company’s accrued and prepaid research        and development expenses is complex due to significant judgment and estimates made by management in determining the required accruals,        which include inputs such as length of treatment and estimating costs for which the Company has not yet been billed.           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.5pt 0pt 0">           </p>          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding-bottom: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <i>             How We Addressed the Matter in Our Audit            </i>           </font>          </td>          <td style="padding-right: 3.5pt; padding-bottom: 12pt">          </td>          <td style="padding-right: 3.5pt; padding-bottom: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            To test the accrual and prepaid for research and development expenses for significant clinical trials, our audit procedures included, among others, testing the accuracy and completeness of the underlying data used in the estimates and evaluating the significant assumptions that are used by management to estimate the recorded accruals and prepayments. To test the significant assumptions, we corroborated the patient enrollment, length of treatment, trial timeline and progress of research and development activities through discussion with the Company’s research and development personnel that oversee the research and development projects, inspected the Company’s contracts with third parties and any pending change orders to assess the impact on amounts recorded, and obtained information directly from vendors of their costs incurred to date. We tested a sample of transactions and compared the costs against related invoices and contracts. We also performed analytics over fluctuations in accruals by trial throughout the year and tested subsequent payments to evaluate the completeness of the accrued expenses and compared the results to the current year accrual.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding-bottom: 10pt">          </td>          <td style="padding-right: 3.5pt; padding-bottom: 12pt">          </td>          <td style="padding-bottom: 12pt">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        /s/ Ernst &amp; Young LLP       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We have served as the Company's auditor since 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Houston, Texas       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        March 9, 2021       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 87 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            2            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">        <b>         Report of IndependentRegistered Public Accounting Firm        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Shareholders and Board of Directors       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Bio-Path Holdings, Inc.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Bellaire, Texas       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Opinion on the Consolidated FinancialStatements        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We have audited the accompanying consolidated balance sheetof Bio-Path Holdings, Inc. (the “Company”) as of December 31, 2019, the related consolidated statements of operations,shareholders’ equity, and cash flows for the year then ended, and the related notes (collectively referred to as the “consolidatedfinancial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, thefinancial position of the Company at December 31, 2019, and the results of its operations and its cash flows for the year thenended        <b>         ,        </b>        in conformity with accounting principles generally accepted in the United States of America.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Basis for Opinion        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        These consolidated financial statements are the responsibilityof the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statementsbased on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States)(“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securitieslaws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We conducted our audit in accordance with the standards of thePCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidatedfinancial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, norwere we engaged to perform, an audit of its internal control over financial reporting. As part of our audit we are required toobtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectivenessof the Company’s internal control over financial reporting. Accordingly, we express no such opinion.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Our audit included performing procedures to assess the risksof material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures thatrespond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures inthe consolidated financial statements. Our audit also included evaluating the accounting principles used and significant estimatesmade by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that ouraudit provides a reasonable basis for our opinion.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 100%; padding: 0.25pt">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">            /s/ BDO USA, LLP           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">            We served as the Company’s auditor        from 2016 to 2020.           </p>          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding: 0.25pt">          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding: 0.25pt; font-size: 10pt; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Salt Lake City, Utah           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding: 0.25pt">          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding: 0.25pt; font-size: 10pt; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            March 5, 2020           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 88 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            3            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Split-Segment; Name: 8 -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         BIO-PATH HOLDINGS, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         <a name="Seng_027">         </a>         CONSOLIDATED BALANCE SHEETS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         (In thousands, except par value)        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           As of December 31,          </td>          <td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           As of December 31,          </td>          <td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="white-space: nowrap; font-size: 10pt">          </td>          <td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           2020          </td>          <td style="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           2019          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: bold 10pt Times New Roman, Times, Serif">           Assets          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">           Current assets          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; width: 70%">           Cash          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">           13,755          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">           20,426          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left">           Prepaid drug product          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1,273          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           776          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">           Other current assets          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           928          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           788          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-align: left">           Total current assets          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           15,956          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           21,990          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">           Fixed assets          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left">           Furniture, fixtures &amp; equipment          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1,029          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1,029          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">           Less accumulated depreciation          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (798          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (726          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           231          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           303          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">           Right of use operating assets          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           288          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           367          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">           Total Assets          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           16,475          </td>          <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           22,660          </td>          <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">           Liabilities &amp; Shareholders' Equity          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">           Current liabilities          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left">           Accounts payable          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           100          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           486          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left">           Accrued expenses          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           975          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           673          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">           Current portion of lease liabilities          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           94          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           85          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left">           Total current liabilities          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1,169          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1,244          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">           Noncurrent lease liabilities          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           236          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           330          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; font: bold 10pt Times New Roman, Times, Serif; text-align: left">           Total Liabilities          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1,405          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1,574          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">           Shareholders' equity          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.375in">           Preferred stock, $.001 par value; 10,000 shares authorized; no shares issued and outstanding          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.375in">           Common stock, $.001 par value; 200,000 shares authorized; 4,542 and 3,692 shares issued and outstanding, respectively          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           5          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           4          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left">           Additional paid in capital          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           82,286          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           77,421          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">           Accumulated deficit          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (67,221          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (56,339          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">           Total shareholders' equity          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           15,070          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           21,086          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">           Total Liabilities &amp; Shareholders' Equity          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           16,475          </td>          <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           22,660          </td>          <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="margin: 0">       </p>       <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        <font style="font: 10pt Times New Roman, Times, Serif">         SEE ACCOMPANYING NOTES TO CONSOLIDATED FINANCIAL STATEMENTS        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">       </p>       <!-- Field: Page; Sequence: 89; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            4            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         BIO-PATH HOLDINGS, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         <a name="Seng_028">         </a>         CONSOLIDATED STATEMENTS OF OPERATIONS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         (In thousands, except per share amounts)        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           Year Ended December 31,          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           2020          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           2019          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">           Operating expenses          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; width: 70%; font: 10pt Times New Roman, Times, Serif; text-align: left">           Research and development          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">           6,578          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">           4,585          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; font-size: 10pt; text-align: left; padding-bottom: 1pt">           General and administrative          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           4,330          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           4,108          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.25in; font-size: 10pt; text-align: left; padding-bottom: 1pt">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.25in; font-size: 10pt; text-align: left; padding-bottom: 1pt">           Total operating expenses          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           10,908          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           8,693          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">           Net operating loss          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (10,908          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (8,693          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">           Other income          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">           Interest income          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           26          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           94          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">           Total other income          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           26          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           94          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">           Net loss          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           (10,882          </td>          <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           (8,599          </td>          <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">           Net loss per share, basic and diluted          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           (2.83          </td>          <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           (3.24          </td>          <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>            </b>           </font>           <font style="font: 10pt Times New Roman, Times, Serif">            <b>             Basic and diluted weighted average number of common shares outstanding            </b>           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           3,847          </td>          <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           2,657          </td>          <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="margin: 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         SEEACCOMPANYING NOTES TO CONSOLIDATED FINANCIAL STATEMENTS        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <!-- Field: Page; Sequence: 90; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            5            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         BIO-PATH HOLDINGS, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         <a name="Seng_029">         </a>         CONSOLIDATED STATEMENTS OF CASH FLOWS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         (In thousands)        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           Year Ended December 31,          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           2020          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           2019          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">           Cash flow from operating activities          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; width: 70%; font: 10pt Times New Roman, Times, Serif; text-align: left">           Net loss          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">           (10,882          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">           (8,599          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">           Adjustments to reconcile net    loss  to net cash used in operating activities          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left">           Stock-based compensation          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           577          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           684          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left">           Amortization of right of use assets          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           79          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           96          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in">           Depreciation          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           72          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           134          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left">           (Increase) decrease in operating assets          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.375in; text-align: left">           Prepaid drug product          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (497          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (444          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.375in; text-align: left">           Other current assets          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (140          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           15          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left">           Increase (decrease) in operating liabilities          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.375in; text-align: left">           Accounts payable and accrued expenses          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (84          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (168          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.375in; text-align: left; padding-bottom: 1pt">           Lease liabilities          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (85          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (79          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.375in; text-align: left; padding-bottom: 1pt">           Net cash used in operating activities          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (10,960          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (8,361          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">           Cash flow from financing activities          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">           Net proceeds from sale of common stock          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           4,289          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           26,700          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">           Net proceeds from exercise of warrants          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           1,083          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.375in; text-align: left; padding-bottom: 1pt">           Net cash provided by financing activities          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           4,289          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           27,783          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">           Net (decrease) increase in cash          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">           (6,671          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">           19,422          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">           Cash,  beginning of period          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           20,426          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           1,004          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">           Cash,  end of period          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           13,755          </td>          <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           20,426          </td>          <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">           Supplemental disclosure of non-cash activities          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">           Non-cash investing activities          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left">           Non-cash leasehold improvements          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           31          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="margin: 0">       </p>       <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         SEEACCOMPANYING NOTES TO CONSOLIDATED FINANCIAL STATEMENTS        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 91; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            6            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         BIO-PATH HOLDINGS, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         <a name="Seng_030">         </a>         CONSOLIDATED STATEMENTS OF SHAREHOLDERS'EQUITY        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         (in thousands)        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt; text-align: center">          </td>          <td style="font-size: 10pt">          </td>          <td colspan="2" style="font-size: 10pt; text-align: center">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td colspan="2" style="font-size: 10pt; text-align: center">          </td>          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           Additional          </td>          <td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="white-space: nowrap; font-size: 10pt">          </td>          <td colspan="2" style="white-space: nowrap; font-size: 10pt; text-align: center">          </td>          <td style="white-space: nowrap; font-size: 10pt">          </td>          <td style="white-space: nowrap; font-size: 10pt">          </td>          <td colspan="2" style="white-space: nowrap; font-size: 10pt; text-align: center">          </td>          <td style="white-space: nowrap; font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="white-space: nowrap; font-size: 10pt; text-align: center">          </td>          <td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="6" style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           Common Stock          </td>          <td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           Paid in          </td>          <td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           Accumulated          </td>          <td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="white-space: nowrap; font-size: 10pt">          </td>          <td colspan="2" style="white-space: nowrap; font-size: 10pt; text-align: center">          </td>          <td style="white-space: nowrap; font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">           Description          </td>          <td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           Shares          </td>          <td style="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           Amount          </td>          <td style="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           Capital          </td>          <td style="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           Deficit          </td>          <td style="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           Total          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 35%; font: bold 10pt Times New Roman, Times, Serif">           Balance at December 31, 2018          </td>          <td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 10%; font: bold 10pt Times New Roman, Times, Serif; text-align: right">           680          </td>          <td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; font: bold 10pt Times New Roman, Times, Serif; text-align: right">           1          </td>          <td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; font: bold 10pt Times New Roman, Times, Serif; text-align: right">           48,957          </td>          <td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; font: bold 10pt Times New Roman, Times, Serif; text-align: right">           (47,740          </td>          <td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; font: bold 10pt Times New Roman, Times, Serif; text-align: right">           1,218          </td>          <td style="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Issuance of common stock, net of fees          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           2,602          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           3          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           26,697          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           26,700          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif">           Exercise of warrants, net of fees          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           410          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1,083          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1,083          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Stock-based compensation          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           684          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           684          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">           Net loss          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (8,599          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (8,599          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">           Balance at December 31, 2019          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">           3,692          </td>          <td style="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">           4          </td>          <td style="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">           77,421          </td>          <td style="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">           (56,339          </td>          <td style="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">           21,086          </td>          <td style="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Issuance of common stock, net of fees          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           850          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           4,288          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           4,289          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Stock-based compensation          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           577          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           577          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">           Net loss          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (10,882          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (10,882          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">           Balance at December 31, 2020          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">           4,542          </td>          <td style="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">           5          </td>          <td style="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">           82,286          </td>          <td style="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">           (67,221          </td>          <td style="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">           15,070          </td>          <td style="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">       </p>       <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         SEEACCOMPANYING NOTES TO CONSOLIDATED FINANCIAL STATEMENTS        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 92; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            7            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Split-Segment; Name: 8 -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         Bio-Path Holdings, Inc.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         <a name="Seng_031">         </a>         Notes to Consolidated Financial Statements        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         December 31, 2020        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">        Unless the context requires otherwise, references in these Notesto the Consolidated Financial Statements to “we,” “our,” “us,” “the Company” and “Bio-Path” refer to Bio-Path Holdings, Inc. and its subsidiary. Bio-Path Holdings, Inc.’s wholly-ownedsubsidiary, Bio-Path, Inc., is sometimes referred to herein as “Bio-Path Subsidiary.”       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 1%; padding-right: 3pt; padding-left: 3pt; text-align: justify; font-size: 10pt">          </td>          <td style="width: 3%; padding-right: 3pt; padding-left: 3pt; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             1.            </b>           </font>          </td>          <td style="width: 96%; padding-right: 3pt; padding-left: 3pt; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Organization and Business            </b>           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company is a clinical and preclinical stage oncology focusedRNAi nanoparticle drug development company utilizing a novel technology that achieves systemic delivery for target specific proteininhibition for any gene product that is over-expressed in disease. The Company’s drug delivery and antisense technology,called DNAbilize®, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intendedto protect the DNA from destruction by the body’s enzymes when circulating        <i>         in vivo,        </i>        incorporated inside of a lipidbilayer having neutral charge. The Company believes this combination allows for high efficiency loading of antisense DNA into non-toxic,cell-membrane-like structures for delivery of the antisense drug substance into cells.        <i>         In vivo,        </i>        the DNAbilize® deliveredantisense drug substances are systemically distributed throughout the body to allow for reduction or elimination of target proteinsin blood diseases and solid tumors. Through testing in numerous animal studies and treatment in over 80 patients, the Company’sDNAbilize® drug candidates have demonstrated an excellent safety profile. DNAbilize® is a registered trademark of the Company.Using DNAbilize® as a platform for drug development and manufacturing, the Company currently has four antisense drug candidatesin development to treat at least five different cancer disease indications.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company was incorporated in May 2000 as a Utah corporation.In February 2008, Bio-Path Subsidiary completed a reverse merger with the Company, which at the time was traded over the counterand had no current operations. The prior name of the Company was changed to Bio-Path Holdings, Inc. and the directors andofficers of Bio-Path Subsidiary became the directors and officers of Bio-Path Holdings, Inc. Effective December 31, 2014,the Company changed its state of incorporation from Utah to Delaware through a statutory conversion pursuant to the Utah RevisedBusiness Corporation Act and the Delaware General Corporation Law.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        On January 17, 2019, the Company effected a reverse stocksplit of its outstanding shares of common stock at a ratio of 1-for-20, and its common stock began trading on the split-adjustedbasis on the Nasdaq Capital Market at the commencement of trading on January 18, 2019. All common stock share and per shareamounts in the Company’s consolidated financial statements have been adjusted to give effect to the 1-for-20 reverse stocksplit.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company’s operations to date have been limited toorganizing and staffing the Company, acquiring, developing and securing its technology and undertaking product development fora limited number of product candidates. As the Company has not begun its planned principal operations of commercializing a productcandidate, the Company’s activities are subject to significant risks and uncertainties, including the potential requirementto secure additional funding, the outcome of the Company’s clinical trials and failing to operationalize the Company’scurrent drug candidates before another company develops similar products.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 1%; padding-right: 3pt; padding-left: 3pt; text-align: justify; font-size: 10pt">          </td>          <td style="width: 3%; padding-right: 3pt; padding-left: 3pt; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             2.            </b>           </font>          </td>          <td style="width: 96%; padding-right: 3pt; padding-left: 3pt; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Summary of Significant Accounting Policies            </b>           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Principles of Consolidation -         </i>        </b>        The consolidatedfinancial statements include the accounts of Bio-Path Holdings, Inc. and its wholly owned subsidiary Bio-Path, Inc. Allintercompany accounts and transactions have been eliminated in consolidation.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Cash and Cash Equivalents -         </i>        </b>        The Company considersall highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Concentration of Credit Risk -         </i>        </b>        Financial instrumentsthat potentially subject the Company to a significant concentration of credit risk consist of cash. The Company maintains its cashbalances with one major commercial bank, JPMorgan Chase Bank. The balances are insured by the Federal Deposit Insurance Corporation(the “FDIC”) up to $250,000. As a result, as of December 31, 2020, approximately $13.5 million of its cash balancewas not covered by the FDIC. As of December 31, 2019, the Company had approximately $20.4 million in cash on-hand, of whichapproximately $20.2 million was not covered by the FDIC. To date, the Company has not incurred any losses on its cash balances.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 93; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            8            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Furniture, fixtures and equipment         </i>         -        </b>        Furniture,fixtures and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of theassets. Depreciation expense was $0.1 million for each of the years ended December 31, 2020 and 2019, respectively.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The estimated usefullives are as follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Computers and equipment- 3 years       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Furniture and fixtures- 7 years       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Scientific equipment-7 years       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Leasehold improvements- Lesser of useful life or lease term       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Major additions and improvements are capitalized, while costsfor minor replacements, maintenance and repairs that do not increase the useful life of an asset are expensed as incurred.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Long-Lived Assets         </i>        </b>        – The Company’slong-lived assets consist of furniture, fixtures and equipment, leasehold improvements and right-of-use operating assets. Long-livedassets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset maynot be recoverable. Recoverability of the asset is measured by a comparison of the asset’s carrying amount to the estimatedundiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimatedundiscounted future cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceedsthe fair value of the asset.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Research and Development Costs -         </i>        </b>        Costs and expensesthat can be clearly identified as research and development are charged to expense. Advance payments, including nonrefundable amounts,for goods or services that will be used or rendered for future research and development activities are deferred and capitalized.Such amounts will be recognized as an expense as the related goods are delivered or the related services are performed. If thegoods will not be delivered, or services will not be rendered, then the capitalized advance payment is charged to expense.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company estimates its clinical trial expense each periodbased on a cost per patient calculation which is derived from estimated start-up costs, clinical trial costs based on the numberof patients and length of treatment and clinical study report costs. These services are performed by the Company’s third-partyclinical research organizations, laboratories and clinical investigative sites. The expense is recorded in research and developmentexpense each period. Amounts that have been prepaid in advance of work performed are recorded in other current assets.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Stock-Based Compensation -         </i>        </b>        The Companyrecords stock-based compensation expense measured using the fair value method. The Company uses the Black-Scholes optionvaluation model to calculate stock-based compensation at the date of grant. Option pricing models require the input of highlysubjective assumptions, including the expected price volatility. The Company's policy is to estimate forfeitures at the grantdate and revise, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Changes in theseassumptions can materially affect the fair value estimate.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Net Loss Per Share -         </i>        </b>        Basic net loss per commonshare is computed by dividing net loss attributable to common stockholders for the period by the weighted average number of commonshares outstanding during the period. Although there were warrants and stock options outstanding during 2020 and 2019, they werenot included in the computation of any diluted per-share amount when a loss exists, as it would be anti-dilutive. Consequently,diluted net loss per share as presented in the financial statements is equal to basic net loss per share for the years 2020 and2019. The calculation of diluted earnings per share for 2020 did not include 274,008 shares and 858,699 shares issuable pursuantto the exercise of outstanding common stock options and warrants, respectively, as of December 31, 2020 as the effect wouldbe anti-dilutive. The calculation of diluted earnings per share for 2019 did not include 67,681 shares and 858,699 shares issuablepursuant to the exercise of outstanding common stock options and warrants, respectively, as of December 31, 2019 as the effectwould be anti-dilutive.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Use of Estimates -         </i>        </b>        The preparation ofconsolidated financial statements in conformity with generally accepted accounting principles in the United States(“U.S.”) requires management to make estimates and assumptions that affect the amounts reported in theCompany’s consolidated financial statements and accompanying notes. On an ongoing basis, the Company evaluates itsestimates and judgments, which are based on historical and anticipated results and trends as well as on various otherassumptions that the Company believes to be reasonable under the circumstances. By their nature, estimates are subject to aninherent degree of uncertainty and, as such, actual results may differ from the Company’s estimates. These estimatesinclude accrued clinical trial costs, stock-based compensation expense, valuation of warrants and valuation of deferred taxassets.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 94; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            9            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Income Taxes -         </i>        </b>        Deferred income tax assets andliabilities are determined based upon differences between the financial reporting and tax bases of assets and liabilities and aremeasured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Liquidity         </i>         -        </b>        Since its inception, the Company hasdevoted substantially all of its efforts to product development, raising capital and building infrastructure, and has not generatedsignificant revenues from its planned principal operations. The Company does not anticipate generating significant revenues forthe foreseeable future. The Company’s activities are subject to significant risks and uncertainties.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company has experienced significant losses since its inception,including net losses of $10.9 million and $8.6 million for the years ended December 31, 2020 and 2019, respectively. As ofDecember 31, 2020, the Company had an accumulated deficit of $67.2 million and $13.8 million in cash and cash equivalents.The Company has no debt commitments. Substantially all of the Company’s net losses have resulted from costs incurred in connectionwith its research and development activities and its general and administrative expenses to support operations. The Company’snet losses may fluctuate significantly from quarter to quarter and year to year.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company believes that its available cash atDecember 31, 2020, together with the net proceeds received from the 2021 Registered Direct Offering, sales of commonstock under the Offering Agreement and warrant exercises subsequent to December 31, 2020, each as described below, willbe sufficient to fund liquidity and capital expenditure requirements for at least the next 12 months from the date ofissuance of these consolidated financial statements. However, the Company expects to continue to incur significant operatingexpenses for the foreseeable future in connection with its ongoing activities, including conducting clinical trials,manufacturing development and seeking regulatory approval of its drug candidates, prexigebersen, prexigebersen-A, BP1002 andBP1003. Accordingly, the Company will continue to require substantial additional capital to fund its projected operatingrequirements. Such additional capital may not be available when needed or on terms favorable to the Company. In addition, theCompany may seek additional capital due to favorable market conditions or strategic considerations, even if it believes ithas sufficient funds for its current and future operating plan. There can be no assurance that the Company will be able tocontinue to raise additional capital through the sale of securities in the future. If the Company is not able to secureadequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliersand/or suspend or curtail planned programs. Any of these actions could materially harm the Company’s business, resultsof operations, financial condition and future prospects.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Recent Accounting Pronouncements -         </i>        </b>        From time totime, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) that are adopted by the Companyas of the specified effective date. There are no recent accounting pronouncements that have a material impact on the Company’sconsolidated financial statements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 1%; padding-right: 3pt; padding-left: 3pt; text-align: justify; font-size: 10pt">          </td>          <td style="width: 3%; padding-right: 3pt; padding-left: 3pt; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             3.            </b>           </font>          </td>          <td style="width: 96%; padding-right: 3pt; padding-left: 3pt; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Prepaid Drug Product            </b>           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Advance payments, including nonrefundable amounts, for goodsor services that will be used or rendered for future clinical development activities are deferred and capitalized. Such amountswill be recognized as an expense as the related goods are delivered or the related services are performed. The Company recognizedcertain expenses and incurred installment costs for its contract drug manufacturing and raw material suppliers with prepaymentstotaling $0.8 million as of December 31, 2019 pursuant to drug supply contracts for the manufacture and delivery of prexigebersenfor testing in a Phase 2 clinical trial and BP1002 for testing in a Phase 1 clinical trial. The Company recognized certain expensesand incurred additional installment costs during 2020, with advanced payments remaining to be expensed totaling $1.3 million asof December 31, 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 1%; padding-right: 3pt; padding-left: 3pt; text-align: justify; font-size: 10pt">          </td>          <td style="width: 3%; padding-right: 3pt; padding-left: 3pt; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             4.            </b>           </font>          </td>          <td style="width: 96%; padding-right: 3pt; padding-left: 3pt; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Other Current Assets            </b>           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        As of December 31, 2020, other current assets includedprepaid expenses of $0.9 million, comprised primarily of prepayments of $0.6 million made for the Company’s clinical trialsfor BP1002 in lymphoma and prexigebersen-A in solid tumors as well as prepaid insurance of $0.3 million. As of December 31,2019, other current assets included prepaid expenses of $0.8 million, comprised primarily of prepayments made for the Company’sclinical trial for prexigebersen in AML of $0.6 million and prepaid insurance of $0.2 million.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 95; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            10            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 1%; padding-right: 3pt; padding-left: 3pt; text-align: justify; font-size: 10pt">          </td>          <td style="width: 3%; padding-right: 3pt; padding-left: 3pt; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             5.            </b>           </font>          </td>          <td style="width: 96%; padding-right: 3pt; padding-left: 3pt; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Property and Equipment            </b>           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The following table summarizes property and equipment as ofDecember 31, 2020 and 2019:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td colspan="2" style="text-align: center; font-size: 10pt">          </td>          <td style="padding-bottom: 1pt; font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           December 31,          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           Estimated Useful Lives          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           2020          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           2019          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">           (in years)          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">           (in thousands)          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; width: 58%; text-align: left">           Leasehold improvements          </td>          <td style="width: 2%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2 to 5           </font>          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 2%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           463          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 2%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           463          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Computers and office equipment          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">           3          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           60          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           60          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Furniture and fixtures          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">           7          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           46          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           46          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Scientific equipment          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">           7          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           460          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           460          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif">           Total          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: center">          </td>          <td style="font-size: 10pt; text-align: center">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1,029          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1,029          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Less: Accumulated depreciation          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="font-size: 10pt; text-align: center">          </td>          <td style="font-size: 10pt; text-align: center">          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (798          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (726          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">           Net property and equipment          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: center">          </td>          <td style="font-size: 10pt; text-align: center">          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           231          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           303          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 1%; padding-right: 3pt; padding-left: 3pt; text-align: justify; font-size: 10pt">          </td>          <td style="width: 3%; padding-right: 3pt; padding-left: 3pt; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             6.            </b>           </font>          </td>          <td style="width: 96%; padding-right: 3pt; padding-left: 3pt; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Accounts Payable            </b>           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        As of December 31, 2020, current liabilitiesincluded accounts payable of $0.1 million, comprised primarily of investor relations expenses and legal and patent fees of $0.1million. As of December 31, 2019, current liabilities included accounts payable of $0.5 million, comprised primarily of amountsowed for external research expenses related to manufacturing costs of $0.3 million and legal and patent fees of $0.2 million.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 1%; padding-right: 3pt; padding-left: 3pt; text-align: justify; font-size: 10pt">          </td>          <td style="width: 3%; padding-right: 3pt; padding-left: 3pt; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             7.            </b>           </font>          </td>          <td style="width: 96%; padding-right: 3pt; padding-left: 3pt">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">            <b>             Accrued Expense            </b>           </p>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        As of December 31, 2020, current liabilities included accruedexpenses of $1.0 million, comprised primarily of expenses related to the Company’s clinical trial for prexigebersen in AMLof $0.4 million, accrued employee vacation and bonus expenses of $0.4 million, manufacturing expenses of $0.1 million and otheraccrued expenses of $0.1 million. As of December 31, 2019, current liabilities included accrued expenses of $0.7 million,comprised primarily of accrued employee vacation and bonus expenses of $0.4 million, clinical and preclinical expenses of $0.2million and other accrued expenses of $0.1 million.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 1%; padding-right: 3pt; padding-left: 3pt; text-align: justify; font-size: 10pt">          </td>          <td style="width: 3%; padding-right: 3pt; padding-left: 3pt; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             8.            </b>           </font>          </td>          <td style="width: 96%; padding-right: 3pt; padding-left: 3pt; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Stockholders’ Equity            </b>           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Issuances of Common Stock         </i>        </b>        - On January 14,2019, the Company entered into an underwriting agreement with H.C. Wainwright &amp; Co., LLC (“Wainwright”) relatingto an underwritten public offering of 429,616 shares of its common stock for gross proceeds of approximately $1.1 million (the “2019 Underwritten Offering”). The offering price to the public in the 2019 Underwritten Offering was $2.60 per share,and Wainwright agreed to purchase the shares in the 2019 Underwritten Offering from the Company pursuant to the underwriting agreementat a price of $2.418 per share. Additionally, the Company issued warrants to purchase up to 25,777 shares of its common stock ina private placement to Wainwright as compensation for its services as underwriter in connection with the 2019 Underwritten Offering.The 2019 Underwritten Offering closed on January 17, 2019. The net proceeds to the Company from the 2019 Underwritten Offering,after deducting the underwriting discounts and commissions and expenses and the Company’s offering expenses, and excludingthe proceeds, if any, from the exercise of the underwriter warrants, were approximately $0.9 million.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        On January 18, 2019, the Company entered into a securitiespurchase agreement with certain investors pursuant to which the Company agreed to sell, in a registered direct offering, an aggregateof 648,233 shares of its common stock for gross proceeds of approximately $1.7 million (the “January 2019 RegisteredDirect Offering”). In a concurrent private placement, the Company also agreed pursuant to the securities purchase agreementto issue to such investors Series A warrants to purchase up to 324,117 shares of its common stock (the “January 2019Private Placement”). Additionally, the Company issued warrants to purchase up to 38,894 shares of its common stock in a privateplacement to Wainwright as compensation for its services as a placement agent in connection with the January 2019 RegisteredDirect Offering and the January 2019 Private Placement. The January 2019 Registered Direct Offering and the January 2019Private Placement closed on January 23, 2019. The net proceeds to the Company from the offerings, after deducting the placementagent’s fees and expenses and the Company’s offering expenses, and excluding the proceeds, if any, from the exerciseof the warrants issued in the offerings, were approximately $1.5 million.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        On March 12, 2019, the Company entered into a securitiespurchase agreement with certain investors pursuant to which the Company agreed to sell, in a registered direct offering, an aggregateof 712,910 shares of its common stock for gross proceeds of approximately $18.5 million (the “March 2019 RegisteredDirect Offering”). Additionally, the Company issued warrants to purchase up to 42,775 shares of its common stock in a privateplacement to Wainwright as compensation for its services as a placement agent in connection with the March 2019 RegisteredDirect Offering. The March 2019 Registered Direct Offering closed on March 14, 2019. The net proceeds to the Companyfrom the offerings, after deducting the placement agent’s fees and expenses and the Company’s offering expenses, andexcluding the proceeds, if any, from the exercise of the warrants issued in the offerings, were approximately $17.0 million.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 96; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            11            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        On November 21, 2019, the Company entered into a securitiespurchase agreement with certain investors pursuant to which the Company agreed to sell, in a registered direct offering, an aggregateof 808,080 shares of its common stock and warrants to purchase up to 606,060 shares of its common stock for gross proceeds of approximately$8.0 million under the Company’s shelf registration statement on Form S-3 filed with the SEC, which was declared effectiveby the SEC on June 5, 2019 (File No. 333-231537) (the “2019 Shelf Registration Statement”) (the “November 2019Registered Direct Offering”). Additionally, the Company issued warrants to purchase up to 48,485 shares of its common stockto Wainwright as compensation for its services as a placement agent in connection with the November 2019 Registered DirectOffering, which warrants and the common stock issuable upon exercise of such warrants were registered under the 2019 Shelf RegistrationStatement. The November 2019 Registered Direct Offering closed on November 25, 2019. The net proceeds to the Companyfrom the offerings, after deducting the placement agent’s fees and expenses and the Company’s offering expenses, andexcluding the proceeds, if any, from the exercise of the warrants issued in the offerings, were approximately $7.3 million.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company did not issue any common stock pursuant to the exerciseof warrants during the year ended December 31, 2020. During the fiscal year ended December 31, 2019, the Company issuedan aggregate of 409,875 shares of its common stock pursuant to the exercise of warrants at a weighted average exercise price ofapproximately $2.67 per share. The net proceeds to the Company from the exercise of the warrants were approximately $1.1 million.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          At-The-Market Offering Agreement         </i>        </b>        - On July 13,2020, the Company entered into an At-The-Market Offering Agreement (the “Offering Agreement”) with Wainwright, as salesagent and/or principal, pursuant to which the Company may offer and sell, from time to time, through or to Wainwright, shares ofthe Company’s common stock. Sales of shares of common stock under the Offering Agreement will be made pursuant to the 2019Shelf Registration Statement and a related prospectus supplement filed with the SEC on July 14, 2020, for an aggregate offeringprice of up to $7.0 million, provided that the Company may be limited in the amount of securities that it can sell under the OfferingAgreement pursuant to Instruction I.B.6 to Form S-3 for so long as the Company’s public float remains less than $75.0million. Under the Offering Agreement, Wainwright may sell shares by any method deemed to be an “at the market” offeringas defined in Rule 415 under the Securities Act of 1933, as amended. The Company will pay Wainwright a commission of 3% ofthe aggregate gross proceeds from each sale of shares under the Offering Agreement and has agreed to provide Wainwright with customaryindemnification and contribution rights. The Company has also agreed to reimburse Wainwright for certain specified expenses.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        As of December 31, 2020, the Company had offered and sold850,000 shares of its common stock under the Offering Agreement for gross proceeds of approximately $4.6 million. The net proceedsfrom the offering, after deducting commissions and the Company’s offering expenses, were approximately $4.3 million.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 1%; padding-right: 3pt; padding-left: 3pt; text-align: justify; font-size: 10pt">          </td>          <td style="width: 3%; padding-right: 3pt; padding-left: 3pt; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             9.            </b>           </font>          </td>          <td style="width: 96%; padding-right: 3pt; padding-left: 3pt; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Stock-Based Compensation Plan            </b>           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          The 2017 Plan         </i>        </b>        – On December 21, 2017,the Company’s stockholders approved the Bio-Path Holdings, Inc. 2017 Stock Incentive Plan (as amended, the “2017Plan”), which replaced the First Amended 2007 Stock Incentive Plan, as amended (the “2007 Plan”). The 2007 Planexpired by its terms in January 2018, and no awards were made under the 2007 Plan from the approval of the 2017 Plan on December 21,2017 until the expiration of the 2007 Plan. The 2017 Plan provides for the grant of Incentive Stock Options, Non-Qualified StockOptions, Restricted Shares, Restricted Share Units, Stock Appreciation Rights, Performance-Based Awards and other stock-based awards,or any combination of the foregoing to the Company’s employees, non-employee directors and consultants. On December 19,2019, the Company’s stockholders approved an amendment to the 2017 Plan to increase the number of shares reserved for grantand issuance pursuant to the 2017 Plan by 600,000 shares to 660,000 shares. As of December 31, 2020, there were 402,724 additionalshares of common stock reserved for future issuance of awards under the 2017 Plan. Under the 2017 Plan, the exercise price of awardsis determined by the Board of Directors or the compensation committee of the Board of Directors, and for options intended to qualifyas qualified Incentive Stock Options, may not be less than the fair market value as determined by the closing stock price at thedate of the grant. Each option and award under the 2017 Plan shall vest and expire as determined by the Board of Directors or thecompensation committee. Options expire no later than ten years from the date of grant. All grants provide for accelerated vestingif there is a change of control, as defined in the 2017 Plan.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Stock option awards granted for the years 2020 and 2019 wereestimated to have a weighted average fair value per share of $4.34 and $16.26, respectively. The fair value calculation is basedon stock options granted during the year using the Black-Scholes option-pricing model on the date of grant. In addition, for allstock options granted, exercise price was determined based on the fair value as determined by the closing stock price at the dateof the grant. For stock options granted during 2020 and 2019 the following weighted average assumptions were used in determiningfair value:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt; text-align: justify">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           2020          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           2019          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 72%; font: 10pt Times New Roman, Times, Serif; text-align: justify">           Risk-free interest rate          </td>          <td style="width: 2%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">           0.50%          </td>          <td style="width: 2%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">           2.23%          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           Expected volatility          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           122%          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           126%          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           Expected term in years          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           6.0          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           6.0          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           Dividend yield          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           -%          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           -%          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 97; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            12            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company determines the expected term of its stock optionawards using the simplified method based on the weighted average of the length of the vesting period and the term of the exerciseperiod. Expected volatility is determined by the volatility of the Company’s historical stock price over the expected termof the grant. The risk-free interest rate for the expected term of each option granted is based on the U.S. Treasury yield curvein effect at the time of grant.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Option activity under the Plans for theyear ended December 31, 2020 was as follows (in thousands, except as noted):       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt; text-align: center">          </td>          <td style="font-size: 10pt">          </td>          <td colspan="2" style="font-size: 10pt; text-align: center">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td colspan="2" style="font-size: 10pt; text-align: center">          </td>          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">           Weighted          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font-size: 10pt">          </td>          <td colspan="2" style="font-size: 10pt; text-align: center">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt; text-align: center">          </td>          <td style="font-size: 10pt">          </td>          <td colspan="2" style="font-size: 10pt; text-align: center">          </td>          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">           Weighted-          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">           Average          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font-size: 10pt">          </td>          <td colspan="2" style="font-size: 10pt; text-align: center">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt; text-align: center">          </td>          <td style="font-size: 10pt">          </td>          <td colspan="2" style="font-size: 10pt; text-align: center">          </td>          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">           Average          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">           Remaining          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">           Aggregate          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt; text-align: center">          </td>          <td style="font-size: 10pt">          </td>          <td colspan="2" style="font-size: 10pt; text-align: center">          </td>          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">           Exercise          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">           Contractual          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">           Intrinsic          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt; text-align: center">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           Options          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           Price          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           Term          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           Value          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td colspan="2" style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">           (per share)          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">           (in years)          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font-size: 10pt">          </td>          <td colspan="2" style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: bold 10pt Times New Roman, Times, Serif">           Year Ended December 31, 2020          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; width: 44%">           Outstanding at December 31, 2019          </td>          <td style="width: 2%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           68          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 2%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           68.56          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 2%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           7.7          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 2%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif">           Granted          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           211          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           5.01          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           9.4          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif">           Forfeited          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (4          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           7.19          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif">           Expired          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (1          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           28.67          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif">           Outstanding at December 31, 2020          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           274          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           20.57          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           8.7          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           3,750          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Vested and expected to vest December 31, 2020          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           238          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           22.66          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           8.7          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif">           Exercisable at December 31, 2020          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           66          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           63.95          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           7.2          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           3,070          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The aggregate intrinsic value represents the total pretax intrinsicvalue (the difference between the Company’s closing stock price on December 31, 2020 and the exercise price, multipliedby the number of in-the-money options) that would have been received by the option holders had all option holders exercised theiroptions on December 31, 2020. This amount changes based on the fair value of the Company’s stock.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Option activity under the Plans for theyear ended December 31, 2019 was as follows (in thousands, except as noted):       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt; text-align: center">          </td>          <td style="font-size: 10pt">          </td>          <td colspan="2" style="font-size: 10pt; text-align: center">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td colspan="2" style="font-size: 10pt; text-align: center">          </td>          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">           Weighted          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font-size: 10pt">          </td>          <td colspan="2" style="font-size: 10pt; text-align: center">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt; text-align: center">          </td>          <td style="font-size: 10pt">          </td>          <td colspan="2" style="font-size: 10pt; text-align: center">          </td>          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">           Weighted-          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">           Average          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font-size: 10pt">          </td>          <td colspan="2" style="font-size: 10pt; text-align: center">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt; text-align: center">          </td>          <td style="font-size: 10pt">          </td>          <td colspan="2" style="font-size: 10pt; text-align: center">          </td>          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">           Average          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">           Remaining          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">           Aggregate          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt; text-align: center">          </td>          <td style="font-size: 10pt">          </td>          <td colspan="2" style="font-size: 10pt; text-align: center">          </td>          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">           Exercise          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">           Contractual          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">           Intrinsic          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt; text-align: center">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           Options          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           Price          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           Term          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           Value          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td colspan="2" style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">           (per share)          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">           (in years)          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font-size: 10pt">          </td>          <td colspan="2" style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: bold 10pt Times New Roman, Times, Serif">           Year Ended December 31, 2019          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; width: 44%">           Outstanding at December 31, 2018          </td>          <td style="width: 2%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           37          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 2%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           112.60          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 2%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           7.5          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 2%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif">           Granted          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           35          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           18.40          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           9.2          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif">           Forfeited          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (3          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           36.68          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif">           Expired          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (1          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           61.18          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif">           Outstanding at December 31, 2019          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           68          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           68.56          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           7.7          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Vested and expected to vest December 31, 2019          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           58          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           76.12          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           7.4          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif">           Exercisable at December 31, 2019          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           26          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           138.77          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           5.5          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The aggregate intrinsic value represents the total pretax intrinsicvalue (the difference between the Company’s closing stock price on December 31, 2019 and the exercise price, multipliedby the number of in-the-money options) that would have been received by the option holders had all option holders exercised theiroptions on December 31, 2019. This amount changes based on the fair value of the Company’s stock.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 98; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            13            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Stock-Based Compensation Expense –         </i>        </b>        Totalstock-based compensation expense for the year ended 2020 was $0.6 million, which consisted of research and development expenseof $0.1 million and general and administrative expense of $0.5 million. As of December 31, 2020, future stock-based compensationexpense for all outstanding unvested options was $0.9 million, which is expected to be recognized over a weighted-average vestingperiod of 2.6 years. Total stock-based compensation expense for the year ended 2019 was $0.7 million, which consisted of researchand development expense of $0.1 million and general and administrative expense of $0.6 million.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 1%; padding-right: 3pt; padding-left: 3pt; text-align: justify; font-size: 10pt">          </td>          <td style="width: 3%; padding-right: 3pt; padding-left: 3pt; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             10.            </b>           </font>          </td>          <td style="width: 96%; padding-right: 3pt; padding-left: 3pt; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Warrants            </b>           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        A summary of warrants outstanding and exercisable as of December 31,2020 is as follows (in thousands, except as noted):       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="text-align: left; font-size: 10pt">          </td>          <td style="padding-bottom: 1pt; font-size: 10pt">          </td>          <td colspan="8" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           Warrants Outstanding          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="5" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           Warrants Exercisable          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-align: left; font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td colspan="2" style="font-size: 10pt; text-align: center">          </td>          <td style="font-size: 10pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">           Weighted          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="font-size: 10pt; text-align: center">          </td>          <td style="font-size: 10pt">          </td>          <td colspan="2" style="font-size: 10pt; text-align: center">          </td>          <td style="font-size: 10pt">          </td>          <td colspan="2" style="font-size: 10pt; text-align: center">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-align: left; font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td colspan="2" style="font-size: 10pt; text-align: center">          </td>          <td style="font-size: 10pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">           Average          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">           Weighted          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="font-size: 10pt; text-align: center">          </td>          <td style="font-size: 10pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">           Weighted          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-align: left; font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td colspan="2" style="font-size: 10pt; text-align: center">          </td>          <td style="font-size: 10pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">           Remaining          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">           Average          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="font-size: 10pt; text-align: center">          </td>          <td style="font-size: 10pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">           Average          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-align: left; font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">           Number          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">           Contractual          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">           Exercise          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">           Number          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">           Exercise          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">           Year Issued          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           Outstanding          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           Life          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           Price          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           Exercisable          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           Price          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-align: left; font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td colspan="2" style="font-size: 10pt; text-align: center">          </td>          <td style="font-size: 10pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">           (in years)          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">           (per share)          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="font-size: 10pt; text-align: center">          </td>          <td style="font-size: 10pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">           (per share)          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; width: 34%; text-align: left">           2016          </td>          <td style="width: 2%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           6          </td>          <td style="width: 2%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           1.0          </td>          <td style="width: 2%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           466.26          </td>          <td style="width: 2%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           6          </td>          <td style="width: 2%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           466.26          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           2017          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           23          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1.4          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           118.95          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           23          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           118.95          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           2018          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           120          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           3.2          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           19.20          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           120          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           19.20          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           2019          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           710          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           3.8          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.125in; text-align: right">           11.31          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           710          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           11.31          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           859          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           3.7          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           18.67          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           859          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           18.67          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 1%; padding-right: 3pt; padding-left: 3pt; text-align: justify; font-size: 10pt">          </td>          <td style="width: 3%; padding-right: 3pt; padding-left: 3pt; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             11.            </b>           </font>          </td>          <td style="width: 96%; padding-right: 3pt; padding-left: 3pt; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Commitments and Contingencies            </b>           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Drug Supplier Project Plan         </i>        </b>        – Total commitmentsfor the Company’s drug supplier project plan are $1.9 million as of December 31, 2020, comprised of $1.4 million forthe manufacture of prexigebersen, BP1002 and BP1003 drug products, $0.2 million for manufacture of the Company’s Grb2 drugsubstance, $0.2 million for manufacturing development and $0.1 million for testing services. The Company expects to incur $1.5million of these commitments over the next 12 months.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 1%; padding-right: 3pt; padding-left: 3pt; text-align: justify; font-size: 10pt">          </td>          <td style="width: 3%; padding-right: 3pt; padding-left: 3pt; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             12.            </b>           </font>          </td>          <td style="width: 96%; padding-right: 3pt; padding-left: 3pt">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">            <b>             Leases            </b>           </p>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In April 2014, the Company entered into a five-year leaseagreement for administrative office space located in Bellaire, Texas. The term of the lease began on August 1, 2014 and wasset to expire on July 31, 2019; however, in May 2019, the Company entered into an amendment to the lease agreement toextend the term of the lease for a period of five years, beginning on August 1, 2019 and ending on October 31, 2024.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In April 2016, the Company entered into a three-year leaseagreement for lab space located in Bellaire, Texas. Theterm of lease began on May 1, 2016 and was set to expire on April 30, 2019; however, in December 2018, the Companyentered into an amendment to the lease agreement to extend the term for a period of three years, beginning on May 1, 2019and ending on April 30, 2022.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        At the inception of an agreement, the Company determinesif the agreement is a lease based on the unique facts and circumstances in each agreement. Lease classification, recognition,and measurement are then determined at the lease commencement date. For agreements that contain a lease, the Companyidentifies lease and non-lease components, determines the consideration in the contract, determines whether the lease is anoperating or financing lease and recognizes right of use (“ROU”) assets and lease liabilities. Lease liabilitiesand their corresponding ROU assets are recorded based on the present value of lease payments over the expected lease term.The interest rate implicit in lease contracts is typically not readily determinable so the Company uses an incrementalborrowing rate based on the information available at the lease commencement date, which represents an estimated rate thatwould be incurred to borrow over a similar term in a similar economic environment. The weighted average incremental borrowingrate utilized on its lease liabilities as of December 31, 2020 was 8.0%.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company’s current leases include options to renewwhich can impact the lease term. The exercise of these options is at its discretion and the Company does not include any of theseoptions within the expected lease term as there is no reasonable certainty these options will be exercised. Fixed lease paymentson operating leases are recognized over the expected term of the lease on a straight-line basis within its consolidated financialstatements. The Company’s leases are included in ROU assets, current portion of lease liabilities and noncurrent lease liabilitiesin its consolidated balance sheet for the year ended December 31, 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 99; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            14            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The following table summarizes the Company’s operatinglease assets and liabilities:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           December 31,          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           2020          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           2019          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">           (in thousands)          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif">           Assets:          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; width: 72%; text-align: left">           Operating lease assets          </td>          <td style="width: 2%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           288          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 2%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           367          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif">           Liabilities:          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Current portion of lease liabilities          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           94          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           85          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Noncurrent lease liabilities          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           236          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           330          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           Total operating lease liabilities          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           330          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           415          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The following table summarizes the Company’s lease relatedcosts:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           December 31,          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           2020          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           2019          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">           (in thousands)          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; width: 72%; text-align: left">           Operating lease costs          </td>          <td style="width: 2%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           115          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 2%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           114          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Variable lease costs          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           6          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           6          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           Total lease costs          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           121          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           120          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company made cash payments for its operating leases of $0.1million for the year ended December 31, 2020. The Company recognized $0.3 million in 2019 for ROU assets and correspondinglease liabilities related to the amendment of its office lease in addition to the $0.1 million recognized upon adoption of thenew lease standard on January 1, 2019.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The following table summarizes the Company’s expectedminimum lease payments:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table align="CENTER" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 65%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td colspan="4" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           As of December 31, 2020          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom">          <td colspan="4" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">           (in thousands)          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; width: 86%; text-align: left">           2021          </td>          <td style="width: 2%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           117          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           2022          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           98          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           2023          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           89          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           2024          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           76          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Future minimum lease payments           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           380          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Less: Interest           </font>          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (50          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Present value of operating lease liabilities           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           330          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        As of December 31, 2020, the weighted average remaininglease term was 3.5 years.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 1%; padding-right: 3pt; padding-left: 3pt; text-align: justify; font-size: 10pt">          </td>          <td style="width: 3%; padding-right: 3pt; padding-left: 3pt; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             13.            </b>           </font>          </td>          <td style="width: 96%; padding-right: 3pt; padding-left: 3pt; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Benefit Plan            </b>           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company initiated a contribution savings plan under Section 401(k) ofthe Internal Revenue Code in 2016. Under the plan, all eligible employees may contribute up to the statutory allowable amount governedby the Internal Revenue Service for any calendar year. The Company makes matching contributions equal to 100% of the first 3% and50% of the next 2% of each employee’s base salary up to the allowable amount, which is fully vested on the date the matchingcontributions are made. For the years ended December 31, 2020 and 2019, matching contributions totaled $30,000 and $29,000,respectively.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 100; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            15            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 1%; padding-right: 3pt; padding-left: 3pt; text-align: justify; font-size: 10pt">          </td>          <td style="width: 3%; padding-right: 3pt; padding-left: 3pt; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             14.            </b>           </font>          </td>          <td style="width: 96%; padding-right: 3pt; padding-left: 3pt; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             IncomeTaxes            </b>           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        At December 31, 2020, the Company had a net operatingloss carryforward for federal income tax purposes of $61.3 million, $35.8 million of which begins to expire in varyingamounts in tax year 2026. Approximately $25.5 million of net operating losses, incurred after December 31, 2017,carryforward indefinitely. During each of the years ended December 31, 2020 and 2019, the Company raised additionalequity capital. IRC Section 382 imposes certain limitations on the use of net operating losses and research anddevelopment tax credits to offset future taxable income when an ownership change has occurred. The Company has yet todetermine whether an ownership change occurred in 2020 or 2019. If an ownership change is determined to have occurred,additional limitations on the Company’s net operating losses incurred prior to the ownership change may apply. TheCompany has a research and development tax credit carryforward of $2.9 million for federal income tax purposes that begins toexpire in varying amounts in tax year 2028.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In assessing the ability to realize its deferred tax assets,management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized.The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods inwhich those temporary differences become deductible. Management considers evidence such as the reversal of deferred tax liabilities,projected future results of operations, and tax planning strategies in making this assessment. Based upon the level of historicaltaxable income, significant book losses during the current and prior periods, and projections for future results of operationsover the periods in which the deferred tax assets are deductible, among other factors, management continues to conclude that theCompany does not meet the “more likely than not” requirement of ASC 740 in order to recognize deferred tax assets.As such, a valuation allowance has been recorded to offset the Company’s net deferred tax assets at December 31, 2020.The Company recorded an increase in the valuation allowance of $3.0 million for the year ended December 31, 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Due to the uncertainty surrounding the realization of thebenefits of its deferred assets, including NOL carryforwards, the Company has provided a 100% valuation allowance on itsdeferred tax assets at December 31, 2020 and 2019. The valuation allowance was $16.4 million and $13.4 million asof December 31, 2020 and 2019, respectively.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The components of the Company’s deferred tax asset areas follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           December 31,          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           2020          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           2019          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">           (in thousands)          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Deferred tax assets – non-current          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; width: 72%; text-align: left">           Accrued bonuses          </td>          <td style="width: 2%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           53          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 2%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           64          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Accrued vacation          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           24          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           16          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Net operating loss (NOL) carryover          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           12,876          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           10,789          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Research &amp; development tax credits          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           2,902          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           2,070          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif">           Share based expense          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           472          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           401          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif">           Other          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           4          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           4          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Right of use lease liability          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           69          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Fixed asset depreciation          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           55          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           61          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Total deferred tax asset          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           16,455          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           13,405          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Less: valuation allowance          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (16,395          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (13,405          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Net deferred tax asset          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           60          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Right of use asset          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (60          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           Net deferred tax asset          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Reconciliation between income taxes at thestatutory tax rate (21%) and the actual income tax provision for continuing operations follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           December 31,          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           2020          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           2019          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">           (in thousands)          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 72%; font: 10pt Times New Roman, Times, Serif; text-align: left">           Loss before income taxes          </td>          <td style="width: 2%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           (10,882          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="width: 2%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           (8,599          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Tax (benefit) at statutory tax rate          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (2,285          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (1,806          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif">           Effects of:          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Exclusion of incentive stock option expense          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           50          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           53          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           R&amp;D tax credits          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (832          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (290          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Increase (decrease) in valuation allowance          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           2,990          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           2,041          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           Carryforward adjustment          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           77          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           2          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">           Provision for income taxes          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 101; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            16            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">        As of December 31, 2020, the Company had no unrecognizedincome tax benefits. The Company’s policy for classifying interest and penalties associated with unrecognized income taxbenefits is to include such items as tax expense. No interest or penalties have been recorded as of the year ended December 31,2020, and no interest or penalties have been accrued as of December 31, 2020 and 2019, respectively.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company’s open years for Internal Revenue Service(IRS) examination purposes due to normal statute of limitation are 2017, 2018 and 2019. However, since the Company has operatingloss carryforwards, the IRS has the ability to make adjustments to items that originate in a year otherwise barred by the statuteof limitations under Section 6501 of the Internal Revenue Code of 1986, as amended, in order to redetermine tax for an openyear to which those items are carried. Therefore, in a year in which a net operating loss deduction was claimed, the IRS may examinethe year in which the net operating loss was generated and adjust it accordingly for purposes of assessing additional tax in theyear the net operating loss was claimed. The Company is not currently under examination by the IRS or any other taxing authorities.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 1%; padding-right: 3pt; padding-left: 3pt; text-align: justify; font-size: 10pt">          </td>          <td style="width: 3%; padding-right: 3pt; padding-left: 3pt; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             15.            </b>           </font>          </td>          <td style="width: 96%; padding-right: 3pt; padding-left: 3pt; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Subsequent Events            </b>           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          At-The-Market Offering         </i>        </b>        - Subsequent to December 31,2020, the Company offered and sold 278,800 shares of its common stock under the Offering Agreement for gross proceeds of approximately$2.3 million. The net proceeds from the offering, after deducting commissions and the Company’s offering expenses, were approximately$2.2 million.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Warrant Exercises         </i>        </b>        - Subsequent to December 31,2020, the Company issued an aggregate of 416,655 shares of its common stock pursuant to the exercise of warrants at a weightedaverage exercise price of approximately $9.90 per share. The net proceeds to the Company from the exercise of the warrants wereapproximately $4.1 million.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          2021 Registered Direct Offering         </i>        </b>        - On February 16,2021, the Company entered into a placement agency agreement with Roth Capital Partners, LLC relating to a public offering of 1,710,600shares of its common stock for gross proceeds of approximately $13.0 million under the 2019 Shelf Registration Statement (the “2021Registered Direct Offering”). In addition, on February 16, 2021, the Company entered into a securities purchase agreementwith certain institutional investors pursuant to which the Company agreed to sell an aggregate of 1,650,000 shares of its commonstock in the 2021 Registered Direct Offering to such investors. The 2021 Registered Direct Offering closed on February 18,2021. The net proceeds to the Company from the offerings, after deducting the placement agent’s fees and expenses and theCompany’s offering expenses, were approximately $12.2 million.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 102; Options: Last -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            17            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>      </text>     </description>    </filename>   </sequence>  </type> </document></body>